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ABSTRACT 
Anaplasma marginale is one of the most prevalent tick-borne pathogens of cattle 
worldwide. Cattle that recover from acute anaplasmosis become carriers in which low or 
microscopically undetectable A. marginale rickettsemia persists. There are currently no 
antimicrobials approved for elimination of persistent infections. In this report we tested the 
efficacy of antimicrobial treatment regimens to clear persistent A.marginale infection from 
cattle. In the first study, administration of oxytetracycline at 30 mg/kg, intramuscularly (IM) 
once or twice 5 days apart was not effective for elimination of the persistent infections. 
Furthermore, the study demonstrated that the current recommended OIE treatment protocol 
of 5 injections of oxytetracycline administered at 22 mg/kg intravenously (IV) was also 
ineffective. In the second study we used flow cytometric analysis (FACS) to evaluate the 
effect of antimicrobials against A. marginale in short-term whole erythrocyte cultures. 
Enrofloxacin inhibited A. marginale in a concentration dependent manner, while higher 
concentrations of imidocarb were less effective in reducing the number of viable organisms. 
Oxytetracycline was found to be the least efficacious antimicrobial in this culture system. 
Cultures of erythrocytes infected with the Oklahoma isolate exposed to 4.0 ng/ml 
enrofloxacin and those of the Virginia and Oklahoma isolates exposed to 1.0 gg/ml appeared 
to be sterilized. Cultures exposed to 16 jxg/ml oxytetracycline were not sterilized. As a result 
of these data we tested the efficacy of enrofloxacin (Baytril® 100, Bayer Animal Health) 
against severe experimental A. marginale infections in splenectomized calves. These data 
indicate that enrofloxacin administered at 12.5 mg/kg twice, 48 h apart ameliorates, but does 
not clear, A. marginale infection in splenectomized calves. Finally we compared the efficacy 
of enrofloxacin, imidocarb and oxytetracycline against persistent A. marginale infections. 
The results suggest that apparent clearance of persistent infections occurred in one calf 
treated with imidocarb dipropionate at 5 mg/kg administered IM twice, 7 days apart, and one 
calf treated with oxytetracycline administered at 22 mg/kg q 24 h for 5 days. No calves 
treated with 5 mg/kg intravenous enrofloxacin for 5 days were cleared. Further studies are 
warranted to investigate whether dose regimens can be identified to reliably eliminate 
persistent A. marginale infections. 
1 
CHAPTER 1. GENERAL INTRODUCTION 
Dissertation organization 
This dissertation is organized into seven chapters. The remainder of this first chapter 
is a brief review of the relevance of research into the chemotherapy of persistent bovine 
anaplasmosis infections and concludes with a statement of the guiding hypotheses studied in 
this report. Chapter 2 is a literature review designed for publication. This is written as a 
critical review of methods for chemosterilization of persistent intra-erythrocytic 
hemoparasitic infections in cattle. Chapter 3 is the first research paper from this doctoral 
project. This study tested the efficacy of three oxytetracycline treatment regimens to clear 
Anaplasma marginale from cattle that were persistently infected. Chapter 4 is the second 
research paper in which we used flow cytometric analysis (FACS) to evaluate the effect of 
antimicrobials against A. marginale in short-term whole erythrocyte cultures. The third 
research paper is presented in chapter 5, which contains the results of a study conducted to 
test the efficacy of enrofloxacin (Baytril®100, Bayer Animal Health) against severe 
experimental A. marginale infections in splenectomized calves. In the final research paper 
presented in chapter 6, we compared the efficacy of enrofloxacin, imidocarb and 
oxytetracycline against persistent A. marginale infections. Chapter 7 presents general 
conclusions drawn from the research described in this dissertation. Also included is a brief 
description of recommendations for continued research. 
The coauthors of the submitted manuscripts contributed in the following ways: 
Michael D. Apley was the major professor and was involved in all aspects of the study 
design, data collection and analysis. Katherine M. Kocan from Oklahoma State University 
and her technicians conducted the examination of stained blood smears for determination of 
parasitemia. She also consulted on study design and data collection and provided isolates for 
experimental infection of study animals. Fred R. Rurangirwa from Washington State 
University conducted the polymerase chain reactions (PCR) in the first and fourth study. 
Joyce Van Donkersgoed from the Alberta Cattle Feeders Association was the study monitor 
and represented the sponsor. Doug Jones was an integral collaborator in the development of 
2 
the flow cytometry method, the performance of flow cytometry and the analysis of FACS 
data. 
Relevance of research into the chemotherapy of persistent A. marginale infections 
Anaplasmosis, caused by the rickettsial hemoparasite, A. marginale, is one of the 
most prevalent tick-transmitted diseases of cattle worldwide (Uilenberg, 1995; Dumler et al., 
2001; Kocan et al., 2003). The cost of a clinical case of anaplasmosis in the United States of 
America has been conservatively estimated to be over $400 per animal (Goodger et al., 1979; 
Alderink et al., 1982). Kocan et al. (2003) in a recent review article estimated the cost of 
anaplasmosis in the USA to be over $300 million per year. Anaplasmosis is currently 
classified in List B of the Office International des Epizootics (OLE) Terrestrial Animal Health 
Code due to its socio-economic importance and significance in terms of restrictions in the 
international trade of animals and animal products (OIE, 2003). 
A. marginale is transmitted via biological and mechanical vectors such as ticks and 
biting flies, and also by contaminated fomites such as needles and surgical instruments 
(Dikmans, 1950). The acute phase of the disease can cause severe anemia due to extra-
vascular hemolysis, abortions, weight loss and death (Potgieter and Stoltsz, 1994). Cattle that 
recover from acute anaplasmosis remain persistently infected with A. marginale. Persistent 
infection is characterized by sequential rickettsemic cycles ranging from 102 107 parasitized 
erythrocytes that occur at approximately 5-week intervals (Kieser et al., 1990). During these 
cycles, infected erythrocytes are not always detectable in stained blood smears, but ticks are 
able to acquire A. marginale infection from carrier cattle (Eriks et al., 1989). Thus, carrier 
animals serve as reservoirs of infection for mechanical transmission and infection of ticks 
which are biological vectors (Reeves and Swift, 1977; Eriks et al., 1989; Futse et al., 2003). 
The ability of A. marginale to persist in a fully immunocompetent host suggests that 
persistence involves a mechanism of escape from the immune response (Barbet et al., 2000). 
The identification of repeated cycles of rickettsemia, each composed of a progressive, 
logarithmic increase in organisms, followed by a precipitous decrease, led to the hypothesis 
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that persistence reflects the sequential emergence and subsequent immune control of 
antigenic variants (Palmer et al., 2000). 
Distinct outer membrane proteins, termed major surface proteins (MSPs) have been 
identified on A. marginale organisms derived from bovine erythrocytes (Barbet, 1995). These 
proteins are targets for the host immune response and can also be used in diagnostic assays. 
MSP1 has been reported to be an adhesin for bovine erythrocytes and tick cells and affects 
the ability of the organism to be transmitted by ticks (de la Fuente et al., 2002). This protein 
has been shown to confer partial protection in immunized cattle. Both MSP2 and MSP3 are 
encoded by large polymorphic multigene families. The MSP2 sequence specifically varies 
during cyclic rickettsemia. It has been demonstrated that unique MSP2 structural variants 
arise in each cycle of persistent rickettsemia and that a specific immune response to MSP2 is 
associated with organism clearance (French et al., 1998). Variance in MSP3 has been shown 
between geographic locations (Kocan et al., 2000). Little is known about MSP4, but MSP5 
has been shown to be conserved on all isolates of A. marginale and has proven to be a good 
diagnostic antigen for use in a newly developed competitive ELIS A test (Torioni De Echaide 
et al., 1998). 
Chlortetracycline (CTC) and oxytetracycline (OTC) are the only approved 
compounds used clinically for treatment of anaplasmosis in the United States. 
Oxytetracycline is a tetracycline derivative obtained from Streptomyces rimosus. 
Tetracyclines are bacteriostatic antibiotics that inhibit protein synthesis by reversibly binding 
to 30S ribosomal subunits of susceptible organisms (Plumb, 2002). However, A. marginale 
infections were not cleared from cattle using recommended therapeutic doses of these 
compounds (Kuttler and Simpson, 1978; Stewart et al., 1979). Previous studies, in which 
successful clearance of persistent A . marginale infections was reported, administered 
oxytetracycline intravenously to cattle at 11-22 mg/kg for 5-12 days (Magonigle et al., 1975; 
Roby et al., 1978). Intramuscular oxytetracycline administered at 20 mg/kg on two, three or 
four occasions at intervals ranging from 3-7 days was also reported to be effective at 
eliminating carrier infections (Roby et al., 1978; Kuttler, 1980; Magonigle and Newby, 1982; 
Kuttler, 1983; Swift and Thomas, 1983; Rogers and Dunster, 1984; Ozlem et al., 1988). 
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The existence of persistent A. marginale infections in cattle despite treatment restricts 
the movement of animals from areas where the disease is prevalent to areas where the disease 
is not regarded as endemic such as Canada. Prior to the publication of the paper presented in 
chapter 3, only limited movement of feeder cattle from selected northern states was permitted 
under the Restricted Feeder Cattle Program (RFCP) (Canadian Food Inspection Agency, 
2002). The RFCP facilitates the export of feeder cattle from the U.S. A to Canada between 1 
October and 31 March (the non-vector season) provided these animals receive oral 
tetracycline for 120 days or 2 injections of a long acting oxytetracycline formulation at a 
dose rate of 20 mg/kg on arrival and 5-7 days later. As a consequence of this, the Canadian 
beef industry was looking for alternative treatments, for example a single injection of long-
acting oxytetracycline, to reduce the current cost of repeat treatments and the risk of 
antimicrobial resistance development from long-term use of feed medications. If a single 
treatment of long-acting oxytetracycline is effective or none of the treatments are effective, 
then the RFCP may need to be modified accordingly. 
Guiding hypotheses of this dissertation 
The hypothesis of the first paper presented in this dissertation was that either a single 
injection of a new long-acting OTC formulation (300 mg/ml OTC) administered at 30 mg/kg 
bodyweight or 2 injections administered 5 days apart IM would be as efficacious as the 
current OIE recommended treatment protocol which requires the administration of 22 mg/kg 
OTC IV for 5 days. In this paper data are presented that support the rejection of this 
hypothesis and also demonstrate that the OIE recommended treatment protocol was 
ineffective. 
As a result of these findings we hypothesized that the failure to sterilize persistent A. 
marginale infections could be attributed to one or more of the following factors: (1) drug 
concentrations at the site of infection were inadequate, (2) drug concentration was 
maintained for an insufficient duration to be effective, (3) the organism was not susceptible 
to the antimicrobial, (4) the pharmacokinetic parameters of the drug were inadequate, and (5) 
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local factors in the environment where the organism was located were not conducive for 
optimal drug activity (Bidgood and Papich, 2003). 
In the second experiment we hypothesized that an in vitro whole blood culture system 
for A. marginale previously described by Kessler et al. (1979) could be used in conjunction 
with a fluorescent activated cell sorting (FACS) method described by Wyatt et al. (1991) to 
evaluate antimicrobials against A. marginale. Once established, this technique could also be 
used to test the hypothesis that anaplasmosis isolates from different geographic locations 
differ in their susceptibility to antimicrobials. This study demonstrated that enrofloxacin 
(ENRO) inhibited A. marginale in a concentration dependent manner, while higher 
concentrations of imidocarb (IMD) were less effective in reducing the number of viable 
organisms. Oxytetracycline (OTC) was found to be the least efficacious antimicrobial in this 
culture system. Differences between isolates were evident at some dilutions. Cultures of 
erythrocytes infected with the Oklahoma isolate exposed to 4.0 pg/ml enrofloxacin and those 
of the Virginia and Oklahoma isolates exposed to 1.0 |ig/ml imidocarb appeared to be 
sterilized. This study appears to be the first in vitro study demonstrating the anti-A 
marginale microbial effect of enrofloxacin. 
Based on the results of the in vitro trial we hypothesized that enrofloxacin could 
potentially be used to sterilize persistent A. marginale infections. Accordingly we designed 
the study reported in chapter 5 to test the efficacy of enrofloxacin (Baytril®100, Bayer 
Animal Health) against severe experimental A. marginale infections in splenectomized 
calves. The results of this study indicated that enrofloxacin administered at 12.5 mg/kg twice, 
48 h apart ameliorates, but does not eliminate, A. marginale infection in splenectomized 
calves. 
Finally we compared the efficacy of enrofloxacin, imidocarb and oxytetracycline 
against persistent A. marginale infections established experimentally using isolates from 
Oklahoma (OK), Virginia (VGN) or Idaho (St Maries; StM). One calf infected with the OK 
isolate treated with imidocarb dipropionate at 5 mg/kg administered IM twice, 7 days apart, 
and one calf infected with the VGN isolate treated with oxytetracycline administered at 22 
mg/kg q 24 h for 5 days failed to develop parasitemia following splenectomy. Subinoculation 
of blood pooled from these calves failed to infect a splenectomized calf. The OTC treated 
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calf and the subinoculated splenectomized calf was negative for the parasite on PCR and 
nPCR, but the IMD treated calf was positive. These data indicate that two of the regimens 
described were efficacious against persistent A. marginale infections in only two animals, 
one infected with an OK isolate and one infected with a VGN isolate. No calves treated with 
5 mg/kg intravenous enrofloxacin for 5 days were cleared of infection. 
Taken together, these studies suggest that reliable clearance of persistent A. 
marginale infections could not be achieved with oxytetracycline, imidocarb dipropionate or 
enrofloxacin at the dose, route, frequency and duration of administration tested. We also 
showed that flow cytometry proved to be useful for screening antimicrobial activity of drugs 
against A. marginale infected bovine erythrocytes. Based on the data obtained from these 
analyses we were able to make predictions about the minimum inhibitory concentration of 
antimicrobials required to be effective against anaplasmosis. We also demonstrated in vitro 
susceptibility differences between a Virginia and Oklahoma isolate especially in the 
imidocarb treated cultures. Enrofloxacin was also identified as a compound that could 
potentially be used against A. marginale. Further research is required to investigate why 
current chemosterilization protocols against A. marginale provide inconsistent results. This 
may require further elucidation of the relationship between pharmacotherapy and the immune 
system, and the determinants of isolate susceptibility differences. 
References 
Alderink, F.J., Dietrick, R.A., 1982. Economic and epidemiological implications of 
anaplasmosis in Texas cattle herds. Proceedings of the 86th Annual Meeting of the United 
States Animal Health Association, pp. 66-75. 
Barbet, A.F., 1995. Recent developments in the molecular biology of anaplasmosis. Vet. 
Parasitol. 57, 43-49. 
Barbet, A.F., Yi, J., Lundgren, A., McEwen, B.R., Blouin, E.F., Kocan, K.M., 2000. 
Antigenic variation of Anaplasma Marginale: Major Surface Protein 2 diversity during cyclic 
transmission between ticks and cattle. Infection and Immunity 69 (5), 3057-3066. 
Bidgood, T.L., Papich, M.G., 2003. Comparison of plasma and interstitial fluid 
concentrations of doxycycline and meropenem following constant rate intravenous infusion 
in dogs. Am. J. Vet. Res. 64 (8), 1040. 
7 
Canadian Food Inspection Agency, 2002. Client Services Information Sheet No. 14-
Restricted Feeder Cattle from the United States, accessed September 17, 2002. 
http : //www. inspection, gc.ca/ english/anima/heasan/import/bovine. shtml. 
de la Fuente, J., Kocan, KM., Garcia-Garcia, J.C., Blouin, E.F., Claypool, P L., Saliki, J.T., 
2002. Vaccination of cattle with Anaplasma marginale derived from tick cell culture and 
bovine erythrocytes followed by challenge-exposure with infected ticks. Vet. Microbiol. 89, 
239-251. 
Dikmans, G., 1950. The transmission of anaplasmosis. Am. J. Vet. Res. 11 (38), 5-16. 
Dumler, J.S., Barbet, A.F., Bekker, P.J., Dasch, G.A., Palmer, G.H., Ray, S.C., Rikihisa, Y., 
Rurangirwa, F.R., 2001. Reorganization of genera in the families Rickettsiaceae and 
Anaplasmataceae in the order Rickettsials: unification of some species of Ehrlichia with 
Anaplasma, Cowdria with Ehrlichia and Ehrlichia, with Neorickettsia, descriptions of six 
new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective 
synonyms of Ehrlichia phagocytophila. Int. J. of Systematic and Evol. Microbiol. 51, 2145-
2165. 
Eriks I.S., Palmer G.H., McGuire T.C., Allred D R., Barbet A.F., 1989. Detection and 
quantitation of Anaplasma marginale in carrier cattle by using a nucleic acid probe. J. of 
Clin. Microbiol. 27 (2), 279-284. 
French, D.M., McElwain, T.F., McGuire, T.C., Palmer, G.H., 1998. Expression of 
Anaplasma marginale Major Surface Protein 2 variants during persistent cyclic rickettsemia. 
Infection and Immunity 66 (3), 1200-1207. 
Futse,J.E., Ueti, M.W., Knowles, D.P., Palmer, G.H., 2003. Transmission of Anaplasma 
marginale by Boophilus microplus: Retention of vector competence in the absence of vector-
pathogen interaction. J. Clin. Microbiol. 41, 3829-3834. 
Goodger, W.J., Carpenter, T., Riemann, H., 1979. Estimation of economic loss associated 
with anaplasmosis in California beef cattle. J. Am. Vet. Med. Assoc. 174 (12), 1333-1336. 
Kessler, R.H., Ristic, M., Sells, D.M., Carson, C.A., 1979. In vitro cultivation of Anaplasma 
marginale: Growth pattern and morphologic appearance. Am. J. Vet. Res. 40 (12), 1767-
1773. 
Kieser, S.T., Eriks, I.S., Palmer, G.H., 1990. Cyclic rickettsemia during persistent Anaplasma 
marginale infection of Cattle. Infection and Immunity 58 (4), 1117-1119. 
Kocan, K.M., Blouin, E.F., Barbet, A.F., 2000. Anaplasmosis control. Past, present and 
future. Ann. NY Acad. Sci. 916, 501-509. 
8 
Kocan, K.M., de la Fuente, J., Guglieilmone, A.A., Melendez, R.D., 2003. Antigens and 
alternatives for control of anaplasma marginale infection in cattle. Clinical Microbiology 
Reviews 16 (4), 698-712. 
Kuttler, K.L., 1980. Pharmacotherapeutics of drugs used in treatment of anaplasmosis and 
babesiosis. J. Am. Vet. Med. Assoc. 176 (10), 1103-1108. 
Kuttler, K.L., 1983. Influence of a second Anaplasma exposure on the success of treatment to 
eliminate Anaplasma carrier infections in cattle. Am. J. Vet. Res. 44 (5), 882-883. 
Kuttler, K.L., Johnson, L.W., Simpson, J.E., 1980. Chemotherapy to eliminate Anaplasma 
marginale under field and laboratory conditions. Proceedings of the 84th Annual Meeting of 
the USAHA, 73-82. 
Kuttler, K.L., Simpson, J.E., 1978. Relative efficacy of two oxytetracycline formulations 
doxycycline in the treatment of acute anaplasmosis in splenectomized calves. Am. J. Vet. 
Res. 39 (2), 347-349. 
Magonigle, R.A., Newby, T.J., 1982. Elimination of naturally acquired chronic Anaplasma 
marginale infections with a long-acting oxytetracycline injectable. Am. J. Vet. Res. 43 (12), 
2170-2172. 
Magonigle, R.A., Renshaw, H.W., Vaughn, H.W., Stauber, E.H., Frank, F.W., 1975. Effect 
of five daily intravenous treatments with oxytetracycline hydrochloride on the carrier status 
of bovine anaplasmosis. J. Am. Vet. Med. Assoc. 167 (12), 1080-1083. 
Office International des Epizootics (OLE). 2003. OIE Classification of Diseases, accessed 28 
July 2003. http://www.oie.int/ eng/maladies/en classification.htm 
Ozlem, M.B., Karaer, Z., Turgut, K, Eren, H., Irmak, K., inci, A., 1988. Efficacy of long-
acting oxytetracycline on bovine anaplasmosis. A. U. Vet. Fak. Derg. 35 (1), 1-5. 
Palmer, G.H., Brown, W.C., Rurangirwa, F.R., 2000. Antigenic variation in the persistence 
and transmission of the ehrlichia Anaplasma marginale. Microbes and Infection 2, 167-176. 
Plumb, D C., 2002. Veterinary Drug Handbook. Iowa State Press, Ames, 643pp. 
Potgieter F.T., Stoltsz, W.H., 1994. Anaplasmosis. In: Coetzer, J.A.W., Thompson, G.R., 
Tustin, R.C.(Eds.), Infectious Diseases of Livestock—With special reference to Southern 
Africa. Oxford University Press, Cape Town, South Africa, pp. 408-430. 
Reeves, J.D., Swift, B.L., 1977. Iatrogenic transmission of Anaplasma marginale in beef 
cattle. Veterinary Medicine/Small Animal Clinician. 72 (5), 911-912. 
9 
Roby, T O., Simpson, I.E., Amerault, T.E., 1978. Elimination of the carrier state of bovine 
anaplasmosis with long-acting oxytetracycline. Am. J. Vet. Res. 39 (7), 1115-1116. 
Rogers, R.J., Dunster, P. J., 1984. The elimination of Anaplasma marginale from carrier 
cattle by treatment with long acting oxytetracycline. Aust. Vet. J. 61 (9), 306. 
Stewart, C.G., Immelman, A., Grimbeek, P., Grib, D., 1979. The use of a short and a long 
acting oxytetracycline for the treatment of Anaplasma marginale in splenectomized calves. J. 
SFVA 50 (2), 83-85. 
Swift, B.L., Thomas, G.M., 1983. Bovine anaplasmosis: Elimination of the carrier state with 
injectable long-acting oxytetracycline. J. Am. Vet. Med. Assoc. 183 (1), 63-65. 
Torioni De Echaide, S., Knowles, D P., McGuire, T.C, Palmer, G.H., Suarez, C.E., 
MeElwain, T.F., 1998. Detection of cattle naturally infected with Anaplasma marginale by 
nested PGR and a competitive enzyme-linked immunosorbent assay using recombinant 
Major Surface Protein 5. J. Clin. Microbiol. 36 (3), 777-782. 
Uilenberg, G., 1995. International collaborative research: Significance of tick-borne 
hemoparasitic diseases to world animal health. Vet. Parasitol. 57, 19-41. 
Wyatt, C.R., Goff, W., Davis, W. C., 1991. A flow cytometric method for assessing viability 
of intraerythrocytic hemoparasites. J. Immun. Meth. 140, 23-30. 
10 
CHAPTER 2. A CRITICAL REVIEW OF METHODS FOR 
CHEMOSTERILIZATION OF PERSISTENT INTRA-ERYTHROCYTIC 
HEMOPARASITIC INFECTIONS IN CATTLE 
A paper to be submitted to Animal Health Research Reviews 
Johann F. Coetzee 
Abstract 
Babesiosis and anaplasmosis are tick transmitted diseases caused by obligate 
intraerythrocytic hemoparasites. It has been estimated that at least 500 million cattle are 
exposed to babesiosis and anaplasmosis worldwide. Following acute infection, both diseases 
establish persistent infections that confer lifelong immunity to the host. The existence of a 
subclinical carrier state in cattle poses a risk when animals are moved from endemic to non-
endemic regions. For this reason these diseases are currently classified in List B of the Office 
International des Epizootics (OIE) Terrestrial Animal Health Code due to their socio­
economic importance and significance in terms of restrictions in the international trade of 
animals and animal products. Current OIE recommendations propose that chemosterilization 
of babesiosis infections can occur with an effective drug such as imidocarb as a single dose 
injection at 2 mg/kg. Persistent A. marginale infections are purported to be sterilized with an 
effective drug such as oxytetracycline for 5 consecutive days at a dose of 22 mg/kg prior to 
export. However, recent studies have failed to eliminate anaplasmosis infections in 
experimentally infected carrier animals using this treatment regime. The purpose of this 
review paper is to examine the antimicrobials currently available for chemosterilization of 
persistent Babesia and Anaplasma infections in cattle and the publications used to support 
these recommendations. The next section will focus on possible reasons why the 
recommended antimicrobial therapies are unsuccessful. Finally, future developments and 
potential areas for continued research into chemosterilization protocols are discussed. 
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introduction 
The tick-borne hemoparasitic diseases of greatest global economic importance in 
cattle are babesiosis, anaplasmosis, theileriosis and cowdriosis (Uilenberg, 1995). Of these, 
only anaplasmosis, caused by Anaplasma marginale and babesiosis, caused by Babesia 
bigemina and Babesia bovis, are intimately associated with erythrocytes and will therefore be 
the main focus of this review. Both diseases are currently classified in List B of the Office 
International des Epizootics (OIE) Terrestrial Animal Health Code due to their socio­
economic importance and significance in terms of restrictions in the international trade of 
animals and animal products (OIE, 2004a, 2004b). 
Following acute disease, A. marginale establishes lifelong persistent infections. These 
infections are characterized by sequential rickettsemic cycles ranging from 102-107 
parasitized erythrocytes that occur at approximately 5-week intervals (Kieser et al., 1990). 
Each cycle arises due to antigenic variation of the immunodominant outer membrane protein 
MSP2, which occurs by combinatorial gene conversion (Brayton et al., 2002). 
Similarly, cattle recovering from babesiosis retain a latent infection lasting six months 
to several years (De Vos et al., 2004). Unlike anaplasmosis, recrudescence of parasitemia 
occurs at irregular intervals (Mahoney, 1977). At least 5 mechanisms have been identified 
which might contribute to evasion of host immunity by Babesia organisms. These include: 
(1) antigenic variation of a variant erythrocyte surface antigen (VESA1), (2) 
cytoadhesion/sequestration, (3) binding host IgM to the surface of infected erythrocytes, 
hiding the parasite from immune recognition, (4) monoallelic expression of different 
members of multigene families, and (5) induction of transient immunosupression (Allred, 
2003). 
Maintenance of persistent infections confers lifelong immunity to the host. The 
carrier state is also important in endemic areas as it contributes to endemic stability of the 
disease. Under these circumstances young animals are exposed to infection before passive 
protection from maternal antibody wanes. Consequently, serious disease outbreaks do not 
occur even though the causal organism is widely distributed in the population (Sergent, 1965; 
Mahoney, 1977). 
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The existence of persistent infections in cattle, in many cases despite treatment with 
prescribed antimicrobial protocols, poses a risk when animals are moved from endemic to 
non-endemic regions. In light of this, Article 2.3.8.2 of the OIE Terrestrial Animal Health 
Code states that when importing cattle from countries considered infected with bovine 
babesiosis, Veterinary Administrations of free countries should require the presentation of an 
international veterinary certificate attesting that the animals (1) showed no clinical sign of 
bovine babesiosis on the day of shipment; and (2) were, since birth, resident in a zone known 
to be free of bovine babesiosis for the previous 2 years; OR (1) showed no clinical sign of 
bovine babesiosis on the day of shipment; and (2) were subjected to a diagnostic test for 
bovine babesiosis with negative results during 30 days prior to shipment; and (3) were treated 
with an effective drug such as imidocarb as a single dose injection at 2 mg/kg or 
amicarbalide at 10 mg/kg (under study) (OIE, 2004a). 
Recent studies that independently verify these recommendations are lacking in the 
published literature. Amicarbalide is no longer commercially available and will therefore not 
be examined in this review (Cooper and Watson, 1989). Essentially the recommendations 
involving imidocarb are based on work conducted by Callow and McGregor (1970), Callow 
et al. (1974a) and Lewis et al. (1981). Since these studies were conducted, it has been 
recognized that the larger babesias (B. bigemina) appear to be more sensitive to imidocarb 
than the smaller organisms like B. bovis (Kuttler and Johnson, 1986). Furthermore, newer 
molecular technologies such as PCR and DNA hybridization have been developed that would 
assist in identifying persistent infections. 
In addition to the recommendations stated under Article 2.3.8.2 for anaplasmosis, 
Article 2.3.7.2 of the terrestrial animal health code states that animals can be treated with an 
effective drug such as oxytetracycline for 5 consecutive days at a dose of 22 mg/kg (under 
study) prior to export (OIE, 2004a). In previous studies where successful clearance of 
persistent A. marginale infections was reported, oxytetracycline was administered 
intravenously to cattle at 11-22 mg/kg for 5-12 days (Magonigle et al., 1975; Roby et al., 
1978). Intramuscular oxytetracycline administered at 20 mg/kg on 2, 3 or 4 occasions at 
intervals ranging from 3-7 days was also reported to be effective at eliminating carrier 
infections (Roby et al., 1978; Kuttler, 1980; Magonigle and Newby, 1982; Kuttler, 1983; 
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Swift and Thomas, 1983; Rogers and Dunster, 1984; Ozlem et al., 1988). A recent study 
conducted by our research group demonstrated that the current recommended OIE treatment 
protocol of 5 daily injections of oxytetracycline administered intravenously at 22 mg/kg did 
not eliminate persistent Oklahoma isolate infections (Coetzee et al., 2005). It therefore seems 
appropriate to re-evaluate many of the prescribed treatment regimens for clearing persistent 
infections especially in light of many of the recent advances in molecular technologies. 
This review paper is divided into 4 sections. Section 1 will review the global 
economic significance of anaplasmosis and babesiosis. Section 2 will review the 
antimicrobials recommended for chemosterilization and the publications used to support 
these recommendations. Section 3 will focus on possible reasons why the recommended 
antimicrobial therapies are unsuccessful. Finally, section 4 will speculate on future 
developments and potential areas for continued research into chemosterilization protocols. 
1. Economic significance of anaplasmosis and babesiosis 
Anaplasmosis, caused by the rickettsial hemoparasite Anaplasma marginale, is one of 
the most prevalent tick-transmitted diseases of cattle worldwide (Uilenberg, 1995; Dumler et 
al., 2001; Kocan et al., 2003). Losses due to anaplasmosis arise from anemia, icterus and 
fever associated with clinical infections and occasional abortions. The disease has been 
reported in Africa, North and South America, Russia, European countries bordering the 
Mediterranean and the Middle and Far East (Kocan et al., 2000). 
The incidence of clinical anaplasmosis has been estimated to be 1.85% in beef cattle 
in California (Goodger et al., 1979), 0.276% in Texas (Alderink and Dietrich, 1982) and up 
to 31% in Louisiana (Morley and Hugh-Jones, 1989). It is estimated that the introduction of 
anaplasmosis into a previously naïve herd can result in a 3.6% reduction in calf crop, a 30% 
increase in cull rate and a 30% mortality rate in clinically infected adult cattle (Alderink and 
Dietrich, 1982). The cost of a clinical case of anaplasmosis in the United States has been 
conservatively estimated to be over $400 US per animal (Goodger et al., 1979; Alderink et 
al., 1982). Kocan et al. (2003) in a recent review article estimated the cost of anaplasmosis in 
the U.S. to be over $300 million per year. 
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In the North American context, the existence of persistent A. marginale infections in 
cattle, despite treatment, restricts the movement of breeding animals from the U. S. to 
Canada where the disease is not regarded as endemic. The losses associated with A. 
marginale becoming established in Canada are estimated between $12.1 and $36.0 million 
CAD. Meanwhile, the estimated cost to the Canadian Food Inspection Agency (CFIA) to 
prevent the spread of the disease is $3 million CAD should anaplasmosis be introduced 
(CFIA, 2003). 
In March, 2004, the Canadian government removed anaplasmosis and bluetongue 
testing and treatment requirements from feeder cattle imported from most U.S. states (CFIA, 
2003). Although these new provisions facilitate year-round movement of feeder cattle from 
39 U.S. states to Canada, there are control provisions for the movement of imported feeders 
between approved feedlots and for Canadian cattle to leave importing feedlots to re-enter 
Canada's breeding herd. Imported animals are eligible to leave the feedlot only for 
immediate slaughter, movement to another feedlot that is approved to import restricted feeder 
cattle or to be re-exported to the U.S. There are requirements for comprehensive management 
programs for animals in the feedlot, enhanced insect vector control programs and periodic 
inspection of animals within importing feedlots. 
Babesia bovis (European Redwater) and Babesia bigemina (African Redwater) are 
responsible for the most significant economic losses associated with babesiosis. In addition 
to fever, hemoglobinuria and anemia associated with intravascular hemolysis, B. bovis is 
responsible for neurological signs associated with sequestration of erythrocytes in the 
cerebral vasculature (De Vos et al., 2004). Abortions in pyrexic animals have also been 
recorded. 
Babesiosis persists in tropical and semi tropical regions between the 32nd parallel in 
the south to the 40th parallel north of the equator. Babesiosis or "Texas fever" was eradicated 
from the U.S. in 1943, following implementation of intensive acaricide dipping to eliminate 
Boophilus annulatus from cattle in accordance with the Animal Industry Act of 1884. In 
1976 the benefit/cost ratio for the Texas program was estimated to be 172 to 1. The direct 
cost of maintaining this barrier was estimated around $5,276,000 in 2001 (APHIS, 2005). 
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However, it is estimated that the first year cost of controlling vector ticks alone should they 
be introduced into the U.S. is over $1.3 billion (Washington State University, 2005). 
De Vos (1992) estimated that at least 500 million cattle are exposed to babesiosis and 
anaplasmosis worldwide. Based on reports from Argentina, Mexico and Australia, it has been 
estimated that annual loss of five dollars (US) per head is due to ticks and tick-borne diseases 
(Buening, AFIP website). There are approximately 175 million cattle residing in tick-infested 
areas of Central and South America; thus the cattle industry of Latin America experiences a 
total loss of $875 million (US) per annum. Worldwide the cost is estimated to be around $2.5 
billion (US). Additional economic costs are related to quarantine and control measures such 
as restriction of cattle movement from endemic to non-endemic zones. 
2. Antimicrobials currently available for chemosterilization of persistent anaplasmosis 
and babesiosis infections 
Introduction 
Prior to the development of the tetracycline antimicrobials and the diamidine 
derivatives, a variety of chemotherapeutic agents, including arsenicals, antimalarials, 
antimony derivatives and dyes, were used to treat acute anaplasmosis and babesiosis in cattle. 
These compounds had little if any chemotherapeutic effect, with the exception of trypan blue 
which was the first specific drug used to successfully treat babesiosis (Kuttler, 1988; 
Potgieter and Stoltsz, 1994). However, trypan blue discolors flesh and body secretions 
therefore giving it limited usefulness in food animals. This compound also fails to sterilize 
infections. 
Chlortetracycline (CTC) and oxytetracycline (OTC) are the only compounds 
approved for use against acute anaplasmosis in the U.S. However, A. marginale infections 
are not sterilized at the usual recommended therapeutic doses of these compounds (Kuttler 
and Simpson, 1978; Stewart et al., 1979). There are currently no antimicrobials labeled for 
the elimination of persistent Anaplasma infections in carrier animals. Previous studies have 
reported chemosterilization of A. marginale infections using tetracycline and oxytetracycline 
IV or IM, chlortetracycline IV or orally, and imidocarb as a single therapy or in combination 
with a-ethoxyethylglyoxal dithiosemicarbazone (Gloxazone) (reviewed by Kuttler, 1980). 
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However, gloxazone was never made commercially available due to concerns relating to the 
toxicity of this compound in lactating cows (Kuttler, 1971). 
Imidocarb diproprionate (Imizol, Schering Plough) and diminazene aceturate 
(Berenil, Hoechst Ltd.) are the most common agents used in the chemotherapy of bovine 
babesiosis. Previously, quinuronium sulfate and amicarbilide isoethionate were available as 
therapeutic options, however, these have been withdrawn because of manufacturing safety 
issues (Cooper and Watson, 1989; Zintl et al., 2003). Imidocarb and diminazene aceturate are 
also not available for use in food animals in the U. S. due to prolonged tissue levels and 
potential carcinogenic effects (EMEA, 2001; Kuttler, 1988). 
Tetracycline antimicrobials 
Pharmacology 
The tetracycline antimicrobials have been extensively reviewed by Scholar and Pratt 
(2000) and Chopra and Roberts (2001). What follows is a brief summary of the pertinent 
information contained within these reviews. 
Chlortetracycline (CTC) and oxytetracycline (OTC), both discovered in the late 
1940s, were the first members of the tetracycline group to be described. Tetracycline 
molecules comprise a fused tetracyclic nucleus to which a variety of functional groups are 
attached. Barragry (1994) and Scholar and Pratt (2000) reviewed the mechanism of uptake of 
tetracyclines by bacterial microorganisms. The tetracyclines are accumulated in both Gram-
positive and Gram-negative bacteria in an energy dependant manner. Two types of uptake 
systems are involved in tetracycline accumulation. There is an initial, rapid uptake that is 
driven by a proton-motive force caused by the difference in the pH between the environment 
and the bacterial cytoplasm (Nikaido and Thanassi, 1993). This mechanism appears to reach 
equilibrium with the tetracycline in the medium in about 5 min. 
The second uptake system is a slower energy-dependant uptake that accumulates 
tetracycline over a period of hours. In Gram-negative bacteria, the tetracyclines pass through 
the outer membrane through the OmpF and OmpC porin channels as positively charged 
cations probably in complex with magnesium (Chopra et al., 1992). In Gram-positive 
bacteria it is assumed to be the electroneutral, lipophilic form that crosses the membrane. 
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Within the cytoplasm, tetracycline molecules are likely to become chelated since the internal 
pH and divalent metal ion concentrations are higher than those outside the cell (Schnappinger 
and Hillen, 1996). The mechanism of entry of tetracyclines into rickettsia has not been 
elucidated. 
Tetracyclines are bacteriostatic agents with broad spectrum antimicrobial activity. 
Tetracycline activity has been demonstrated against Gram-positive and Gram-negative 
bacteria, atypical organisms such as chlamydiae, mycoplasmas, and rickettsiae and protozoan 
parasites. They are also used prophylactically for the prevention of malaria caused by 
mefloquine-resistant Plasmodium falciparum (Chopra and Roberts, 2001). There has been 
widespread emergence of efflux- and ribosome-based resistance to chlortetracycline and 
oxytetracycline in veterinary and human medicine, which has been hypothesized to be due to 
the widespread and sometimes indiscriminate use of these compounds (Acar, 1997; Chopra 
et al., 1992). 
The tetracyclines bind to ribosomes and mRNA. However, the inhibition of protein 
synthesis is mediated principally through reversible binding with the 30S ribosomal subunit. 
Six tetracycline-binding sites, with no common structural trait and which demonstrate 
different binding affinities, have been identified on the 30S subunit (as reviewed by 
Auerbach et al., 2002). In bacteria, the primary binding site lies in a clamp-like pocket 
formed by the head, at the A site of the mRNA-ribosome complex. The tetracycline at this 
site interacts with the sugar-phosphate backbone of H34 through a magnesium ion. 
Reversible binding of tetracycline to the A-site blocks the attachment of aminoacyl-tRNA. 
The reversible nature of this association provides an explanation for the bacteriostatic effects 
of the drug (Chopra et al., 1992). The significance of the remaining five binding sites is not 
known, but it has been hypothesized that these could act synergistically to contribute to the 
bacteriostatic effect of the drug. The four proteins that interact with tetracycline at these 
alternate sites are primary rRNA binding proteins. Disruptions of these may therefore disturb 
the assembly steps of the 30S subunit. 
Tetracyclines, as a class, are widely distributed in the body with a volume of 
distribution of 0.8 L/kg reported in cattle. The amount of plasma protein binding for 
oxytetracycline is about 10—40%. Pharmacokinetic studies in cattle have found that the 
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maximum plasma concentration (Cmax) following IM administration of a long acting 
formulation containing 200 mg/ml oxytetracycline at a dose rate of 20 mg/kg bodyweight 
was 8.56 ng/ml achieved at 2.53 h after injection. The AUC was 236 n g/ml «h and the 
elimination half time (T1/2) was 16.5 h. The Cmax following IM administration of a long acting 
formulation containing 300mg/ml oxytetracycline at a dose rate of 30 mg/kg bodyweight was 
10.72 ng/ml achieved at 4.64 h after injection. The AUC was 384 pg/ml'h and the 
elimination half time (T1/2) was 20.8 h (Clark and Dowling, 2003). Judging this data set 
probably overestimates both curves. 
In a study reported by the manufacturer, American Cyanamid, aureomycin (CTC) 
was fed orally to 6 Angus heifers (ave. 425 lbs. bodyweight) at a dose rate of 5 mg/lb (11 
mg/kg) in 4 lb of concentrate for 4 days (American Cyanamide Company, 1991). A peak 
plasma drug concentration of approximately 0.2 jig/ml was achieved approximately 12 h 
after feeding. Studies to independently confirm these data in the peer-reviewed literature are 
lacking. 
Nouws et al. (1983) found that OTC exhibits age-dependent pharmacokinetics in 
ruminants. Following intravenous administration of OTC at 7.5 mg/kg bodyweight to 3-
week-old calves, the AUC was 3569 mg/min*L and the T1/2 was 13.5 h. The volume of 
distribution (Va (area)) in calves was 2.48 ± 0.19 L/kg. In adult dairy cows, at drying off, 
administered OTC intravenously at 7.94 mg/kg bodyweight, the AUC was 8774 mg/min*L 
and the T1/2 was 10.3 h. The volume of distribution (Va (area)) in calves was 0.8 ± 0.11 L/kg. 
These authors surmised that the difference in AUC was related to decreases in Va (area) and 
plasma clearance associated with decreases in extracellular and total body water. They 
concluded that the recommended dose levels of OTC in young calves should be twice those 
employed in cows for obtaining similar plasma OTC concentration-time profiles. Differences 
in volume of distribution were also reported by Ames et al. (1983) who compared the 
pharmacokinetics of OTC in sick and healthy calves. 
Cunha and Mattoes (2002) reviewed the pharmacodynamics of tetracyclines that were 
described as time-dependant. In other words, the time that plasma drug concentrations remain 
above the minimum inhibitory concentration (MIC) of the pathogen (T > MIC) is the best 
predictor of antimicrobial activity. These authors state that if the area under the plasma 
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concentration versus time curve (AUC) approaches 2-4 times the MIC value of the organism, 
the bacteriostatic effect is maximized. Generally for these agents the T > MIC should be at 
least 50% of the dosing interval for immunocompetent patients, whereas 
immunocompromised patients may require T > MIC for 100% of dosing interval. The 
specific pharmacodynamics of OTC against rickettsial organisms has not been described in 
the published literature. 
Chemosterilization of persistent A. marginale infections with tetracyclines 
Tetracyclines administered by injection 
Foote and Wulf (1952) were the first to report successful chemosterilization of A. 
marginale infections using aureomycin (Chlortetracycline). This study treated 3 animals with 
a 2% solution of aureomycin. The first cow was treated during the acute phase of the disease 
when the percent parasitized erythrocytes (PPE) was 65%. An initial dose of 10 mg/lb (22 
mg/kg) was administered followed by a dose of 11 mg/kg and a third dose of 22 mg/kg 
administered at 24-hour intervals. Two days later the cow received 11 mg/kg, and 8 h later a 
further 5.5 mg/kg aureomycin. Blood from this cow was inoculated into two susceptible 
splenectomized calves, 30 days apart. Neither calf developed anaplasmosis. 
The second cow in this experiment had been classified as a carrier for 4 years. This 
cow received an initial dose of 13.6 mg/lb (30 mg/kg) followed by a second injection of 15 
mg/kg administered 12 h later. On the second day, 10 h after the second injection, this cow 
received 9.09 mg/lb (20 mg/kg) followed by another 6.81 mg/lb (15mg/kg) administered 12 h 
later. A final injection of 15 mg/kg was administered 12 h after the 4th injection. The third 
cow in this experiment had been a carrier for 4 months and was treated initially with 17.86 
mg/lb (40 mg/kg) followed by an injection of 7.14 mg/lb (16 mg/kg) 12 h later. On the 
second day this cow received 10.71 mg/lb (24 mg/kg) followed by another injection of 16 
mg/kg 12 h later. This was repeated for the last time 12 h after the 4th injection. Six days after 
treatment 40 ml of blood from each animal was subinoculated into splenectomized calves. 
Neither calf developed clinical anaplasmosis. 
There are a number of factors that confound this first report. Essentially this is a case 
report as animals were not randomly assigned to treatment groups. At the outset, the route of 
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administration was not specified although presumably this was IV. Furthermore, there was 
inconsistency in the dose regimens that were used and there was no control group. In addition 
there were only three animals tested, only two of which were carriers. Based on the 
pharmacokinetics of tetracycline it is likely that animals may still have had circulating drug 
levels at the time when blood was inoculated into splenectomized calves 6 days after 
treatment. Combined, these factors serve to limit any inferences that can be made from these 
results. These deficiencies became more apparent when Splitter and Miller (1953) later 
reported that subinoculation of blood from the cows treated in this experiment proved 
infectious at 67 days after treatment. 
Splitter and Miller reported the apparent eradication of the anaplasmosis carrier state 
in a study conducted in 1953. Ten animals ranging from 80-1,100 lbs were infected with 
carrier blood. These were confirmed infectious by subinoculation of blood into 
splenectomized calves at the time of treatment, which occurred between 33 and 180 days 
after infection. Complement fixation tests were also run to confirm seropositivity. Two 
calves received terramycin (oxytetracycline) at 5 mg/lb/day (11 mg/kg) administered in 
divided doses IV for 14 days. Blood from both animals was not infectious when inoculated 
into splenectomized calves after 240 days post-treatment. One calf received terramycin 
(oxytetracycline) at 1 mg/lb/day (2.2 mg/kg/day) IV for 16 days. This treatment failed. Three 
calves received terramycin (oxytetracycline) by IM injection at 11 mg/kg/day for 14 days. 
One of these received divided doses. Blood from these animals was not infectious when 
inoculated into splenectomized calves after 60 days post-treatment. One calf received 
terramycin (oxytetracycline) at 11 mg/kg/day IM for 12 days. This animal was also negative 
for anaplasmosis at 60 days. Two calves received 15 mg/lb/day (33 mg/kg) aureomycin IV 
for 16 days and one calf received 2.5 mg/lb/day (5.5 mg/kg) for 20 days. The two calves 
treated at the higher dose failed to infect a splenectomized calf at 16 days while the animal 
treated at the lower dose was infectious. 
This case report is also confounded by inconsistency in the dose regimens that were 
applied. In addition to this there were very few replicates tested, which makes comparisons 
difficult. However, in contrast with the study conducted by Foote and Wulf (1952), animals 
were monitored for an extended period of time after treatment and the results therefore 
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appear to be credible. One animal appears to have been cleared of infection, as it proved 
susceptible to re-infection 1 year after treatment. 
Pearson et al. (1957) studied the use of tetracycline against persistent A. marginale 
infections in 30 cattle naturally exposed to infection in Oklahoma. Carrier status was 
determined by a history of clinical anaplasmosis, subinoculation or positive CF test. Cattle 
were divided into three treatment groups comprising 10 animals per group. Within each 
group five animals was treated by IV injection and five animals received intramuscular 
injections. Group A received tetracycline at 5 mg/lb (11 mg/kg) once a day for 5 days. Group 
B received 11 mg/kg once daily for 5 days, were rested for 5 days, and then received an 
additional 5 days of tetracycline at the same dose rate. Group C received 11 mg/kg 
tetracycline for 10 consecutive days. Blood was subinoculated into splenectomized calves at 
intervals ranging from 52-237 days after treatment. Intramuscular treatment was successful 
in all lots. Of those cattle treated intravenously, chemosterilization was successful in two out 
of five cattle in group A, 4 out of 5 cattle in group B and all the cattle in group C. Based on 
these data the administration of tetracycline at 11 mg/kg once daily for 10 days was 
recommended. 
Magonigle et al. (1975) evaluated the effect of five daily treatments with 
oxytetracycline hydrochloride at a dose of 22 mg/kg IV on the carrier status of bovine 
anaplasmosis in eleven 2- to 3-year-old serologically positive cattle. Infection was acquired 
through natural infection on ranches in Idaho. The duration from infection to treatment is 
unknown. Carrier status was confirmed by rapid card agglutination (RCA), complement 
fixation (CF) and inoculation into non-splenectomized calves 8-12 months of age. Carrier 
clearance was confirmed by inoculating 10 ml of blood from carrier cows into 
splenectomized calves at 4 and 12 months after treatment. These calves did not exhibit 
serological, hematological or clinical evidence of A. marginale during the 60-day observation 
period. The results of this study formed the basis for the current OIE recommendation for the 
clearance of the carrier state. The results of this and subsequent studies are summarized in 
Table 1. 
Roby et al. (1978) reported elimination of the A. marginale carrier state with long-
acting oxytetracycline (Liquamycin LA 200, Pfizer Animal Health.). Fourteen 12- to 16-
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month-old Holstein-Friesian calves were experimentally infected with an unspecified number 
of parasitized erythrocytes (Virginia isolate) contained in 5 ml of heparinized blood from a 
known carrier cow. Calves developed clinical anaplasmosis with a rickettsemia between 1% 
and 10% in 3—4 weeks after infection and recovered spontaneously in 60 days. At 64 days 
post-infection, the following treatments were applied to groups of four animals: Group A, 20 
mg/kg IM twice, 7 days apart; Group B, 20 mg/kg on three occasions, 7 days apart; and 
Group C, 20 mg/kg on four occasions, 7 days apart. Two animals were treated with 11 mg/kg 
OTC, IV for 12 days as treated controls. At 83 days after treatment, 80 ml of whole 
heparinized blood was subinoculated into splenectomized calves to confirm that the carrier 
cows were free from anaplasmosis. 
Kuttler (1980) repeated this experiment using five Holstein-Friesian cows. Three 
animals were artificially infected with 2 ml carrier blood infected with a Texas isolate and 
two cows received 2 ml blood infected with a Virginia isolate. Animals developed a 
parasitemia and illness. Ten months after infection the cows were treated with 20 mg/kg long 
acting OTC, administered IM twice, 7 days apart. Carrier clearance was confirmed following 
injection of 50 ml blood into splenectomized calves at 124 days after last treatment. 
Magonigle and Newby (1982) successfully cleared carrier infections in fourteen 10-
to 15-year-old cows naturally infected with an Indiana isolate of A. marginale. Carrier status 
was confirmed by CF and RCA following infection the previous summer. Cows were treated 
with 20 mg/kg long-acting OTC administered IM at 3-day intervals for four treatments. 
Carrier clearance was confirmed by inoculation of 10 ml blood into splenectomized calves at 
5 months after last treatment. Calves were monitored for 56 days using RCA and CF. 
Kuttler (1983) successfully cleared carrier infections in 6 cows aged approximately 7 
years and weighing 630 kg. Three animals were artificially infected with a Texas isolate of A. 
marginale and 3 animals were infected with a Virginia isolate. The inoculation dose and 
parasitemia is not known. Animals were confirmed CF and RCA positive after infection. At 
308 days after infection cows were treated with 20 mg/kg long-acting OTC administered IM 
on 2 occasions, 7 days apart. Carrier clearance was confirmed by inoculation of 50 ml blood 
into splenectomized calves at 120 days after last treatment. Calves were CF negative by 52 
days and RCA negative by 72 days following treatment. 
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Swift and Thomas (1983) conducted a carrier clearance experiment using 16 cows of 
unknown age weighing between 491 and 677 kg at the time of treatment. Cows had acquired 
infection through natural exposure to A. marginale infections in Wyoming. Cows were 
confirmed CF and RCA positive although the time from infection to treatment was unknown. 
Cows were divided into two groups of eight cows. The first group received 20 mg/kg long-
acting OTC administered IM on three occasions, 3 days apart. The second group received LA 
OTC at 20 mg/kg IM on four occasions, 3 days apart. Carrier clearance was confirmed by 
inoculation of 5 ml blood from each animal, pooled and injected into three splenectomized 
calves at 120 days after last treatment. 
Rogers and Dunster (1984) demonstrated clearance of carrier infection in 4 yearling 
calves artificially infected with 10 ml of 1% parasitized blood obtained from a 
splenectomized calf infected with a North Queensland (Australia) isolate of A. marginale. 
Parasitemias were confirmed at 7-11 days after infection. Reactions in three cattle were 
controlled with 3 mg/kg imidocarb, 12 days after infection and in the fourth animal with 10 
mg/kg OTC. Animals were confirmed ELISA positive following these treatments. At 73 days 
following infection animals were treated with 20 mg/kg LA OTC divided between IM and 
subcutaneous routes. Injections were administered on 3 occasions, 7 days apart. Carrier 
clearance was confirmed by inoculation of 500 ml blood injected into splenectomized calves 
at 65 days after last treatment. Calves failed to show signs of anaplasmosis for 93 days after 
inoculation. The ELISA test used became negative in 20 days after treatment. 
Ozlem et al. (1988) reported the successful chemosterilization of 4 cows and 13 
young bulls following natural infection with A. marginale in Turkey. Eight animals (four 
Holstein-Friesian cows and four young bulls) had previously shown signs of acute 
anaplasmosis and the remaining nine cattle appeared in good health but demonstrated 
parasites on blood smear. The group of acutely infected animals was treated with 20 mg/kg 
oxytetracycline administered IM on three occasions, 3 days apart. The group of nine 
asymptomatic cattle was treated with 20 mg/kg on two occasions 3 days apart. The authors 
claimed that the absence of parasites on blood smear was evidence of chemosterilization. 
However persistent infection is characterized by sequential rickettsemic cycles ranging from 
102—107 parasitized erythrocytes that occur at approximately 5-week intervals. During these 
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cycles, infected erythrocytes are not always detectable in stained blood smears, but ticks 
were able to acquire A. marginale infection from carrier cattle (Eriks et al., 1989). 
In summary, these data suggest that successful clearance of persistent A. marginale 
infections can be established by administering oxytetracycline intravenously to cattle at 11 to 
22 mg/kg for 5-12 days (Magonigle et al., 1975; Roby et al., 1978). Intramuscular 
oxytetracycline administrations of 20 mg/kg on 2, 3 or 4 occasions at intervals ranging from 
3-7 days were also reported to be effective at eliminating carrier infections (Roby et al., 
1978; Kuttler, 1980; Magonigle and Newby, 1982; Kuttler, 1983; Swift and Thomas, 1983; 
Rogers and Dunster, 1984; Ozlem et al., 1988). 
A major limitation of these previous studies was the dependence on the CF or RCA 
test to determine seronegativity. This criterion was used in many cases as an indicator of 
successful chemosterilization. Recent studies have shown that the CF test detects antibodies 
sooner than the RCA test, but does not detect carriers for as long (reviewed by Potgieter and 
Stoltsz, 2004). Recently a new competitive ELISA test, which uses recombinant A. 
marginale Major Surface Protein 5 (MSP-5), has been developed and marketed in the U. S. 
(Anaplasma Antibody Test Kit, VMRD, Inc. Pullman, WA; Torioni De Echaide et al., 1998). 
Bradway et al. (2001) demonstrated that the sensitivity of the CF test was 20% with a 
specificity of 98%. When this is compared with a sensitivity of 96% and specificity of 95% 
demonstrated for the cELISA test by Torioni De Echaide et al. (1998), it suggests that 
previous studies may have wrongly concluded that seronegativity indicated successful 
chemosterilization. 
A second limitation of many of the published reports is the use of isolates obtained 
from a single location or rarely two locations. Multilocation studies were however 
confounded by small numbers (Kuttler, 1980). Recent studies using modern molecular 
diagnostic techniques have identified distinct phylogenetic differences between isolates of A. 
marginale obtained from different geographic locations (de la Fuente, 2001a). Studies have 
demonstrated that these differences can translate into dramatic differences in the ecology of 
the disease, de la Fuente et al. (2001b) demonstrated that a Florida isolate of A. marginale 
was not tick transmissible whereas an Oklahoma isolate was. This difference was associated 
with changes in MSP-la. Based on these observations it is possible that other phylogenetic 
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differences exist that may translate into differences in antimicrobial susceptibility (see 
section 3). 
Tetracyclines administered in feed 
Brock et al. (1959) first reported a study in which fourteen, 2-year-old Hereford cattle 
were previously experimentally infected with anaplasmosis and therefore assumed to be 
carriers. Cattle were randomly assigned to one of three treatment groups. The dose rate of 
CTC was determined by the average weight of the animals in the lot. Cattle in pen 1 received 
5 mg/lb (11 mg/kg) CTC daily for 60 days. Cattle in pen 2 received 2.5 mg/lb (5.5 mg/kg) 
CTC daily for 60 days and cattle in pen 3 received 1.5 mg/lb (3.3 mg/kg) CTC daily for 60 
days. A CF test was run at 2 weekly intervals during the treatment period and thereafter 
monthly for 3 months. Subinoculation of calves with 500 ml blood from each treated animal 
was conducted at the end of the 60-day treatment period and again 60 days later. 
Splenectomized calves were monitored for 60 days using the CF test and hematological 
methods. All animals were found to be CF negative after the 60-day feeding period. All of 
the calves remained negative for a 60-day period following subinoculation indicating that 
subinoculated blood was not infectious. 
In a second experiment 475 Angus cattle were tested for anaplasmosis using the CF 
test. Nineteen of the animals were positive to the test. One of these was sold and the 
remaining 18 were fed 5 mg/lb (11 mg/kg) CTC for 60 days. Fifteen of these were CF 
negative after 2 months of feeding. No subinoculation tests were conducted to verify that 
blood from these animals was not infectious. Although these studies were not published in a 
peer-reviewed journal, the results of the first study appear credible given that blood from 
each animal was subinoculated twice into splenectomized calves. 
Franklin et al. (1965) conducted two experiments in Texas in which 20 anaplasmosis 
reactor cattle were fed chlortetracycline at 5 mg/lb (11 mg/kg) for 30 and 60 days, 
respectively. Data were compared with a group of 10 known carrier animals, which served as 
a control group. In the first experiment, 10 animals, weighing 690-990 lbs were fed 
medicated feed individually for 30 days. Blood samples were collected monthly for 8 months 
to determine serological status by CF testing. Following treatment, 8 out of 10 cows 
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demonstrated a decrease in serum antibody titer. Blood from treated cattle was inoculated 
into intact calves between 6 and 8 months after treatment. All calves remained negative 
following subinoculation. However it is noteworthy that the method used to determine 
negativity, the subinoculation dose and the duration of monitoring following subinoculation 
was not specified. This significantly curtails the inferences that can be drawn from these data. 
In the second experiment, 10 reactor cows with an average weight of 896 lbs were 
hand-fed 11 mg/kg chlortetracycline for 60 days. Five cows were confirmed carriers by 
subinoculation and the remaining 5 cows originated from an enzootic herd. Blood samples 
for CF testing were collected monthly for 5 months after treatment. At 120 days after 
treatment individual intact calves were inoculated with 5ml of blood from each reactor. 
Seven out of 10 reactors demonstrated a decrease in serum antibody titer at the end of the 
feeding period. All treated cattle failed to infect intact calves following subinoculation. 
However the method used to determine this and the duration of monitoring post-inoculation 
was not specified. Inferences that can be made from these data are also confounded by the 
fact that animals originated from one locality. Furthermore, in the second experiment, 
animals were hand fed which facilitates greater control of intakes than occurs when CTC is 
fed to range cattle. 
Franklin et al. (1966) examined two range herds consisting of 600 cattle that were fed 
various levels of CTC. One herd of approximately 300 head was fed 0.5 mg/lb (1.1 mg/kg) 
daily for 120 days during the winter. Prior to initiation of the feeding trial 60% of the herd 
were found to be CF positive. One hundred twenty days after feeding, 8% of the herd was CF 
positive whereas no animals were found positive on the RCA test. In the second herd of 300 
cattle, the herd was divided into groups that were fed 1 mg/lb, 2.5 mg/lb and 5 mg/lb for 30-
or 60-day periods. The initial herd was 70-75% positive on the CF test. This study was 
primarily conducted to measure the agreement between the CF and RCA test. The results 
indicate that the RCA test was preferable in field situations. Again this paper was not peer 
reviewed and sterilization of infections was not confirmed by subinoculation into 
splenectomized calves. 
Franklin et al. (1967) conducted a study that examined medium and low level feeding 
of chlortetracycline with comparison between the CF and RCA test. In the first experiement, 
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eight intact carrier calves, 8-12 months of age, were fed 2.5 mg/lb CTC per head per day for 
45 days. All calves were negative on both the CF and CA tests at 17 days following 
treatment. All animals were splenectomized at 75 days after the end of feeding. Three calves 
were not fed any antimicrobial and were designated untreated controls. Splenectomized 
calves did not demonstrate any signs of infection although the monitoring period was not 
specified. In a second trial, only 2 carrier calves were fed CTC at 0.5 mg/lb or 1 mg/lb daily 
for 90 and 41 days, respectively. Both calves were negative to the CF and RCA tests after 
treatment and remained negative following splenectomy and challenge. Deficiencies in the 
sensitivity and specificity of these tests make it difficult to comment on whether carrier 
clearance was actually achieved in these animals. The authors conclude that low level daily 
feeding of CTC at 0.5-1 mg/lb CTC for 60-90 days respectively can eliminate the carrier 
state in the non-vector season. 
Sweet and Stauber (1978) conducted a regional serological survey followed by oral 
antibiotic therapy in infected herds in Idaho and southeastern Washington. Of the 3,920 cattle 
from 31 herds that were tested, 214 (5.5%) were found to positive on either or both the CF 
and RCA test. One hundred ten carrier cattle identified in this way were segregated and 
treated by feeding a molasses-barley pellet containing 22 or 110 g/kg oxytetracycline or 
crumbles containing 4.4 g/kg oxytetracycline. Carriers were treated for 45 days to achieve a 
daily consumption of 11 mg/kg/day. There was no difference in the effectiveness of the two 
tetracyclines tested. All 110 animals were found to be seronegative but the paper does not 
specify how long after treatment this testing was conducted. Goff et al. (1990) observed that 
application of the antimicrobial interrupted continuity of stimulation of antibody as detected 
by complement fixation. It may be that these animals were in this refractory period when this 
testing occurred. Furthermore, this study did not include any subinoculation studies. This 
study is therefore confounded by the deficiencies in the sensitivity and specificity of the CF 
test highlighted previously. 
Studies failing to establish chemosterilization using published tetracycline protocols 
Kuttler and others (1980) reported the results of a field trial in Texas involving 43 
naturally infected cows (see Table 2). A. marginale carrier status was identified by CF and 
28 
RCA tests and confirmed by subinoculation of 4 ml of blood from groups of three cows into 
splenectomized calves. Once persistent infections were confirmed, cows were divided into 
three treatment groups. Group A consisted of 15 cows that received 20 mg/kg LA OTC 
administered IM, twice, 7 days apart. Group B consisted of 14 cows that received the same 
dose administered on 4 occasions at 3- or 4-day intervals. Group C consisted of 14 animals 
that received the same injection on 3 occasions, 7 days apart. Animals were tested at 40 and 
90 days after treatment. 
At 40 days, 20 ml of blood from nine cows from each group was collected. In each 
group, three cows were tested individually on a one-to-one basis with splenectomized calves. 
The blood from the remaining 6 cows was pooled and injected into 2 splenectomized calves. 
At 90 days after treatment, 20 ml blood from 3 cows in group A and C and 4 cows in group B 
was inoculated on a one-to-one basis into splenectomized calves. At the end of the study only 
4 of the 43 treated cows were negative for anaplasmosis although serological tests suggested 
a higher number. The authors concluded that the failure in chemosterilization came about due 
to the active circulation of A. marginale infection in the herd at the time of treatment. 
Goff et al. (1990) attempted chemosterilization of 52, eight-month-old steers and 13 
adult cows naturally infected with a Washington strain of A. marginale. Six animals were 
found to be positive on the CF test and 60 animals were positive using an indirect 
immunofluoresence test (IIF). One animal was removed from the study. The remaining 64 
test animals were identified as positive using a DNA probe. At the end of testing, all animals 
were treated with 20 mg/kg LA OTC administered IM on four occasions, 3 days apart. One 
month after treatment, 1 animal was CF positive, 44 animals were IIF positive and 2 animals 
were identified as positive using the DNA probe. Two months after treatment 2 animals 
remained CF positive, 17 animals were positive on IIF and samples from 2 new animals 
hybridized with the DNA probe. 
These data suggest that the drug did not eliminate infections in all cattle. Some may 
have been cleared but in the absence of subinoculation data it would be hard to definitively 
ascertain successful chemosterilization. In this study the drug did clear the level of infection 
to below the sensitivity of the DNA probe and interrupted stimulation of antibodies. These 
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data also indicate that the DNA probe would not be a substitute for using splenectomized 
calves to determine successful clearance of persistent infections. 
The first study to comprehensively question many of the accepted approaches to 
chemosterilization was conducted by our research group and is presented in chapter 3 of this 
dissertation (Coetzee et al., 2005). Forty Angus X S immental steers aged 7 to 9 months at the 
time of treatment were infected with 2 x 109 parasitized erythrocytes obtained from a field 
case of anaplasmosis in Oklahoma. After the steers recovered from acute infection, 
seroconverted, and were confirmed infected using nested PCR followed by DNA 
hybridization, the carrier status of each animal was confirmed by sub-inoculation of blood 
into a separate, splenectomized Holstein calf. 
Carrier steers were blocked by bodyweight and randomly assigned as follows to four 
treatment groups: Treatment A, 300 mg/ml solution of oxytetracycline (Tetradure LA-300, 
Merial Canada Inc.) administered at 30 mg/kg, by intramuscular (IM) injection on day 0; 
Treatment B, the same 300mg/ml solution of oxytetracycline administered at 30 mg/kg, IM 
on day 0 and again on day 5; Treatment C, a 200 mg/ml solution of oxytetracycline 
(Liquamycin LA-200, Pfizer Animal Health) administered at 22 mg/kg, intravenously (IV), q 
24 h for 5 days (a treatment dose that corresponds with current OIE recommendations for 
treatment prior to export). The fourth group consisted of untreated infected control cattle. All 
steers remained positive by nested PCR and cELISA positive at 60 days after treatment. 
Infection was confirmed by subinoculation of blood into splenectomized Holstein calves. 
These results demonstrated that all the treatment regimens tested failed to clear A. marginale 
infections in carrier cattle. 
Aromatic diamidines and carbanilides 
In contrast with the tetracycline antimicrobials, much less is known about the 
aromatic diamidines and carbanilides. This is probably due to their limited application to the 
treatment of protozoal infections in livestock and their high toxicity profile. The action of 
certain aromatic diamidines on Babesia canis was reported by Lourie and Yorke (1939). 
Some of these compounds have since proven safe in the treatment of bovine babesiosis and, 
in some cases, anaplasmosis. Diamidines are either aromatic (diminazene aceturate, 
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pentamidine isethionate, phenamidine isethionate) or carbanilide (amicarbalide, imidocarb 
dipropionate) (reviewed by Lindsay and Blagburn, 2004). Only diminazene aceturate and 
imidocarb dipropionate are currently available for use in cattle in certain territories and will 
be discussed further in this section. 
Diminazene aceturate (Berenil, Hoechst) 
Pharmacology 
Diminazene aceturate was discovered on 16 March 1954 in the research laboratories 
of Farbwerke Hoechst A G. (Gummow et al., 1994). For almost half a century it has been an 
important compound for the treatment of trypanosomiasis and babesiosis. In territories where 
this compound is approved, it is labeled for the cure and prevention of redwater in cattle and 
the cure of babesiosis in dogs and horses. It is also labeled for the prevention of B.a bovis 
infection for 2 weeks and B. bigemina for 4 weeks (De Vos, 1979). This compound is known 
to modulate the effect of primary infection, but also allows the development of premunity, 
which is advantageous in endemic areas (Kuttler, 1988). This feature however precludes the 
widespread use of this compound in chemosterilization protocols at the usual recommended 
dose rate. 
The exact mechanism of action and in vivo behavior of diminazene has only recently 
been elucidated. Initially it was thought that selective blocking of kinetoplast DNA 
replication was the major mode of action against trypanosomes (reviewed by McDougald and 
Roberson, 1988). Newton (1967) reported that diminazene is rapidly and irreversibly bound 
to calf thymus DNA in a ratio of 1 molecule diminazene for every 4 to 5 DNA nucleotides. 
This binding was thought to interfere with DNA synthesis as the spacing of the amidino 
groups of diminazene appeared to be critical to allow the formation of complexes with DNA. 
Contrary to a previous hypothesis, there was no evidence that diminazene intercalated 
between adjacent nucleotide pairs. These trials have not been repeated using DNA derived 
from babesial organisms. 
Pilch et al. (1995) conducted a study that demonstrated that diminazene binds to DNA 
duplexes and to a RNA duplex. DNA binding was accepted to be via complexation into the 
minor groove of AT-rich domains of DNA double helices. However later research found that 
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diminazene can bind to RNA as well suggesting intercalative as well as minor groove 
binding properties. The authors speculate that these findings support previous reports that 
diminazene may also act by inhibiting topoisomerase enzymes. This activity may prevent 
DNA supercoiling and decatenation of original chromosomes and replicates. 
The pharmacokinetics of diminazene in cattle has been studied over the past 10 years. 
Gummow et al. (1994) found that a two-compartment model best described the 
pharmacokinetic behavior of diminazene in cattle. Peak concentrations of diminazene (3.24 ± 
0.16 (ig/ml) were reached 49.8 ± 7.6 min after intramuscular administration of 3.5 mg/kg 
diminazene. Diminazene is widely distributed in the body with a volume of distribution 
(VdSs) of 2.1 L/kg. The compound also appears to be very slowly eliminated (T% = 222h). 
This resulted in a mean residence time of 13.27 days. The authors suggested that these data 
support a pre-slaughter withdrawal period of 66-83 days. This has precluded the registration 
of this compound in many territories including the European Union and the U.S. 
Chemosterilization of persistent Babesiosis infections with diminazene aceturate 
The clinical application of diminazene therapy has been reviewed by Kuttler (1981). 
The usual intramuscular dose rate is 3-5 mg/kg but Kuttler found that it was effective against 
B. bigemina at much lower levels. Dosages ranging from 0.5-3.0 mg/kg were highly 
effective. This study concluded that 0.5 mg/kg was the lowest effective dose. There was no 
evidence of continued carrier infection at 1-3 mg/kg but this was not confirmed by 
subinoculation. 
Barnett (1965) studied the chemotherapy of B. bigemina (Onderstepoort isolate) 
infection in splenectomized calves as the course of parasitemia in intact calves was thought 
to be too mild for chemotherapy trials. Four calves in this study were aged 12-18 months. 
Diminazene was administered subcutaneously as a 7% solution at 1.5 mg/kg, 2.5 mg/kg, 3.5 
mg/kg and 5 mg/kg to each of the four calves. The animal treated with 1.5 mg/kg died. At 2.5 
mg/kg, animals recovered with no relapses. Following administration at 3.5 mg/ kg, blood 
was cleared of parasites in 24-32 h. The animals that received 2.5 mg/kg and 3.5 mg/kg were 
immune to challenge at 78 and 109 days, respectively, after treatment. The calf treated with 5 
mg/kg was challenged at 68 days after treatment and died from the resulting infection. The 
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author concluded that a dose of 5 mg/kg resulted in chemosterilization based on the 
assumption that circulating parasites would have maintained a state of premunity. However, 
it is impossible to make general recommendations based on a study involving one animal and 
an expansion of this trial involving a larger number of intact animals has not been done. 
Denning (1974) reviewed studies examining the chemosterilization potential of 
diminazene against babesiosis in cattle. These studies also support the finding that B. 
bigemina responds to lower dose rates than B. bovis. Variable chemosterilization was 
reported after treatment at a dose rate of 5 mg/kg bodyweight. Denning concluded that these 
findings make it impossible to make recommendations about the dose rate for sterilization of 
B. bigemina infections. He speculated that eradication of B. bigemina should be reached at 
dose rates of 7-10 mg/kg bodyweight. However no data was provided to support this 
hypothesis. 
Dwivedi and Gautam (1977) found that injecting diminazene at 6 mg/kg between 4 
and 6 days post-infection with B. bigemina resulted in inadequate development of immunity 
causing animals to be susceptible to reinfection. These results suggest that this dose was 
sufficient to sterilize the infection in the early stage of disease thereby preventing the 
development of a preimmunizing carrier state (Sergent, 1965). In a second experiment these 
authors treated four B. bigemina carrier animals with 10 mg/kg diminazene. This dose 
appeared to sterilize infections based on the failure of 500 ml subinoculated blood from 
treated animals to infect susceptible splenectomized calves. 
For B. bovis, Denning (1974) suggested that a dose rate of 7 mg/kg bodyweight was 
required for chemosterilization. However it is noteworthy that the same review found that 
dose rates of 10.6 mg/kg were not able to sterilize Babesia argentina infections. Subsequent 
studies have shown that B. bovis and B. argentina are in fact synonymous, which calls into 
question the validity of the 7 mg/kg chemosterilization dose rate reported for B. bovis 
(Potgieter, 1978). 
Chemosterilization #/Babesia infections with diminazene in other species 
In horses a dose rate of 5 mg/kg administered on two occasions, 24 h apart was found 
to eliminate Babesia caballi infections (Kirkham, 1969; Frerichs and Holbrook, 1974). Dogs 
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infected with Babesia gibsoni were treated with diminazine administered at 11 mg/kg twice, 5 
days apart (Fowler, 1972). These animals had demonstrable parasites when they were 
euthanized 79-93 days after treatment was started. Failure of chemosterilization was 
demonstrated by the inoculation of an intact dog with blood from a treated animal taken prior 
to euthanasia. Diminazene is not recommended for administration at dosages in excess of 7 
mg/kg due to the risk of CNS toxicity (Kuttler, 1988). 
Use of diminazene against anaplasmosis infections 
In a study conducted by Sharma (1986), the therapeutic and chemoprophylactic 
effects of diminazene and LA OTC against A. marginale were compared. Both compounds 
were administered at 20 mg/kg, which is almost 6x the recommended dose rate for 
diminazene. Diminazene was found to have negligible prophylactic effects whereas LA OTC 
ameliorated subsequent anaplasmosis infections. However, calves treated with OTC or 
diminazene and oxytetracycline showed normalization in body temperature and a reduction 
in parasitemia within 7-9 days of treatment. No other reports of chemotherapeutic effects of 
diminazene against A. marginale could be found in the published literature. 
Imidocarb dipropionate (Imizol, Schering Plough Animal Health) 
Pharmacology 
Imidocarb dipropionate is a carbanilide derivative that has been used for over 30 
years in the treatment of bovine babesiosis and anaplasmosis in certain territories (McHardy 
and Simpson, 1974). It is also used for the treatment of babesiosis in horses and dogs. 
Schmidt et al. (1969) screened a large number of di-basic compounds against experimental 
Babesia rodhaini infection in mice. Compound No. 3, which was designated as 3,3 -bis-(2-
imidazolin-2-yl) carbanilide (4A65) was found to be most effective. This compound was 
later named imidocarb. 
Early formulations utilized the dihydrochloride salt, but this was replaced by the 
dipropionate salt, which was found to produce less tissue irritation (Roby and Mazzola, 1972; 
Kuttler, 1988). Imidocarb is usually administered by subcutaneous or intramuscular injection 
to cattle at a dose rate of 2.1 mg/kg for activity against anaplasmosis. The recommended dose 
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rate for the treatment of B. bigemina, B. bovis and B. divergens infections is 1-3 mg/kg 
administered IM or SC (Callow and McGregor, 1970). Intravenous administration is 
contraindicated (Kuttler, 1981). 
The mode of action of imidocarb is uncertain although two mechanisms have been 
proposed. The first is interference with the production and/or utilization of polyamines and 
the second is prevention of entry of inositol into the erythrocyte containing the parasite 
(EMEA, 2001). Bacchi et al. (1981) examined the effect of injecting polyamines into mice 
infected with Trypanosoma brucei and then treated with imidocarb or amicarbalide. These 
workers found that therapy with carbanilide antimicrobials was highly efficacious without 
concurrent polyamine administration. However, administration of the polyamine spermadine 
blocked cures by imidocarb administered at 5 and 10 mg/kg. At doses of 30 mg/kg and 
higher, spermadine decreased survival time. In an earlier experiment these workers 
demonstrated that imidocarb and amicarbalide at 250 p.M inhibited uptake of radiolabeled 
spermadine by 26% and 29%, respectively (Bacchi et al., 1980). Similar studies have not 
been conducted using A. marginale or Babesia organisms. However it is thought that these 
drugs would act in a similar manner against these organisms. 
Pharmacokinetic data and reports on plasma concentrations of imidocarb that may be 
effective for therapy in cattle are deficient in the published literature. Studies in sheep, goats, 
dogs and horses have been conducted. 
Aliu et al. (1977) conducted a study that evaluated the absorption, distribution and 
excretion of imidocarb in sheep. Unfortunately the authors did not conduct any 
pharmacokinetic modeling of these data, which significantly limits the usefulness of this 
information. In the first part of the study, imidocarb was administered IV at a dose rate of 2 
mg/kg to three sheep. A mean initial plasma drug concentration of 10.8 gg/ml was recorded 
which decreased to 1.9 fig/ml within 1 h. In the second part of the experiment 4.5 mg/kg was 
administered IM toseven sheep. A mean peak plasma drug concentration of 7.9 ng/ml was 
achieved within 4 h, which decreased to 4.6 (xg/ml within the next 2 h. 
Trace amounts of imidocarb were still present in the plasma at 4 weeks after 
administration. The concentration of the drug in the plasma and red blood cells were 
approximately equal. It was found that 11-17% of the administered IM dose was excreted in 
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the urine after 24 h. Renal clearance of imidocarb was less than the glomerular filtration rate, 
indicating net tubular reabsorption. The authors suggest that this process is probably by 
passive back diffusion rather than by an active transport mechanism. From the 3rd day to the 
28th day, plasma T% was calculated to be 10.9 days. Imidocarb appeared to be between 20.7% 
and 53.3% protein bound. 
Abdullah and Baggot (1983) examined the pharmacokinetics of imidocarb in seven 
normal dogs and eight goats. An intravenous bolus dose of a 12% imidocarb dipropionate 
solution was administered at 4 mg/kg. A two-compartment model most closely described the 
disposition of imidocarb in dogs but in individual goats a three-compartment model was 
more appropriate. Since imidocarb is a weak base, a comparatively large volume of 
distribution was observed (Vdarea = 0.432 L/kg in dogs and 0.544 L/kg in goats). The half-life 
was determined to be 3.45 h in dogs and 4.18 h in goats. 
The larger volume of distribution in goats was thought to be due to passive diffusion 
of the drug into the rumen fluid where it may become ion trapped. Complete elimination of 
imidocarb appeared to be prolonged in goats as evidenced by a high ratio of the 
concentration in the peripheral versus central compartment (6:1) compared with 2.5:1 in 
dogs. This could be attributed partially to passive reabsorption of unchanged imidocarb from 
the renal tubules as was reported in sheep. As imidocarb is a weak base, it will be completely 
ionized in the more acidic urine of dogs and therefore more completely excreted. 
Belloli et al. (2002) described the pharmacokinetics of imidocarb dipropionate in 
horses after intramuscular injection. Eight horses received a single injection of 2.4 mg/kg 
imidocarb which was followed by blood, fecal, urine and milk sampling. Twelve h after 
treatment, no detectable plasma concentrations were recorded in any of the treated animals. 
Disposition of imidocarb conformed to a two-compartment model. The drug appeared to be 
rapidly absorbed with a mean peak plasma concentration (CmaX) of 0.39 ng/ml attained at 
1.16 h (Tmax) after injection. The AUC was 1.02 gg/mleh and the elimination half time (Ti/%) 
was 5.14 h. 
The only published study describing the kinetics of imidocarb in cattle was presented 
by Good (1998) at the 50th meeting of the Joint FAO/WHO Committee on Food Additives 
(JECFA). In a study which complied with the principles of Good Laboratory Practice, six 
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lactating cows and eight calves were given a single subcutaneous injection of 3 mg/kg 14C-
imidocarb dipropionate which was formulated as Imizol Injection (Schering Plough Animal 
Health). A mean peak blood concentration of 1300 jig-equivalents/kg was attained 1 h after 
treatment and the concentration remained at this level for approximately 4 h. The labeled 
product was 72-90% bound to plasma proteins. Furthermore, excretion was very slow over 
the first 10 days. Residues in tissues were also very persistent, particularly in the liver where 
mean residues of 2200 jxg-equivalents/kg were found 90 days after treatment (Ferguson, 
1996). These observations are confirmed by other reports suggesting a prolonged retention of 
the drug in edible tissues (EMEA, 2001). This has restricted the use of this compound in food 
producing animals in many territories including the U.S. 
Adams and Corrier (1980) studied the toxicity of imidocarb dipropionate in cattle. 
Calves were injected twice, intramuscularly with 0, 5, 10 or 20 mg/kg doses. Transient 
dosage-dependent signs of toxicity consisted of excessive salivation, serous nasal discharge, 
diarrhea and dyspnea. Microscopic lesions at high doses included acute severe renal tubular 
necrosis and focal hepatocellular necrosis. Injection site reactions varied from microscopic 
areas of necrotizing myositis at the 5 mg/kg dosage to grossly visible areas of necrosis at the 
20 mg/kg dosage. All five calves injected with 20 mg/kg died. Mortality did not occur at the 
5 or 10 mg/kg dosages. Many of the toxic effects are associated with rapid but reversible 
inhibition of acetylcholine esterase (Michell et al., 1986). 
Chemosterilization of persistent Babesiosis infections with imidocarb 
Callow and McGregor (1970) were the first to examine the chemosterilization of 
imidocarb against B. argentina (bovis) and B. bigemina infections in cattle. Fourteen of 18 
steers treated for primary B. argentina infections using 0.25-1 mg/kg imidocarb were 
examined at 7-13 weeks after treatment. All except one steer was shown to be infected. Two 
calves treated with 0.6 mg/kg and one treated with 0.4 mg/kg imidocarb were examined 1 
month after treatment for B. bigemina infections. No signs of infection were apparent on 
blood smear. Following this, 100 ml of blood from each calf was inoculated IV into 
susceptible splenectomized calves. These transmission tests were negative although the 
37 
authors do not specify how animals were monitored or for how long after inoculation this 
monitoring was conducted. 
In a second experiment, these authors established mixed B. argentina (bovis) and B. 
bigemina infections in 16 steers. Eight steers were administered 10 mg/kg imidocarb SC. 
Transmission tests using 500 ml of blood were negative for the eight treated animals but the 
eight control animals produced mixed infections in the splenectomized calves. In a third 
experiment these authors studied established B. argentina (bovis) infections in 20 steers that 
had recovered from clinical infections. These were allocated to five groups of four animals 
per group. Groups were treated with 0.5, 1, 2, 4 or 8 mg/kg imidocarb. On examination all 
steers treated with 2, 4 and 8 mg/kg were negative but again the authors did not specify after 
how long, in what way or for what period time animals were monitored. 
Roy-Smith (1971) infected splenectomized calves with blood from an apparently less 
susceptible strain of Babesia bigemina in Australia. The origin of this strain was an animal 
that had been prophylactically treated with 2 mg/kg imidocarb 23 days previously. The 
splenectomized calves were treated with 0.4 mg/kg imidocarb as described by Callow and 
McGregor (1970). However in this instance, chemosterilization was not achieved at this dose 
rate. 
Callow et al. (1974a) conducted a series of experiments aimed at evaluating the 
immunity of animals subsequent to sterilization. In the first experiment, splenectomized 
calves were exposed to 2 x 107S. argentina (bovis) parasites given by subcutaneous 
injection. Infection was confirmed by the presence of parasites on blood smear. To eliminate 
infections, imidocarb was administered at doses of 2 mg/kg or greater based on the results of 
Callow and McGregor (1970). An indirect fluorescent antibody test (IFA) test was used to 
test for the effectiveness of sterilization treatments. This approach is less than optimal given 
the shortcomings of many of the earlier diagnostic tests. As a definitive test, brain smears 
from treated and control animals were examined at 176 days after treatment. Subinoculation 
of blood into susceptible calves would have been preferable as cerebral location is variable. 
This was evidenced by the absence of parasites on the brain smear of one of the control 
animals. 
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This study was repeated by this research group (Callow et al., 1974b) with similar 
results. Only blood from animals not receiving imidocarb was subinoculated into 
splenectomized calves to test persistent infections. It was found that some of these animals 
had apparently eliminated infections and other had not. Both these studies would have been 
greatly strengthened by the subinoculation of splenectomized calves to confirm 
chemosterilization. 
Lewis et al. (1981) conducted a study to examine the effect of treatment with 
imidocarb dipropionate on the course of Babesia divergens infections in splenectomized 
calves. Calves were splenectomized at 3-4 months of age and inoculated 3-5 months later 
with 2 ml of blood containing 1.8 x 106 parasitized erythrocytes. Three groups of three 
animals were treated on day 7, 14 and 21 after infection. Twenty-one days later, 20 ml blood 
was taken from each of the three animals treated with imidocarb on day 21, pooled, and 
inoculated into a splenectomized calf. This process was repeated on day 28 and 35 after 
treatment. All these splenectomized calves remained free of infection although the authors do 
not specify how, or for what period time, animals were monitored. 
Chemosterilization of Babesia infections with imidocarb in other species 
Ogunkoya et al. (1981) reported that imidocarb administered once at 5mg/kg 
bodyweight was found to be highly effective against canine babesiosis caused by B. canis. 
These authors observed that at least 4% of animals treated with this regimen relapsed with 
babesiosis within 3 months. Adeyanju and Aliu (1982) report a study in which 260 dogs with 
clinical B. canis infections were treated with one injection of imidocarb at 5 mg/kg. 
Following treatment, 249 dogs recovered, which represents 95.8% of treated cases. 
Penzhom et al. (1995) first reported successful chemosterilization of B. canis 
infections using imidocarb alone or in combination with diminazene. Seven beagle dogs were 
infected with 2 ml of a whole blood stabilate containing B. canis parasites. Following 
infection dogs were randomly assigned to three treatment groups. Group A consisted of two 
dogs treated with 7.5 mg/kg imidocarb by subcutaneous injection. Group B consisted of four 
dogs treated with 3.5 mg/kg diminazene SC followed by 6 mg/kg imidocarb administered SC 
the next day. Group C consisted of one dog that received trypan blue at 10 mg/kg IV. At 28 
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days after treatment, 5 ml blood was collected in heparinized tubes from the dogs in group A, 
pooled and inoculated into a recipient dog. Similarly blood from the four dogs in group B 
was pooled and subinoculated into a second recipient dog. Fourteen days after first 
subinoculation the animals were subinoculated for a second time using the same procedure. 
None of the treated animals in group A and B or recipient animals developed signs of 
babesiosis during the monitoring period. The dog in group C, however, demonstrated a 
recrudescence of parasitemia on day 15 after treatment. 
Kirkham (1969) reported successful chemosterilization of Babesia caballi infections 
in six horses using imidocarb at 1 mg/lb (2.2 mg/kg) administered on 2 consecutive days. All 
six horses were cleared of the carrier state as determined by subinoculation into a 
splenectomized pony. These authors were not able to clear persistent Babesia equi infections. 
Frerichs and Holbrook (1974) conducted a study using 10 horses infected with B. 
caballi. These were divided into five groups of two horses per group, which were treated 
with 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg imidocarb, respectively. Each animal received two 
injections IM at 24-h intervals. Eight other infected horses were treated with 2 mg/kg 
imidocarb. Four of these horses were in the acute stage of the disease and four were deemed 
carriers. One donkey was kept as an untreated control. B. caballi was eliminated from all 18 
horses as was demonstrated by subinoculation into susceptible horses at 45 days after 
treatment. Drug reactions were minimal at dosage rates up to and including 2.0 mg/kg. 
Frerichs et al. (1973) studied the effect of imidocarb on B. equi infections. Three 
horses and one donkey were assigned to each of three treatment groups. Two horses in each 
group were proven carriers of B. equi by positive subinoculation 30 days previously. The 
other horse and the donkey in each group were in the early stages of infection. Groups were 
treated with 4 mg/kg imidocarb on 4 occasions at 24-, 72- and 168-h intervals, respectively. 
Blood was collected at 18—40 days after final treatment and inoculated into susceptible 
ponies at a rate of 1 ml/kg. Following subinoculation only one animal in Group A (24-h 
interval) and one animal in Group C (168-h interval) appeared to be chemosterilized. All 
animals in Group B (72 hour interval) were negative. All four horses that were still infected 
after the first trial were isolated for 3 months and re-treated with four injections of imidocarb 
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administered IM at 4 mg/kg. All these animals were found to be negative on subinoculation 
after this regimen. 
Chemosterilization of persistent A. marginale infections with imidocarb 
Kuttler (1971) first reported the use of imidocarb for the elimination of Anaplasma 
marginale infections from splenectomized calves. This paper was not published in a peer-
reviewed publication. In the first experiment, two calves were each treated with 15 mg/kg 
imidocarb SC on one occasion. In both cases the animals relapsed at 38 and 35 days after 
treatment. In a second experiment four calves were treated once daily for 3 days with IM 
injections of imidocarb. One calf received a dose of 4 mg/kg, two received 5mg/kg doses and 
one calf received 6 mg/kg. All treated animals failed to show signs of relapsing infections at 
90 days after treatment. A subinoculation dose of 200 ml of whole blood was taken at 90 
days after treatment from one calf treated with 4 mg/kg and the calf treated with 6 mg/kg 
imidocarb. This blood was injected into susceptible splenectomized calves, which were 
monitored for 30 days. Although this study demonstrated that three injections of imidocarb 
administered at 4 mg/kg at 24-h intervals cleared carrier infections, it is confounded by the 
fact that it was conducted in splenectomized calves. Furthermore, the sample size of the 
study was small and the method of assignment to treatment groups was not well defined. 
Roby and Mazzola (1972) reported the elimination of A. marginale carrier infections 
with imidocarb. Ten non-splenectomized adult cattle, aged 2-7 years were obtained from an 
anaplasmosis-free herd. These were infected with 10 ml of heparinized blood from a carrier 
animal originating from Virginia. Four months to two years later animals were enrolled in the 
study. All animals were CF positive. Furthermore, 50ml of blood from each animal had also 
been subinoculated into susceptible splenectomized calves 1 month previously and all 
animals were demonstrated to be infectious. Two salts of imidocarb were used in this 
experiment. The first was the dihydrochloride salt, which had previously shown marked 
swelling and inflammation at the injection site following administration. This reaction was 
attributed to the high acidity of the aqueous solution of the drug (pH = 3.1). The dipropionate 
salt had a pH much closer to neutrality (6.5) and therefore caused fewer injection site 
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reactions. Both salts were injected IM or SC at 5 mg/kg. Where 2 doses were given, the 
second injection was given 14 days later. 
In the first study, five carriers were given a single injection of imidocarb. Two 
animals received the dihydrochloride salt SC, one animal received the dipropionate salt SC 
and two received this salt IM. In the second study, five carriers were given two injections of 
imidocarb, 14 days apart. Three of these received the dipropionate salt IM and the remainder 
received the dihydrochloride salt. Three carrier animals were maintained under similar 
conditions to serve as untreated controls. 
Three tests were used to determine drug efficacy. Complement fixation (CF) tests 
were conducted at 30-day intervals as an indicator of infectivity. Thereafter, 50ml of blood 
was subinoculated into susceptible splenectomized calves at 6 months after treatment. 
Finally, the spleen was surgically removed from treated cattle that had negative results 
following the calf inoculation tests. Giemsa-stained blood smears from splenectomized 
calves were monitored twice a week for 60 days in order to detect the presence of parasites. 
The carrier state was not eliminated from the five cattle given a single injection of 
either salt of imidocarb. The CF test for these five cattle remained positive for 6 months and 
all five cattle were infective for splenectomized calves. In Group 2, which received two 
injections of imidocarb 14 days apart, the CF titre became negative between 4 and 6 months 
after treatment. Susceptible cattle inoculated with this blood did not develop signs of 
infection on blood smear or CF test. All calves were susceptible to A. marginale infection 
after 60 days. Four of the five treated carriers were then splenectomized and none of them 
developed signs of anaplasmosis. The non-treated control animals remained positive for the 
duration of the study. It was also observed that the dipropionate salt caused fewer injection 
site reactions than the dihydrochloride salt. This study seems to be very well conducted 
although there were a limited number of experimental animals examined. 
Kuttler (1975) examined the use of imidocarb to control anaplasmosis in 469 cattle. 
Imidocarb dipropionate was injected intramuscularly, twice, 14 days apart at a dose rate of 5 
mg/kg. Treatment was deemed "therapeutically effective" based on an initial drop in CF 
titres noticed after treatment. This was followed by a gradual increase in titer thought to be 
due to reinfection. One year after treatment the CF level had returned to pretreatment levels. 
42 
It is impossible to draw any inferences from this study given that definitive tests to determine 
the carrier status of animals before and after treatment were not conducted. 
3. Possible explanations for inconsistent elimination of persistent A. marginale 
infections with tetracycline based protocols 
Successful antimicrobial therapy depends on (1) the susceptibility of the organism to 
the antimicrobial, (2) achieving adequate drug concentrations at the site of infection, (3) 
ensuring that drug concentration is maintained for a sufficient duration to be effective, (4) 
pharmacokinetic parameters of the drug, and (5) the local environment (Bidgood and Papich, 
2003). The purpose of this section is to briefly evaluate the chemotherapy of erythrocyte 
associated organisms in light of these requirements. This section aims to highlight some of 
the recent molecular advances that may shed some light on the inconsistent results obtained 
recently with previously published chemosterilization protocols. 
Determining the antimicrobial susceptibility of the organism 
Traditionally pharmacodynamic considerations for bacterial pathogens have been 
addressed in vitro using antimicrobial susceptibility tests such as the Mueller-Hinton broth 
dilution test or the Kirby-Bauer disk diffusion test. These are readily performed for bacteria 
given that these can be grown on agar plates in a laboratory. Susceptibility tests facilitate the 
determination of a minimum inhibitory concentration (MIC), which is the lowest 
concentration of an antimicrobial agent that prevents visible growth of a microorganism in an 
agar or broth dilution susceptibility test (NCCLS, 2002). The extension of these techniques to 
include cell-associated organisms such as A. marginale and Babesia spp. has been 
complicated by the need to grow these organisms in cell culture systems. 
Up until the late 1970s the normal method for screening compounds for activity 
against Babesia infections was based on testing the compound in laboratory rats or mice 
infected with Babesia rodhaini. Schmidt et al. (1969) used this technique to screen basically 
substituted carbanilides, which led to the discovery of imidocarb. However most compounds 
screened against B. rodhaini in this way did not give satisfactory results (Irvin and Young, 
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1977). This was seen as justification to develop an in vitro test, which would also reduce the 
time, cost and numbers of animals involved. 
Irvin and Young (1977) first described a technique utilizing whole blood cultures that 
were incubated overnight in the presence of 3H-hypoxanthine. Incorporation of 3H-
hypoxanthine was measured the next day by liquid scintillation counting. These authors used 
this system to evaluate the inhibitory effects of imidocarb, amicarbalide and diminazene 
against B. rodhaini, B. divergens, B. major and B. ovis. The first two compounds were found 
to be most active against B. rodhaini and B. divergens while diminazene was most active 
against B. major and B. ovis. The authors speculate that this system was successful as 
incorporation of hypoxanthine was essential for nucleic acid synthesis in Babesia. This test 
was therefore a measure of the degree of drug-induced inhibition of nucleic acid synthesis. 
Preliminary studies were also conducted using diminazene-resistant strains of B. rodhaini, 
which suggested that this system could also be used to determine drug resistant patterns. 
Erp et al. (1978) first described a system to culture B. bovis in bovine erythrocyte 
cultures. Blood from parasitized splenectomized calves was incubated at 37° C in a mixture 
of 50% medium 199 and 50% normal bovine serum. Cells were maintained in suspension by 
slow stirring and medium was replaced at 24-h intervals. Persistent multiplication of the 
organism was demonstrated in this system using a short series of subcultures. This suggested 
that this system was capable of being used for the continuous culture of Babesia organisms. 
This system formed the basis of subsequent techniques that culminated in the development of 
the microaerophilus stationary phase (MASP) culture technique by Levy and Ristic (1980). 
The major difference between these techniques was the use of a stationary layer of 
erythrocytes rather than a suspension culture. This proved to be more convenient given that 
the constant stirring demanded by the Erp method was not required. This system has since 
been adapted to perform a variety of screening procedures for potential babesiacides (Nott et 
al., 1990). Excellent reviews of the cultivation of Babesia and Babesia-like blood parasites 
have been published (Kellermann et al., 1988; Schuster, 2002). 
Wyatt et al. (1991) described a method for evaluating the growth and viability of 
cultured intraerythrocytic protozoan hemoparasites using flow cytometry. This assay utilized 
the selective uptake and metabolic conversion of hydroethidine (HE) to ethidium by live 
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parasites in intact erythrocytes. The intercalation of ethidium, a DNA binding fluorochrome, 
into viable parasites allowed the use of fluorescence-activated cell sorting (FACS) to 
distinguish between erythrocytes containing viable organisms and those containing dead or 
no parasites. This system was found to correlate very highly with manual counting of the 
parasite using Giemsa-stained blood films (0.91 for all cell types). Studies with the 
hemoparasite B. bovis utilized this fluorochromasia technique to monitor the effect of 
diminazene on parasites in vitro. As HE conversion and intercalation into DNA is not biased 
by variations in growth rate or life-cycle stages, the interpretation of these data is simpler 
than studies evaluating 3H-hypoxanthine incorporation. Another major advantage of this 
system is the speed with which data can be obtained. 
Initial attempts to grow A. marginale outside the bovine host using cultures of bovine 
bone marrow, rabbit bone marrow, bovine lymph nodes and tissue derived from the mosquito 
Aedes albopictus were only moderately successful (Hidalgo, 1975; Kessler et al., 1979; 
McHolland and Trueblood, 1981). Kessler et al. (1979) demonstrated an initial increase in 
the percentage of parasitized erythrocytes (PPE) within 48 h after the establishment of a 
whole blood culture of A. marginale based on a method used to cultivate Plasmodia. The 
viability of the organism in blood was demonstrated by inoculation of susceptible calves with 
blood collected from the 13 and 33 day cultures in the first and second experiments, 
respectively. Kessler and Ristic (1979) also demonstrated the invasion and development of A. 
marginale in noninfected erythrocytes. 
Davis et al. (1978) demonstrated the synthesis of DNA and protein by A. marginale in 
bovine erythrocytes during short term culture. This was achieved by examining the 
incorporation of radio-labeled [3H] thymidine and [14C] methionine by anaplasmosis in 
culture. These studies illustrate that in vitro cultured anaplasmosis supports many of the 
metabolic processes that are targets for modern antimicrobials and would therefore facilitate 
evaluation of these compounds in vitro. 
In spite of these findings, this whole blood culture system does not support growth of 
the organism for an extended period of time. Recently Munderloh et al. (1996) cultivated A. 
marginale in a cell line derived from embryos of the tick Ixodes scapularis. This system was 
capable of maintaining an infective isolate for more than 4 years (Blouin et al., 2000). 
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Blouin et al. (2002) were able to use this system to examine the effect of tetracycline 
on development of A. marginale in cultured I. scapularis cells. Various concentrations of 
tetracycline (0, 0.01, 0.1, 1.0, 5, 10, 20 and 100 ng/ml) were added in medium to cultures 48 
h after cell monolayers were inoculated with A marginale. Growth of A. marginale was 
evaluated by indirect ELIS A at day 7 post-infection and daily by light and electron 
microscopy. Tetracycline doses of 5, 10, 20 and 100 p.g/ml resulted in significant inhibition 
of A. marginale growth as determined by ELIS A. These concentrations also resulted in 
morphologic deterioration of the organism. Infected cell cultures treated with medium 
containing 20 ng/ml OTC proved non-infective when inoculated into susceptible 
splenectomized calves. These data would suggest that the MIC for oxytetracycline against A. 
marginale would be 20 pg/ml. However it is not known how susceptibility determined in a 
tick cell culture system would correlate with the ability of the drug to inhibit growth of the 
organism in vivo. 
Recently a number of studies have demonstrated the successful use of the human 
promyelocyte leukemia cell line HL-60 to determine the in vitro susceptibility of Anaplasma 
(Ehrlichia) phagocytophilum to a number of antimicrobials (Klein, 1997; Horowitz, 2001). 
This organism is closely related to A. marginale, and is reported to be the cause of human 
granulocytic ehrlichiosis (HGE) (Dumler et al., 2001). A further study using this system 
demonstrated a difference in susceptibility to chloramphenicol and levofloxacin in A. 
phagocytophilum isolates taken from different geographic locations in the U. S. (Maurin et 
al., 2003). In vitro MICs varied from 0.06-0.5 ng/ml, which is reported to be close to the 
maximum levels achievable in human serum. 
Conflicting reports regarding the success of chemosterilization protocols against 
anaplasmosis suggest that possible differences in susceptibility between isolates may exist. 
This hypothesis is supported by the recent identification of two multidrug resistance pumps 
in the genome of A marginale-, although the clinical significance of these pumps has yet to 
be elucidated (Brayton et al., 2005). In the absence of any other obvious differences between 
studies that report carrier clearance and studies that failed to clear the carrier state, the 
concept of resistance should be considered as a possibility. This may be further supported by 
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the fact that nearly 20 years has passed since many of these "successful" studies were 
published. This supports further research in this area. 
Challenges associated with achieving adequate drug concentrations at the site of infection 
The treatment of anaplasmosis and babesiosis, where the primary site of infection is 
within the erythrocyte, is challenging. Sequestration of the organism within the host cells 
limits drug penetration and, consequently, drug efficacy (Shaw et al., 2001). This effect is 
compounded in anaplasmosis where the organism is located within an endocytic vesicle in 
the cytoplasm of the erythrocyte. This would suggest that two barriers to the movement of 
antimicrobials may exist. 
Aliu et al. (1977) found that the concentration of imidocarb in the plasma and 
erythrocytes of sheep were approximately equal. On the other hand, tetracycline 
antimicrobials are not actively accumulated in mammalian cells other than those involved in 
absorption and excretion of the drug. Tetracyclines may however enter cells with altered 
membrane permeability such as occurs following exposure to polymyxin B or amphotericin 
B. It has been hypothesized by Scholar and Pratt (2000) that rickettsiae such as anaplasmosis 
and chlamydiae must be more sensitive to tetracyclines. This is inferred by the fact that these 
organisms grow within the host cells and are therefore exposed to lower concentrations of 
tetracyclines than extracellular organisms. However, few studies have succeeded in 
quantifying the extent to which antimicrobials are taken up by mammalian cells under 
normal conditions. This would be significant in terms of our understanding of the 
chemotherapy of intracellular pathogens. 
A study conducted by Gabier (1991) investigated the fluxes and accumulation of 
tetracyclines by human blood cells (RBCs). Doxycycline (Dc) was found to rapidly enter red 
blood cells with the intracellular concentrations reaching a plateau after approximately 8 min. 
The ratio between intracellular and extracellular tetracycline concentrations ranged from 2.2 -
3.4 in favor of the intracellular concentration. This is not surprising given that Dc is highly 
lipophilic. The addition of 90% serum reduced Dc uptake by 78% but the addition of EDTA 
restored most of the uptake. The accumulation of three other tetracyclines by RBCs was also 
studied. In all cases the rank uptake by RBCs was doxycycline > chlortetracycline = 
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tetracycline > oxytetracycline. The mean intracellular oxytetracycline was estimated to be 6.1 
± 2.0 pg/ml but in the presence of serum this was reduced to 0.9 ± 0.5 (ig/ml. It can therefore 
be concluded that tetracyclines can penetrate RBCs but that this uptake is severely reduced in 
the presence of serum. This raises the question why tetracyclines have proven to be effective 
against intraerythrocytic pathogens given that the site of infection appears to be partially 
sequestered from the drug. 
It is noteworthy that the presence of anaplasmosis infection significantly reduced 
erythrocyte membrane acetylcholinesterase activity. This is associated with an increase in 
osmotic fragility and permeability of erythrocytes. Wallace (1967) conducted a study in six 
splenectomized calves, 4-5 months old, that were inoculated with 50 ml of blood with a 
parasitemia of 70%. Erythrocyte AChE activity was assayed following centrifugation and 
washing of erythrocytes with sodium chloride and standardization of the pH. Two millilitres 
of acetylcholine bromide was added and the mixture was incubated for 1 h at 25 °C. The 
AChE activity was expressed as the corrected change in pH/hour with the correlation being 
made for a negative sample containing water. The results of this study indicated a reduction 
in AChE activity relative to peak anaplasmosis infection. The concomitant increase in 
cellular permeability may lead to a greater accumulation of tetracyclines that would occur in 
the intact erythrocytes. This effect may be enhanced by imidocarb administration, which is 
characterized by rapid but reversible inhibition of acetylcholine esterase. 
Brown et al. (1986) studied blood magnesium values in healthy cattle and in cattle 
affected with anaplasmosis and eperythrozoonosis. Mean erythrocyte magnesium values 
were found to increase significantly from previous periods during hemoparasite infection. 
The mean plasma, serum and erythrocyte magnesium concentrations were correlated to the 
mean percent parasitemia and the packed cell volume (PCV). The erythrocyte magnesium 
levels increased significantly after the parasitemia reached 20% and the PCV began to 
decrease. A strong correlation was observed between the erythrocyte magnesium values and 
the parasitemia occurring 5 days previously and the PCV occurring 3 days previously. 
The observation of increased intracellular magnesium is noteworthy when one 
considers that tetracycline molecules in the cytoplasm are likely to become chelated with 
magnesium since the internal pH and divalent metal ion concentrations are higher than those 
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outside the cell (Schnappinger and Hillen, 1996). Reversible binding of tetracycline through 
a magnesium ion to the A-site of the 30-S ribosomal subunit blocks the attachment of 
aminoacyl-tRNA. An increase in intracellular magnesium concentration due to A. marginale 
infection may therefore trap tetracyclines in the cytoplasm of the erythrocyte. This would 
increase the local concentration of the drug thereby prolonging the attachment of tetracycline 
to the A-site of the ricketttsia. This may also be one of the reasons why tetracyclines appear 
effective during high parasitemias (when intracellular magnesium is high), but are less 
effective during the carrier stage when parasitemias are microscopically undetectable and 
intracellular magnesium concentration is low. 
DeLoach et al. (1981) and DeLoach and Wagner (1984) conducted two experiments 
using imidocarb dipropionate and tetracycline encapsulated in erythrocytes to attempt to 
increase drug concentrations at the site of infection. In the first study, up to 700 jxg imidocarb 
was encapsulated per ml of bovine carrier erythrocytes with no effect on the carrier cells. 
About 22 p.g of drug was found to bind to 1 ml of cells. Drug loaded carrier cells had an in 
vivo half-life of 28-32 days. Injection of drug loaded carrier erythrocytes at 0.1 mg/kg 
bodyweight provided cattle with protection against B. bovis infection for at least 35 days. 
This dose rate is 10-fold lower than the usual dose rate for imidocarb. In the second 
experiment, carrier erythrocytes containing tetracycline were injected into calves and were 
studied for their pharmacokinetic constants. The half-life of the drug was calculated to be 6.7 
h. 
Based on these data it is apparent that encapsulating tetracycline in erythrocytes has 
limited potential for increasing the efficacy of the drug since the elimination of encapsulated 
and free drug is essentially the same. In the case of imidocarb, however, the use of 
encapsulated drugs may offer some advantages if the effect is to lower the required dose. 
Retention of imidocarb in the edible tissue resulting in prolonged meat withhold periods has 
limited the use of this drug in food producing animals in many territories. This technique 
may reduce the amount of drug required and therefore reduce the risk to consumers. 
However, encapsulating erythrocytes is technically demanding and would be difficult to 
apply to field situations. This would significantly limit the application of this technology. 
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Drug pharmacokinetics and challenges to ensure that drug concentration is maintained 
for a sufficient duration to be effective 
The pharmacokinetics of the various tetracycline formulations was reviewed in 
section 2. As discussed previously, Blouin et al. (2002) determined the MIC of tetracycline 
against A. marginale in cultured I. scapularis cells to be 20 (J.g/ml. The applicability ofMICs 
derived using this system has not been investigated and these data should therefore be 
interpreted with caution. 
Pharmacokinetic studies in cattle have found that the maximum plasma concentration 
(Cmax) following IM administration of a long acting formulation containing 200 mg/ml 
oxytetracycline (OTC) at a dose rate of 20 mg/kg bodyweight was 8.56 jig/ml achieved at 
2.53 h after injection. The AUC was 236 pig/ml'hrs and the elimination half time (T,#) was 
16.5 h (Clark and Dowling, 2003). Based on these data, plasma concentrations of OTC above 
the MIC are not attainable following IM administration. The same applies to plasma 
chlortetracycline (CTC) concentrations following oral administration, which do not peak 
above 0.2 gg/ml. Theoretically, therefore, it would appear as though neither IM or orally 
administered tetracyclines achieve adequate serum drug concentrations to be effective against 
A. marginale based on a cell culture derived MIC of 20 ng/ml. 
In vivo pharmacokinetic studies report a mean oxytetracycline plasma concentration 
of 38.5 ± 6.3 fAg/ml achieved at 1 h following IV administration at 22 mg/kg bodyweight to 
adult cows (Bretzlaff et al., 1982). This corresponds with the dose rate and route of 
administration recommended by the OIE. The mean elimination half-life (T 1/2,3) was 6.52 h. 
These data suggest that plasma drug concentrations will decrease to concentrations below an 
MIC of 20 ng/ml within 7-8 h after administration. 
Cunha and Mattoes (2002) state that if the area under the plasma concentration versus 
time curve (AUC) for tetracyclines approaches 2—4 times the MIC value of the organism, the 
bacteriostatic effect is maximized. This criterion appears to be met for OTC against A. 
marginale following IV administration although this has not been validated for rickettsial 
organisms. The second requirement is for plasma OTC concentrations to be above the MIC 
for at least 50% of the dosing interval for immunocompetent patients, whereas 
immunocompromised patients require T > MIC for 100% of dosing interval. The immune 
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status of A. marginale carriers will be discussed in more detail in the next section. However it 
would appear as if these should be classified as immunocompromised. Under these 
circumstances, the IV dosing interval would need to be 8 h in order to maintain plasma drug 
concentrations above the MIC. In vivo studies to confirm the validity of this hypothesized 
dose rate and interval have not been conducted. 
The effect of the local environment, most notably the immune system, on 
chemosterilization protocols. 
The ability of A. marginale to persist in a fully immunocompetent host suggests that 
persistence involves a mechanism of escape from the immune response. The identification of 
repeated cycles of rickettsemia, each composed of a progressive, logarithmic increase in 
organisms followed by a precipitous decrease, led to the hypothesis that persistence reflects 
the sequential emergence and subsequent immune control of antigenic variants (Palmer et al., 
2000). 
Distinct outer membrane proteins, termed major surface proteins (MSPs) have been 
identified on A. marginale organisms derived from bovine erythrocytes. These proteins are 
targets for the host immune response and can also be used in diagnostic assays. MSP1 has 
been reported to be an adhesin for bovine erythrocytes and tick cells and affects the ability of 
the organism to be transmitted by ticks (de la Fuente et al., 2002). This protein has been 
shown to confer partial protection in immunized cattle. 
MSP2 and MSP3 are both encoded by large polymorphic multigene families. The 
MSP2 sequence specifically varies during cyclic rickettsemia. It has been demonstrated that 
unique MSP2 structural variants arise in each cycle of persistent rickettsemia and that a 
specific immune response to MSP2 is associated with organism clearance (French et al., 
1998). Variation in MSP3 has been demonstrated between geographic locations (Kocan et 
al., 2000). Antigenic variation in MSP2 and MSP3 occurs by gene conversion of whole 
pseudogenes and small segments of pseudogenes into a single expression site. This provides 
an efficient mechanism to generate the large number of variants seen during sequential cycles 
of persistent infections (Brayton et al', 2003). Little is known about MSP4, but MSP5 has 
been shown to be conserved on all isolates of A. marginale and has proven to be a good 
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diagnostic antigen for use in a newly developed competitive ELIS A test (Torioni De Echaide 
et al., 1998). 
Bacteriostatic antimicrobials by definition arrest bacterial growth and therefore 
require a competent host immune response in order to facilitate elimination of the infectious 
agent under treatment. This is especially relevant in the case of the tetracycline 
antimicrobials where binding to the 30S ribosomal subunit is reversible. The absence of a 
synergistic relationship between oxytetracycline activity and the host immunity in carrier 
animals may therefore give rise to the variable success observed in clearing these infections 
in carrier animals. 
Taylor-Robinson and Furr (2000) concluded that successful antibiotic intervention 
with oxytetracycline in Mycoplasma infections depends to a large extent on the ability of the 
host to mount an adequate immune response. This was demonstrated by contrasting the 
successful eradication of Mycoplasma infections following tetracycline therapy in 
immunocompetent mice with the failure to eradicate infection following therapy in immune 
incompetent nude mice. 
The importance of an activated cell-mediated immune response (CMI) in clearing the 
carrier state of anaplasmosis following oxytetracycline therapy was reported by Eckblad et 
al. (1979) and Lincoln et al. (1982). These workers investigated the effect of administration 
of a long acting oxytetracycline formulation during the prepatent period of anaplasmosis 
infection. Each carrier cow was infected with an intramuscular injection of 15 ml of pooled 
blood from two carrier cows with a 1% and 4% parasitemia, respectively. Oxytetracycline 
treatment was initiated at a dose rate of 20 mg/kg by deep intramuscular administration with 
a maximum injection site volume of 10 ml/site. The three treatment groups received 
treatment on day 7 (T2); day 7 and 14 (T3); and day 7, 14 and 21 (T4) after the day of 
exposure. 
All cows developed evidence of infection as seen by a 0.5% or greater parasitemia 
and a positive CF and RCA test. The mean prepatent period for groups T1 through T4 was 
17, 44, 55 and 62 days, respectively. Although treatment with oxytetracycline did not prevent 
infection, drug exposure did appear to ameliorate the severity of clinical disease. Given the 
failure of any of the treatment regimens to clear the carrier state, the authors hypothesized 
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that a synergism was required between the drug and the acquired immune response. The 
authors concluded that the administration of oxytetracycline in the prepatent period would 
suppress growth of the organism, but because the CMI system was not fully activated, the 
effect was to prolong the incubation period without eliminating infection. 
Abbott et al. (2005) recently reviewed the immune response of cattle against 
persistent A. marginale infections. The control of the sequential rickettsemic cycles during 
persistent infection is associated with development of a variant-specific IgG response, in 
particular, IgG2 (French et al., 1999). Furthermore, numerous MHC class II-restricted CD4+ 
T cell epitopes in the conserved and hypervariable region induce T cell help in order to 
generate variant specific antibodies. IgG responses appear to be directed primarily against 
epitopes in the hypervariable region, whereas CD4+T cell proliferative and IFN-7 responses 
are directed against multiple epitopes within the conserved and hypervariable region (Brown 
et al., 2001). 
In a study to investigate the stimulation and maintenance of anamnestic responses by 
specific MSP2 variants to which animals had been immunized, Abbott et al. (2005) describe 
the rapid and long-term disappearance of CD4+ T lymphocyte responses specific for A. 
marginale MSP2 in vaccinate animals following challenge with live A. marginale. This 
report suggests that this finding indicates a newly discovered immune modulation whereby 
antigen-specific T cell responsiveness is lost upon rickettsial challenge. These findings may 
be significant in terms of our understanding of the relationship between the immune response 
and the effect of an antimicrobial against persistent A. marginale infections. It is apparent 
that the relationship between chemotherapy with rickettsiastatic antimicrobials and the 
immune system is extremely complex and requires further examination. 
4. Future developments in the field of chemosterilization of persistent rickettsial 
infections 
Recently a number of studies have demonstrated the successful use of the human 
promyelocyte leukemia cell line HL-60 to determine the in vitro susceptibility of Anaplasma 
phagocytophilum to a number of antimicrobials (Klein et al., 1997; Horowitz, 2001). This 
organism is closely related to A. marginale and is reported to be the cause of human 
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granulocytic ehrlichiosis (HGE) (Dumler et al., 2001). This system has highlighted the 
fluoroquinolones as a class of antimicrobial with efficacy against A. phagocytophilum. 
Enrofloxacin is a fluoroquinolone antimicrobial which inhibits bacterial DNA-gyrase 
(topoisomerase II) and topoisomerase IV (Blondeau, 2004). This activity prevents DNA 
supercoiling and decatenation of original chromosomes and replicates. The bactericidal 
activity of enrofloxacin is concentration dependent, with susceptible bacteria cell death 
occurring within 20-30 min of exposure. 
Two published reports indicate that enrofloxacin (Baytril®, Bayer Animal Health) is 
effective against acute A. marginale infections at dose rates of 5-10 mg/kg (Schroder et al., 
1991; Guglielmone et al., 1996). However the dynamics of the infection following treatment 
and the potential for elimination of the carrier state has not been assessed. The need for 
additional trials to study whether enrofloxacin is useful to control severe anaplasmosis 
infections has been identified (Guglielmone et al., 1996). 
Schrevel et al. (1996) recently reviewed new trends in chemotherapy of human and 
animal blood parasites. These workers highlight a recent study that demonstrated activity of 
the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, Lovastatin 
and Simvastatin against in vitro cultured Plasmodium falciparum and B. divergens (Grellier 
et al., 1994). These agents are believed to work on the isoprenoid pathway, which is 
important for the activation of mitogenic proteins. These agents are currently used in human 
medicine to treat hypercholesterolemia, but in the future they may be used to potentiate the 
effect of many existing antimicrobials used in chemosterilization protocols. 
In addition to these agents, Schrevel et al. (1996) describe studies examining the 
effect of microtubular drugs, paclitaxel (Taxol) and its analog, docetaxel (Taxotere), on P. 
falciparum erythrocyte development. These compounds bind to polymerized tubulin 
stoichiometrically and inhibit depolymerization. These anti-tumor agents may play a role in 
blocking nuclear division in the parasite. Stich et al. (2004) recently demonstrated that 
Anaplasma marginale assembles an actin filament bundle during intracellular infection. 
These F-actin appendages are assembled on the cytoplasmic surface of a vacuole containing 
several organisms. Interestingly, comparison of the Florida, Illinois, St.Maries and Virginia 
strains revealed substantial polymorphism in the gene encoding the appendage associated 
54 
protein. This suggests that while the actin filament bundle may serve as a useful target for 
antimicrobials, the response to therapy may vary between isolates. 
Future advances in molecular biology and x-ray crystallography may allow the 
identification of novel drug targets resulting in the development of a new generation of 
antimicrobials. Techniques must be developed to effectively screen these new compounds in 
vitro and ultimately to evaluate efficacious compounds in a representative population of 
animals. Finally, novel drug delivery systems may be required to optimize exposure of the 
organism to efficacious plasma drug concentrations. 
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Table 1: Summary of published papers successfully using parenteral oxytetracycline (OTC) to clear the persistent A. 
marginale infections 
Reference Age/Weight 
of Carrier 
Type of 
Infection 
and Source 
Carrier Confirmation Infection to Treatment 
Sample 
Size 
Ilf 
Route No. of Treatments 
Confirmation of 
Clearance 
Magonigle 2 to 3 years Natural RCA, CF, Inoculation Unknown 11 22 IV Daily for 10 ml blood into 
etal. (1975) (Idaho) onto NON-
SPLENECTOMIZED 
8-12 month Calves 
5 days SPLENECTOMIZED 
calves at 4 and 12 
months after treatment 
(monitored for 60 days); 
RCA -ve/ CF +ve 
Roby et al. 12 to 16 Artificial Infection 3 to 4 weeks 64 Days 4 20 IM Twice 80 ml blood into 
(1978) months (Virginia) after inoculation 7 days apart SPLENECTOMIZED 
(254 to 343 5 ml of (1 - 10% parasitemia) 4 20 IM 3 times calves at 83 days after 
kg) carrier blood CF POSITIVE 
4 
2 
20 
11 
IM 
IV 
7 days apart 
4 times 
7 days apart 
Daily for 
12 days 
last treatment 
Kuttler Holstein- Artificial Parasitemia and illness. 10 Months 5 20 IM Twice 50 ml blood into 
(1980) Friesian 
Cows 
3 Texas 
2 Virginia 
2 ml of 1:10 
dilution 
Seropositive 7 days apart SPLENECTOMIZED 
calves at 124 days after 
last treatment 
Magonigle 
and Newby 
(1982) 
10 to 15 
years 
(494 kg 
ave) 
Natural 
(Indiana) 
Serology 
(RCA and CF) 
Diagnosis in 
previous 
summer 
14 20 IM 3 day 
intervals 
for 4 
treatments 
10 ml blood into 
SPLENECTOMIZED 
calves at 5 months after 
treatment (monitored for 
56 days); 
RCA -ve/1 CF +ve 
Kuttler 
(1983) 
7 years 
(630 kg 
avg) 
Artificial 
3 Texas 
3 Virginia 
CF and RCA positive 308 Days 6 20 IM 2 Injections 
7 days apart 
50 ml blood into 
SPLENECTOMIZED 
calves 120 days after 
treatment. 
CF -ve 52 days/ RCA -
ve 72 days 
Table 1 (continued) 
Reference 
Swift and 
Thomas 
(1983) 
Age/Weight 
of Carrier 
Unknown 
491-677 kg 
Type of 
Infection 
and Source 
Carrier Confirmation Infection to Treatment 
Sample 
Size 
Drug 
Dose 
jssâsl 
Natural 
Wyoming 
CF and RCA positive Unknown 20 
20 
Route 
IM 
IM 
No. of 
Treatments 
3 Injections 
3 days apart 
4 injections 
3 days apart 
Confirmation of 
Clearance 
5 ml blood from each 
animal POOLED and 
inoculated into 3 
SPLENECTOMIZED 
calves 120 days after 
treatment 
Rogers and Yearling Artificial 10ml of 1% parasitemia 
Dunster Australia blood inoculated IV. 
(1984) Parasitemias 7-11 days 
later. Reactions in 3 
cattle controlled with 
Imidocarb 12 days after 
infection. Remaining 
animal got 10 mg/kg 
OTC at 15 days. ELIS A 
positive. 
73 Days 20 IM/S 
C 
3 Injections 
7 days apart 
500 ml of blood into 
SPLENECTOMIZED 
calves 65 days after 
treatment. Monitored for 
93 days. ELISA 
negative in 20 days after 
treatment. 
ON 
00 
Ozlem et al 
(1988) 
Unknown Natural 
Infection 
(Turkey) 
Acute Clinical Infection Unknown 
Blood smear Unknown 
3 injections 
3 days apart 
2 injections 
3 days apart 
Parasite negative 
Table 2: Summary of published papers failing to demonstrate sterilization of persistent A. marginale infections using 
parenteral oxytetracycline (OTC). 
Reference 
Kuttler 
(1980) 
Age/Weight 
of Carrier 
Type of 
Infection 
and Source 
Carrier Confirmation 
Cows; Natural Cows identified with 
Unknown Texas CF/ RCA. 4ml of blood 
from 3 cows pooled and 
inoculated into a 
splenectomized calf 
Infection to 
Treatment 
Unknown 
Sample 
Size 
Drug 
Dose 
(mg/kg) 
15 
14 
14 
20 
20 
20 
Route 
IM 
IM 
IM 
No. of 
Treatments 
Twice, 
7 days apart 
4 treat­
ments at 3 
or 4 day 
intervals 
3 
treatments 
7 days apart 
Confirmation of 
Clearance 
Tested at day 40 and 
day 90 using 20 ml of 
blood. 3 Individual and 
the rest POOLED blood 
inoculated into 
SPLENECTOMIZED 
calves. ONLY 4/43 
CATTLE TESTED 
NEGATIVE. 
Goff et al 
(1990) 
5 2 x 8  
month old 
steers; 
13 cows 
Natural 
Washington 
6 CF positive/60 IF AT/ 
64 DNA probe positive 
Unknown 64 20 IM 4 One month after 
treatments treatment: 1 CF , 44 
at 3 day IF AT, 2 DNA probe 
intervals positive. 
Two months after 
treatment: 2 CF, 17 
IF AT, and 2 new 
animals DNA positive; 
4 apparent treatment 
failures 
Coetzee et 
al 
(2005) 
Chapter 3 
Steers 
7 - 9  
months at 
treatment 
Artificial 
2x 10' 
organisms 
Oklahoma 
Following artificial 
infection: PCV, 
cELISA, PPE, Ht. 
Inoculated into 
splenectomized calves. 
All animals cELISA 
positive, No visible 
PPE at time of 
treatment 
65 Days 10 30 IM Once cELISA at 30 and 60 
days. 
50 ml blood into 
SPLENECTOMIZED 
calves at 60 days after 
last treatment. 
NO CLEARANCE 
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CHAPTER 3. COMPARISON OF THREE OXYTETRACYCLINE 
REGIMENS FOR THE TREATMENT OF PERSISTENT ANAPLASMA 
MARGINALE INFECTIONS IN BEEF CATTLE 
A paper published in Veterinary Parasitology 127, 61-73 
Johann (Hans) F. Coetzee, Michael D. Apley, Katherine M. Kocan, Fred R. Rurangirwa and 
Joyce Van Donkersgoed 
Abstract 
Anaplasmosis, caused by the tick-borne rickettsia, Anaplasma marginale, is an 
economically important disease of cattle in the United States and worldwide. Cattle that 
recover from acute infection become carriers in which low or microscopically undetectable 
A. marginale rickettsemia persists. Tetracycline antimicrobials are currently the only drug 
used in the U.S. for treatment of acute anaplasmosis. There are currently no drugs 
specifically licensed for elimination of persistent infections. This study tested the efficacy of 
three oxytetracycline treatment regimens to clear A. marginale from cattle that were 
persistently infected. Forty Angus X S immental steers, aged 6-12 months were 
experimentally infected with A. marginale. After the steers recovered from acute infection, 
seroconverted, and were confirmed infected using nested PCR followed by DNA 
hybridization, the carrier status of each animal was ascertained by sub-inoculation of blood 
into a separate, splenectomized Holstein calf. The steers were then blocked by bodyweight 
and randomly assigned as follows to 4 treatment groups: Treatment A, 300 mg/ml solution of 
oxytetracycline (Tetradure LA-300, Merial Canada Inc.) administered at 30 mg/kg, by 
intramuscular (IM) injection on day 0; Treatment B, the same 300mg/ml solution of 
oxytetracycline administered at 30 mg/kg, IM on day 0 and again on day 5; Treatment C, a 
200 mg/ml solution of oxytetracycline (Liquamycin LA-200, Pfizer Animal Health) 
administered at 22 mg/kg intravenously (IV) q 24 h for 5 days (a treatment dose that 
corresponds with current Office International des Epizootics (OLE) recommendations for 
treatment prior to export). The fourth group consisted of untreated infected control cattle. All 
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steers were still nested PCR and cELISA positive at 60 days after treatment. Infection was 
confirmed by subinoculation of blood into a splenectomized Holstein calf. These results 
demonstrated that the treatment regimens tested failed to clear A. marginale infections in 
carrier cattle. 
Introduction 
Anaplasmosis, caused by the rickettsial hemoparasite, Anaplasma marginale, is one 
of the most prevalent tick-transmitted diseases of cattle and selected ruminants worldwide 
(Uilenberg, 1995; Dumler et al., 2001; Kocan et al., 2003). The cost of a clinical case of 
anaplasmosis in the United States of America has been conservatively estimated to be over 
US $ 400 US per animal (Goodger et al., 1979; Alderink et al., 1982). Kocan and others 
(2003) in a recent review article estimated the cost of anaplasmosis in the USA to be over $ 
300 million per year. Anaplasmosis is currently classified in List B of the Office 
International des Epizootics (OIE) Terrestrial Animal Health Code due to its socio-economic 
importance and significance in terms of restrictions in the international trade of animals and 
animal products (OIE Web site, 2003). 
Cattle that recover from acute anaplasmosis remain persistently infected with A. 
marginale. Persistent infection is characterized by sequential rickettsemic cycles ranging 
from 102 to 106—107 that occur at approximately 5-week intervals. During these cycles, 
infected erythrocytes are not always detectable in stained blood smears, but ticks were able to 
acquire A. marginale infection from carrier cattle (Eriks et al., 1989). Thus, carrier animals 
serve as reservoirs of infection for mechanical transmission and infection of ticks which are 
biological vectors (Reeves and Swift, 1977; Eriks et al., 1989; Futse et al., 2003). 
Oxytetracycline is a tetracycline derivative obtained from Streptomyces rimosus. 
Tetracyclines are bacteriostatic antibiotics that inhibit protein synthesis by reversibly binding 
to 30S ribosomal subunits of susceptible organisms (Plumb, 2002). Chlortetracycline and 
oxytetracycline are the only compounds used for treatment of anaplasmosis in the United 
States (Food and Drug Administration (FDA) Web site, 2003). However, A. marginale 
infections were not cleared from cattle using recommended therapeutic doses (Kuttler et al., 
1978; Stewart et al., 1979). 
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The existence of persistent A. marginale infections in cattle despite treatment restricts 
the movement of animals from areas where the disease is prevalent to areas where the disease 
is not regarded as endemic such as Canada. Currently, limited movement of feeder cattle 
from selected Northern States is permitted under the Restricted Feeder Cattle Program 
(RFCP) (Canadian Food Inspection Agency Web site, 2002). The RFCP facilitates the export 
of feeder cattle from the U.S. A to Canada between 1 October and 31 March (the non-vector 
season) provided these animals receive oral tetracycline for 120 days or 2 injections of a 
long-acting oxytetracycline formulation at a dose rate of 20mg/kg on arrival and 5-7 days 
later. The Canadian beef industry is looking for alternative treatments, for example a single 
injection of long-acting oxytetracycline, to reduce the current cost of repeat treatments and 
the risk of antimicrobial resistance development from long-term use of feed medications. If a 
single treatment of long-acting oxytetracycline is effective or none of the treatments are 
effective, then the RFCP may need to be modified accordingly. 
The purpose of this study was to compare the efficacy of a single or repeated 
intramuscular injections of a new long-acting oxytetracycline formulation containing 
300mg/ml oxytetracycline (Tetradure LA-300, Merial Canada Inc., Baie d'Urfe, Quebec) 
with 5 consecutive daily intravenous injections of a 200mg/ml long-acting oxytetracycline 
product (Liquamycin LA-200, Pfizer Animal Health, Exton, PA) and untreated control cattle. 
Materials and methods 
This protocol was approved by the Committee on Animal Care (COAC) at Iowa State 
University. 
Experimental cattle 
Forty-six Angus and S immental cross-bred beef steers were initially enrolled in this 
study to make provision for possible fatalities, but only 40 cattle were eventually selected to 
enter the treatment phase as study animals. These steers from the Beef Teaching and Beef 
Nutrition Facilities at Iowa State University were aged approximately 160-230 days and 
weighed between 214 and 346 kg at the time of selection. Cattle had not received treatment 
with chlortetracycline or oxytetracycline in the 4-week period prior to study commencement. 
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The study was conducted in the winter months between 5 November, 2002 and 15 April, 
2003, to minimize the risk of vector borne spread of A. marginale among test cattle. All 
cattle were clinically evaluated prior to infection and a blood sample was also taken from 
each animal for serological screening by a competitive enzyme linked serologic assay 
(Anaplasma Antibody Test Kit, VMRD, Inc. Pullman, WA) (cELISA) for the detection of A. 
marginale antibodies (Torioni De Echaide et al., 1998). Packed cell volume (PCV) testing 
was also carried out in order to obtain baseline data and to confirm that animals were 
uninfected with A. marginale. 
Housing and husbandry 
Cattle were housed in group pens at the Iowa State University Beef Nutrition farm. 
Following infection and prior to treatment, animals were grouped according to similar size in 
eight pens of five or six animals per pen. Each pen was 11m long and 4 m wide with a 4 m 
bunk space. Following randomization and treatment, the steers were regrouped in pens 
containing five steers per pen according to their treatment groups. Each treatment group was 
housed in two immediately adjacent pens and separated from other treatment groups by an 
empty pen. Drinking troughs were not shared between treatment groups. Pens were bedded 
with shredded paper, which was replaced as required. 
Infection with anaplasmosis 
An isolate of A. marginale derived from a cattle herd in Oklahoma in 1999 (Blouin et 
al., 2000) was used in this study. This isolate was genotyped and characterized as being tick 
transmissible and susceptible to oxytetracycline in vitro prior to inoculation (Blouin et al., 
2000, 2002). The isolate was preserved in dimethylsulphoxide (DMSO) and maintained as a 
frozen stabilate in liquid nitrogen prior to inoculation of a splenectomized calf at Oklahoma 
State University. Three hundred and fifty milliliters of blood was collected from the calf in 
sterile syringes coated with heparin when the PCV was 34% and the percent parasitized 
erythrocytes (PPE) were 21.6%. Infection in the test steers was established by inoculating 
each animal intravenously with 1 ml of blood containing approximately 2.6 x 109 infected 
erythrocytes. 
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Post-infection monitoring 
Following infection, the steers were monitored daily for the clinical signs of 
anaplasmosis, including anorexia, depression and listlessness. Blood samples were collected 
at 9, 13, 16, 20, 24, 28, 30, 34, 41, 44 and 62 days post-infection for PPE, PCV and cELISA 
serology. Body temperature was also measured at selected time points. Blood samples were 
collected by jugular venipuncture using 18 G, 1 in. needles (Air-tite Products Co. Inc., VA). 
For serum collection, 10 ml Monoject® No Additive Sterile glass tubes (Sherwood Medical, 
St Louis, MO) were used. For whole blood (PCV, Hematology and nPCR), 7 ml K3EDTA 
glass tubes (Beckton Dickenson Vacutainer Systems, NJ) were used. Blood in EDTA was 
refrigerated prior to PCV testing or packaged in insulated material for delivery by overnight 
courier to Oklahoma State University for determination of the PPE. 
Blood smears for PPE determination were stained using a 30-s, three-step staining 
technique (Hema 3® Staining System, Fisher Scientific) comparable to the Wright-Giemsa 
method. Two slides were prepared for each blood sample and examined for the presence of 
A. marginale at lOOx magnification using a grid. A total of 500 cells were counted within the 
four squares of the grid and the number of infected cells was recorded. The PPE was the 
number of infected cells divided by the total number of cells counted, multiplied by 100. 
Serologic testing by cELISA was conducted by the Iowa State University Diagnostic 
Laboratory. The test was conducted in accordance with the method described in the OIE 
manual of Standards for diagnostic tests and vaccines and the manufacturer 
recommendations (OIE, 2000; VMRD, 2003). Results are given as percentage inhibition. 
PCVs were determined by partially filling heparinized capillary tubes (Chase Scientific 
Glass, Inc., Rockwood, TN) with blood, which were then centrifuged for 10 min using an 
Adams Micro-Hematocrit centrifuge (Clay Adams, Inc., New York, Model CT 2900) preset 
to spin blood at a constant rate of 11,500 rpm. 
Infected steers were classified as carriers based on the presence of antibodies on the 
cELISA test and after rickettsemias had fallen below or equal to 1%. After 45 study animals 
met these criteria, blood from each animal was subinoculated into a separate splenectomized 
Holstein calf. 
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Splenectomized calves 
The first group of splenectomized calves used to confirm the carrier status of the test 
system comprised 45 Holstein calves aged approximately 6 to 12 weeks of age and weighing 
between 45 and 112 kg at the time of surgery. Calves were obtained from the Iowa State 
University Dairy Breeding Research facility at Ankeny, IA, and a commercial calf rearing 
facility located in Marshall County, IA. Both facilities are known to have a low incidence of 
anaplasmosis. Calves were assessed by clinical examination and cELISA to confirm that they 
had not been previously exposed to A. marginale and then splenectomized to increase their 
susceptibility to A. marginale infection. 
Splenectomies were performed using the technique described by Thompson et al. 
(1992). None of the calves received treatment with oxytetracycline in the 4 weeks prior to 
study commencement. During the 5-day acclimation period and following subinoculation, 
calves were housed in the livestock infectious diseases isolation facility (LIDIF) at Iowa 
State University. The calves were divided between three pens in each of three separate 
rooms. Five calves from a study group were housed together in pens with separate waterers. 
The room temperature was maintained at approximately 20 °C. 
Subinoculation of carrier blood 
For each of the 45 steers determined to be cELISA positive with an A. marginale 
rickettsemia <1%, 50 ml blood was collected in a heparinized syringe and inoculated into a 
splenectomized calf. Filled syringes were stored on ice prior to sub-inoculation which 
occurred within 8 h of blood collection. 
Following inoculation, splenectomized calves were monitored for signs of 
anaplasmosis by daily observation. Weekly determinations of the PCV were also conducted. 
The presence of A. marginale infection was confirmed by microscopic examination of 
stained blood smears, an increase in cELISA values, and a PCV below 20%. Calves were 
euthanized and necropsied once these criteria were met. Based on the PPE results, 5 carrier 
steers corresponding to the splenectomized calves with the lowest rickettsemia were rejected 
from the study and remaining steers were then randomized into treatment groups. 
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Group assignment and randomization procedures 
Carrier steers were blocked by bodyweight before being randomly assigned to 
treatment groups in order to ensure a similar weight distribution between groups. Each 
animal was then randomly assigned to treatment within a weight block by assigning random 
numbers (Microsoft Excel, Microsoft Corporation). 
Treatment application 
The test formulation of oxytetracycline, Tetradure LA-300, was a sterile long-acting 
aqueous solution nominally containing oxytetracycline dihydrate equivalent to 300 mg 
oxytetracycline base per milliliter. A new vial was used on each treatment day. The control 
antimicrobial, Liquamycin LA-200, was a sterile ready to use solution nominally containing 
200 mg oxytetracycline base as oxytetracycline dihydrate per milliliter. 
Tetracycline dose administered 
The test and control formulations were administered at the following dose rates and 
dosing frequency: Treatment A consisted of a 300 mg/ml solution of oxytetracycline 
(Tetradure LA-300) administered at a dose of 30 mg/kg, intramuscularly to 10 steers. 
Treatment B consisted of a 300 mg/ml solution of oxytetracycline (Tetradure LA-300) 
administered at a dose of 30 mg/kg intramuscularly on day 0 and again on day 5 to 10 steers. 
Treatment C consisted of a 200 mg/ml solution of oxytetracycline Liquamycin LA-200 
administered at a dose of 22 mg/kg, intravenously, once a day for 5 days to 10 steers. 
Treatment D consisted of 10 untreated controls. 
The test formulation was administered to Group A and B by deep intramuscular 
injection using a 16 gauge x 1.5 in. needle in the left and right neck which is one of the 
recommended routes of administration. The nominal oxytetracycline content for the 
formulation and the animal bodyweights obtained immediately prior to administration were 
used in conjunction with a dosage calculation table to calculate the theoretical dose for each 
animal. For dosing, a 20 ml hypodermic syringe was used and the required dose was rounded 
to the nearest whole milliliter with a maximum dose volume of 15 ml per injection site. 
The control formulation was administered to Group C by slow intravenous injection 
into the left or right jugular vein. This is one of the recommended routes of administration. A 
77 
16 gauge x 1.5 in. needle was used for each administration. In the presence of swelling or 
perivascular edema, the contralateral vein was used. In one animal, it was necessary to place 
a 16 G intravenous catheter into the vein for two administrations. The nominal 
oxytetracycline content for the formulation and the bodyweights obtained immediately prior 
to administration were used in conjunction with a dosage calculation table to calculate the 
theoretical dosage for each animal. For dosing, a 60 ml hypodermic syringe was used and the 
required dose was rounded to the nearest whole milliliter. 
Post-treatment monitoring 
Blood samples were taken prior to treatment and at 31 and 60 days post-treatment for 
direct polymerase chain reaction (PGR), semi-nested polymerase chain reaction (nPCR) and 
DNA hybridization using the method described by Torioni De Eschaide et al. (1998). Testing 
was conducted at Washington Animal Disease Diagnostic Laboratory, Washington State 
University. Briefly, genomic DNA was isolated from 300 pi of blood using a DNA isolation 
kit (Purogene, Gentra Systems, Inc.) following the manufacturer's instructions. DNA of each 
sample was resuspended in 100 ju.1 of hydration solution. Primers were designed from the 
published sequence of msp5 from A. marginale Florida as described by Torioni De Eschaide 
et al. (1998) and were as follows (5'-3' sequence and location): external forward, 5-GCA 
TAG CCT CCG CGT CTT TC-3' (msp5 positions 254-273); external reverse, 5'-TCC TCG 
CCT TGG CGC TCA GA-3' (msp5 positions 710-692); internal forward, 5'-TAC ACG TGC 
CCT ACC GAG TTA-3' (msp5 positions 367-387). Two PGR rounds in a final volume of 50 
pi consisting of 5 jxl of lOx PGR buffer [200 mM Tris-HCl (pH8.4), 0.1 mM KC1 ], 1.5 pi of 
50mM MgCb.l pi dNTPS 10 mM, 1 pi of 20 pmol of each external primers, 1 pi of Taq 
DNA polymerase [GIBCO, 5 U / pi], 34.5 pi of H2Q and finally 5 pi of the sample DNA in 
case of direct PGR or 5 pi of the amplicon from the direct PGR in case of the semi-nested 
PGR were carried out in a Perkin Elmer GeneAmp 9600 thermocycler. Cycling conditions 
were preheating at 95 °C for 3 min and 35 cycles of 94 °C for 15 s, 65 °C for 58 s, and 72 °C 
for 70 s with final extension at 72 °C for 10 min for each round. nPCR was carried out only 
on samples that were negative for direct PGR. PGR and nPCR products were visualized in a 
2% agarose gel following electrophoresis and staining with ethidium bromide. 
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The treated steers were also tested at 31 and 60 days after first oxytetracycline 
administration using the cELISA test. A period of 60 days after administration was allowed 
for clearance of oxytetracycline from the blood in the treated steers prior to post-treatment 
inoculation of calves. 
Determination of post-treatment infectivity 
At 60 days post-treatment, approximately 50 ml of blood was collected from each 
steer and again used to challenge a splenectomized calf per steer using the procedure 
described previously. The presence or absence of A. marginale infection in these 
splenectomized calves was confirmed as described previously. Calves were euthanized once 
clinical signs were confirmed and a necropsy was performed on each animal. 
Statistics 
The mean values and the standard error of the mean (SEM) at each time point for 
cELISA, body temperature, PPE and PCV were calculated using a Microsoft Excel 
spreadsheet. Hypothesis tests were conducted using IMP 5 (SAS Institute, Inc., Cary, NC, 
USA). Analysis of baseline variables was performed using analysis of variance (ANOVA). 
Subsequent body temperature, cELISA, PCV and PPE results were analyzed using repeated 
measures analysis. The null hypothesis was that there was no difference between treatment 
groups. The analysis of variance approach to repeated measures data was used based on a 
review by Everitt (1995). Multivariate analysis of variance (MANOVA) for repeated 
measurements over time was selected for these analyses as the assumption of sphericity for 
univariate tests could not be satisfied. Assuming sphericity in these circumstances would lead 
to an increase in type 1 error (Everitt, 1995). The sphericity assumption can be regarded as an 
extension of the homogeneity of variance assumption in independent measures ANOVA. 
MANOVA makes no assumptions about the form of the covariance matrix of the repeated 
measures although this method has relatively lower power when the sphericity assumption is 
valid. 
Statistical significance was designated a priori as a P-value less than or equal to 0.05. 
The Wilk's lambda test was selected to evaluate within group interactions and evidence of 
time x group interactions. This test is a likelihood ratio statistic for testing that a multivariate 
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contrast is zero, assuming multivariate normality and further assuming equality of covariance 
matrices across groups (Everitt and Dunn, 2001). Where the Wilk's lambda test indicated a 
statistically significant difference between groups, a one-way analysis of variance (ANOVA) 
using the Tukey-Kramer HSD method was used to compare the four treatment groups in 
order to identify which group was statistically different from the rest. Dunnett's method was 
used to correct the tendency toward type 1 error when comparing treatment groups 
individually to the control group. 
A two-tail Fisher's exact test using a f-value of 0.05 to designate significance was 
used to test whether there was a difference between the number ofPCR positive and negative 
steers in each treatment group. The Fisher's exact procedure calculates an exact probability 
value for the relationship between two dichotomous variables and is regarded as the gold 
standard of testing tools for 2 x 2 tables (Ramsey and Schafer, 2002). 
Results 
Carrier Steer Infection Phase of the Study 
The results of the infection stage of the study are summarized in Fig. 1 and Table 1. 
Prior to inoculation all animals were seronegative for anaplasmosis (<30% 
inhibition). Nine days after infection the mean cELISA (±SEM) was 24.82 ± 2.86% 
inhibition and 19 animals were classified as positive. Four days later the mean cELISA had 
risen to 66.84 ± 1.55% inhibition with all animals demonstrating evidence of A. marginale 
infection based on a mean PPE (±SEM) of 0.62% ± 0.1. At 20 days post-infection the mean 
cELISA percent inhibition had increased to 83.92 ± 0.62 which coincided with a mean PPE 
of 9% ± 1.57 (range: 3-24%). The mean body temperature was 39.68 ± 0.17 at 24 days after 
infection and the mean PCV was 23 ± 0.46%, the lowest recorded during the study. Sixty-
two days post-infection, a maximum of one parasitized erythrocyte in 500 cells could be 
detected in all study animals and the mean cELISA was 86.29 ± 1.07% inhibition. The PCV 
and mean body temperature of all animals was within normal limits. Following assignment to 
treatment groups these data were retrospectively analyzed and no statistical difference 
between groups was evident. 
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Post-infection subinoculation of carrier blood into splenectomized calves 
Prior to inoculation on 20 December 2002, all splenectomized animals were 
seronegative for anaplasmosis (<30% inhibition) and it was assumed that the PPE was zero. 
Eleven days post-subinoculation, 17 animals were positive on cELISA (>30% inhibition). At 
15 days post-subinoculation A. marginale intraerythrocytic inclusions were found in all blood 
smears with a mean PPE (±SEM) of 16.60 ± 5.98% (range: 1-75%) and the mean cELISA 
was 29.85 ± 5.98%. Forty-five animals were euthanized approximately 17 days after 
subinoculation at which time the mean cELISA was 52.55 ± 6.17%. All animals 
demonstrated an increase in cELISA although only 35 were classified as positive. The mean 
PCV (±SEM) at the time of euthanasia was less than 15.45 ± 2.55%. Post-mortem 
examinations of the subinoculated calves showed gross pathological changes consistent with 
anaplasmosis infection (Potgieter and Stoltsz, 1994). The carrier steers which were used to 
inoculate the five calves with a PPE of less than 1% were rejected from the study. 
Treatment phase in carrier steers 
Post-treatment molecular diagnostic test results 
Prior to the first day of treatment on 10 January 2003, 35 carrier steers were positive 
for A. marginale by direct PCR and all 40 steers were confirmed positive by DNA 
hybridization and nested PCR. 
Thirty-one days post-treatment, 26 animals were positive for A. marginale by direct 
PCR: Seven in Group A, five in Group B, seven in Group C and three in the control group 
(Group D). The difference between the number of direct PCR positive animals in Groups A 
and C and Group B, and Group B and D was not significant (P = 0.65). There was also no 
significant difference between groups A and C, and group D (P = 0.18). All animals were 
positive for A. marginale on nested PCR and DNA hybridization at this time point. 
Post-treatment competitive ELIS A (cELISA) 
Thirty-one days after treatment, the mean cELISA between groups was 76.47 ± 
1.70% inhibition in Group C and 88.78 ± 0.77% inhibition in Group A. There was a 
significant (P < 0.01) difference between the cELISA of Group C and Group A and Group D. 
None of the other means were different from each other. At 60 days after first treatment there 
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was no difference between cELISA (p = 0.07). Using the Tukey-Kramer HSD method, a 
significant (P < 0.05) difference was found between the cELISA of Group D and Group B. 
None of the other means were different from each other. 
At 90 days after first treatment, there was no significant difference between cELISA 
(P = 0.55). 
Post-treatment subinoculation of blood into splenectomized calves 
The results following subinoculation of carrier blood into splenectomized calves prior 
to carrier treatment are summarized in Fig. 2 and Table 2. 
Percent parasitized erythrocytes results 
Prior to subinoculation on 11 March 2003, it was assumed that the PPE for all 
splenectomized calves was zero due to negative cELISA results. At 14 days after 
subinoculation, A. marginale intraerythrocytic inclusions were detected in 35 blood smears. 
The PPE was monitored at two subsequent time points and at the time of necropsy. The peak 
PPE recorded over the monitoring period ranged from 1-26% in Group A and 0-33% in 
Group B. In Group C the peak rickettsemia ranged from 2—45%. Animals in the control 
group (Group D) had a peak rickettsemia ranging from 2-34%. A. marginale organisms were 
therefore detected in all animals except one animal which died on 27 March 2003. A 
complete necropsy was conducted on this animal which included bacterial culture and 
histology. Bacteriological investigation revealed that this animal was suffering from a 
Salmonella kentucky infection presumably exacerbated by the immune suppression caused by 
splenectomization. 
Competitive ELISA (cELISA) 
Prior to subinoculation, the mean group cELISA was negative. Seven days after 
infection, the cELISA in all animals remained below the positive threshold of 30% 
inhibition. At 2 weeks after subinoculation, 8 animals demonstrated a cELISA greater than 
30% inhibition. By 27 days after subinoculation, 33 animals had been euthanized. All except 
1 of the remaining animals had seroconverted. On completion of the study the mean group 
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cELISA (±SEM) ranged from 30.3 ± 9.6 to 50.7 ± 3.9% inhibition. There were no significant 
differences between groups over time (P = 0.08). 
Packed cell volume (PCV) results 
Prior to subinoculation the mean PCV for all animals was within normal limits (24— 
46%) (Smith, 1996). All study animals had either died or were euthanized by 35 days after 
subinoculation. The PCV determined at necropsy in Group A ranged from 6-22% and from 
7-30% in Group B. The PCV at necropsy in Group C ranged from 7-16% while animals in 
the control group (Group D) had a necropsy PCV ranging from 7-22%. There were no 
significant differences between groups over time (P - 0.47). 
Post-mortem examination 
Post-mortem examinations were conducted on all animals 14—35 days after 
subinoculation. Most animals showed gross pathological changes consistent with 
anaplasmosis infection. Hepatomegaly was noted in 30 animals. Twelve animals also had 
friable livers and 17 livers were mildly to severely icteric or pale. Moderate to severe renal 
lesions were also noted. Thirty animals were found to have some degree of renal pelvic 
edema. In 16 animals, multifocal petechial hemorrhages were observed on the kidney 
surface. Macroscopically, "watery" blood was noted in 36 animals. Petechial hemorrhages 
were also noted in the epicardium of 19 animals and ecchymoses in the epicardium was 
observed in six cattle. 
Discussion 
Our study found that none of the treatment regimens cleared A. marginale infection in 
the persistently infected cattle. These results are contradictory to findings of previous studies 
in which successful clearance of anaplasmosis carrier infections was achieved using 
intravenous oxytetracycline dosing regimens ranging from 11 to 22 mg/kg given for 5-12 
days (Magonigle et al., 1975; Roby et al., 1978). Previous studies reported clearance of the 
carrier state in cattle using intramuscular oxytetracycline at 20 mg/kg following two, three or 
four administrations at intervals ranging from 3 to 7 days (Roby et al., 1978; Kuttler, 1980; 
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Magonigle et al., 1982; Kuttler., 1983; Swift et al., 1983; Rogers., 1984; Ozlem., 1988). Our 
results are however in agreement with those of Kuttler et al. (1980) and Goff et al. (1990) 
who report a failure of carrier clearance in naturally infected range cattle using two injections 
of long-acting oxytetracycline administered at 20 mg/kg by intramuscular injection. 
The study design used in our study was comparable with the design of two previous 
studies. These reported clearance of persistent infections, but were conducted prior to the 
availability of more sensitive molecular diagnostic techniques and the cELISA test for 
identification of carrier cattle. Magonigle et al. (1975) evaluated the effect of five daily 
treatments with oxytetracycline hydrochloride at a dose of 22 mg/kg IV on the carrier status 
of bovine anaplasmosis in 11, 2 to 3-year-old serologically positive cattle. Carrier clearance 
was confirmed by inoculating ten milliliters of blood from carrier cows into splenectomized 
calves at 4 and 12 months after treatment. These calves did not exhibit serological, 
hematological or clinical evidence of A. marginale during a 60-day observation period. The 
results of this study formed the basis for the current OIE recommendation for the clearance 
of the carrier state. The major difference between this study and the present study was that 
the former study incorporated the use of older, naturally infected animals and a considerably 
longer period between treatment and subinoculation of blood into splenectomized calves. The 
significance of this in terms of the outcome of this study is not known. 
Roby et al. (1978) reported elimination of the A. marginale carrier state with two 
injections of long-acting formulation of oxytetracycline (Liquamycin LA 200, Pfizer Inc.) at 
20 mg/kg administered 7 days apart as opposed to the 30 mg/kg dose given 5 days apart in 
our study. Following experimental infection with an unspecified number of parasitized 
erythrocytes in 5 ml of heparinized blood from a known carrier cow, the 12 to 16 month 
Holstein-Friesian calves developed clinical anaplasmosis with a rickettsemia between 1 and 
10% and recovered spontaneously in 60 days. This is lower than the rickettsemia recorded in 
our study which ranged from 3.1% to 24.1% at the peak of infection although the recovery 
period of 60 days is similar. Furthermore, a longer period of time elapsed (83 days as 
opposed to 60 days after treatment) before the subinoculation of 80 ml of whole heparinized 
blood into splenectomized calves to confirm that the carrier cows were free from 
anaplasmosis. 
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Tetracycline antimicrobials are bacteriostatic rather than bacteriocidal and the activity 
of these compounds are believed to be dependant on the time that drug concentrations remain 
above the minimum inhibitory concentration (MIC) for the target organism. Bacteriostatic 
antimicrobials arrest bacterial growth. A competent host immune response is usually 
necessary for elimination of the pathogen. Tetracyclines bind to ribosomes and mRNA and 
inhibition of protein synthesis is mediated principally through reversible binding with the 
30S ribosomal subunit. In bacteria, this binding blocks the attachment of aminoacyl-tRNA to 
the A site of the mRNA-ribosome complex (Scholar and Pratt, 2000). 
Several studies have suggested that oxytetracycline is rickettsiostatic rather than 
rickettsiocidal against anaplasmosis infections. Eckblad et al. (1979), Lincoln et al. (1982) 
and Kuttler (1983) demonstrated that administration of oxytetracycline during the prepatent 
period suppressed multiplication of A. marginale and prolonged the prepatent period. Kuttler 
(1983) concluded that tetracyclines retarded A. marginale multiplication rather than actually 
killing the pathogen. Stewart et al. (1979) observed that the therapeutic dose of long-acting 
oxytetracycline administered during acute infection was insufficient to eliminate carrier 
infection. These studies suggest that the immune response to A. marginale may not be fully 
competent during acute infection or that the rickettsemia during this stage overwhelms the 
ability of oxytetracycline and the immune response to work in concert to eliminate infection. 
There may be several reasons why the treatment regimens evaluated in this study 
failed to eliminate A. marginale. Firstly, based on the pharmacodynamics of oxytetracycline 
it might be hypothesized that the concentrations of oxytetracycline achieved in the present 
study were not maintained above the MIC for anaplasmosis for a sufficient period of time to 
eliminate the persistent infection. Blouin et al. (2002) studied the effect of oxytetracycline in 
vitro on A. marginale in a cell culture system using a tick cell line derived from embryonic 
Ixodes scapularis. Tetracycline doses of 5, 10, 20 and 100 pg/ml significantly inhibited 
growth of A. marginale after 7 days of exposure as determined by ELISA and morphological 
deterioration determined by electron microscopy. A. marginale infected cell cultures treated 
with medium containing 20 jxg/ml were non-infective when inoculated into splenectomized 
calves. In vivo pharmacokinetic studies have found that the maximum plasma concentration 
(Cmax) following IM administration of a conventional long-acting oxytetracycline 
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formulation at 20 mg/kg was 8.56 p.g/ml achieved at 2.53 h after injection. The Cmax of 
Tetradure LA-300 was 10.72 (ig/ml achieved at 4.64 h after administration (Clark and 
Dowling, 2003). These results would suggest that plasma concentrations of these 
formulations of oxytetracycline following parenteral administration may be insufficient to 
kill the Anaplasma organism. This might explain why studies conducted with oxytetracycline 
given at more frequent intervals demonstrated successful elimination of persistent infections. 
Secondly, the location of A. marginale during the prepatent period and carrier stage 
has not been reported and this may be associated with failure to eliminate the organism. It 
may be that the organisms are not detectable during the prepatent period simply because of 
the low probability of detecting an infected erythrocyte among the enormous number of non-
infected cells. Infected erythrocytes may, however, be sequestered in a "privileged site", for 
example the spleen, where oxytetracycline concentrations may be below the minimum 
inhibitory concentration for the organism (Kuttler, 1983; Potgieter and Stoltsz, 1994). 
Landoni and Errecalde (1992) found that the theoretical area under the tissue concentration 
vs. time curves (AUC) in the spleen for a period of up to 72 h following intramuscular 
administration of 20 mg/kg oxytetracycline was 49.47jxg/g h which was in contrast with an 
AUC of 535.54 pg/g h in the liver and 558.67 pg/g h in the kidney. However, these AUCs 
were determined from tissue homogenates and therefore assumes that oxytetracycline 
penetrates all regions of the organ uniformly which may not be the case. The effective AUC 
specifically against A. marginale has not been reported. 
The results of the infection phase of the study suggest that the cELISA test results 
correspond with rickettsemia in the early stages of the disease (Table 1). The first detectable 
PPEs in this study were concurrent with the first positive cELISA test in all animals and the 
cELISA peaked at the same time as the peak in the PPE (Fig. 1). The administration of 
oxytetracycline appears to have reduced circulating rickettsemia in the carrier animals. A 
significant decrease in cELISA was seen in the group treated with five injections of 
oxytetracycline (Group C) when compared with the control group and the group treated with 
only one injection of oxytetracycline (Group A). Further testing involving molecular methods 
is required in order to establish the extent to which oxytetracycline administration influences 
antibody response. 
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It is noteworthy that in both phases of the study involving splenectomized calves, a 
positive (>30%) cELISA test was not detected in all calves, although they were parasitemic 
and experienced a notable decrease in the packed cell volume consistent with acute 
anaplasmosis. Antibodies may have been bound to organisms in the acute phase of the 
infection or decreased antibody levels may have been a result of immunosuppression 
resulting from splenectomy. Furthermore, the cELISA was validated on adult cattle and the 
test was not used to screen A. marginale antibodies in splenectomized calves. Our protocol 
also required animals to demonstrate a change in cELISA level and not necessarily a positive 
cELISA test. The presence of organisms and positive molecular diagnostic techniques should 
therefore be regarded as the definitive test for confirmation of A. marginale infection in 
splenectomized calves. 
The results of this study demonstrated that subinoculation of blood from all except 
one of the carrier steers treated with one of the three regimens of oxytetracycline resulted in 
infection and clinical anaplasmosis in splenectomized calves. The splenectomized calf in 
which infection could not be confirmed did, however, die in the early stages of the study and 
it may be possible that it was still in the prepatent period. Administration of a 300 mg/ml 
solution of oxytetracycline (Tetradure LA-300) administered at a dose of 30 mg/kg, 
intramuscularly once or twice 5 days apart was not effective for elimination of the persistent 
A. marginale in beef cattle. Furthermore, the study demonstrated that the current 
recommended OIE treatment protocol of five injections of a 200 mg/ml solution of 
oxytetracycline administered at a dose of 22 mg/kg intravenously was also not effective for 
elimination of persistent A. marginale infection. 
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Fig. 1: Summary of mean clinical parameters following carrier steer infection with 2.6 x 
109 Anaplasma marginal (Oklahoma Isolate) parasitisd erythrocytes 
PCV: Packed Cell Volume; cELISA: Competitive Enzyme Linked Immunosorbent 
Assay; PPE: Percent Parasitized Erythrocytes 
Table 1: Summary of Mean Clinical Parameters3 Following Carrier Steer infection with 2.6 x 109 Anaplasma marginale 
(Oklahoma Isolate) Parasitized Erythrocytes 
Days Post Infection 0 9 13 16 20 24 28 30 34 41 44 62 
PPE (%) 0.00 0.00 0.62 2.72 9.17 8.17 4.31 2.46 1.01 0.55 0.59 0.00 
Standard Error 0.00 0.00 0.10 0.41 1.57 1.77 1.40 0.81 0.27 0.14 0.16 0.00 
MANOVA P value = 0.74 
Wilkes Lambda Test P = 0.62 
cELISA (% inhibition) 
Standard Error 
MANOVA P value = 0.47 
Wilkes Lambda Test P = 0.94 
Body Temperature (°C) 
Standard Error 
MANOVA P value = 0.63 
Wilkes Lambda Test P = 0.31 
PCV (%) 
Standard Error 
MANOVA P value - 0.14 
Wilkes Lambda Test P = 0.81 
aPCV: Packed Cell Volume; cELISA: Competitive Enzyme Linked Immunosorbent Assay; PP Percent Parasitized Erythrocytes 
0.00 24.82 66.84 N/A 83.92 N/A 75.71 N/A 75.56 78.45 N/A 86.29 
0.00 2.86 1.55 N/A 0.62 N/A 0.69 N/A 0.85 0.85 N/A 1.07 
39.21 39.19 39.03 38.75 39.56 39.68 38.95 38.86 39.11 38.95 N/A N/A 
0.12 0.11 0.12 0.174 0.154 0.166 0.188 0.124 0.094 0.106 N/A N/A 
38.03 36.35 35.43 34.00 27.58 23.23 25.40 26.78 29.43 32.35 32.75 35.83 
0.46 0.41 0.41 0.41 0.47 0.46 0.63 0.67 0.58 0.59 0.56 0.43 
Table 2: Summary of Mean Parameters taken from Splenectomized Calves (Phase 2) Subinoculated with 50 ml of 
Blood from Carrier Steers 60 days after Treatment with Oxytetracycline 
Days from Start End Start Peak Mean 
Date of Necropsy Inoculation PCVa PCVa cELISA" cELISA3 PPE* 
Group Ab 19.2 29.5 11.9 2.0 40.3 6.9 
Standard Error 2.7 3.3 2.0 1.7 6.0 2.3 
Group B 22.3 32.6 13.5 0.0 30.3 15.6 
Standard Error 1.5 0.9 2.2 2.9 9.6 3.8 
Group C 22.5 32.8 11.4 3.6 45.9 16.2 
Standard Error 1.6 0.7 1.0 3.4 7.5 4.7 
Group D 21.1 313 12.8 4.0 50.7 12.3 
Standard Error 1.0 0.7 1.5 2.5 3.9 3.3 
ANOVA P Value 0.9 0.5 
MANOVA P value 0.47 0.08 
aPCV: Packed Cell Volume; cELISA: Competitive Enzyme Linked Immunosorbent Assay; PPE: Percent Parasitized 
Erythrocytes 
bGroup A: 300 mg/ml solution of oxytetracycline (Tetradure LA-300) administered at a dose of 30 mg/kg, by 
intramuscular injection. 
Group B: 300 mg/ml solution of oxytetracycline (Tetradure LA-300) administered at a dose of 30 mg/kg by 
intramuscular injection on day 0 and again on day 5. 
Group C: 200 mg/ml solution of oxytetracycline (Liquamycin LA-200, Pfizer Animal Health) administered at a dose of 
22 mg/kg, intravenously, once a day for 5 days. 
Group D: Untreated infected controls. 
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CHAPTER 4. EVALUATION OF THE EFFECT OF SELECTED 
ANTIMICROBIALS ON ANAPLASMA MARGINALE 
USING FLOW CYTOMETRY 
A paper to be submitted to Veterinary Parasitology 
Johann F. Coetzee, Michael D. Apley, Katherine M. Kocan and Douglas E. Jones 
Abstract 
Anaplasma marginale is one of the most prevalent tick-borne pathogens of cattle 
worldwide. Cattle recovering from acute infection remain persistently infected despite 
treatment with tetracyclines. These carrier cattle serve as reservoirs of infection for 
mechanical spread and infection of ticks. In this study we used flow cytometric analysis to 
evaluate the effect of antimicrobials against A. marginale in short-term whole erythrocyte 
cultures. Erythrocytes infected with the Virginia (VGN) or Oklahoma (OK) isolates of A. 
marginale were tested with doubling dilutions of oxytetracycline (OTC), imidocarb (IMD) 
and enrofloxacin (ENRO). Parasite viability was assessed by F ACS for 7 days using the vital 
dye hydroethidine (HE) which, when converted to ethidium bromide (EB) by live parasites, 
is detectable by F ACS. After 7 days, infectivity of selected cultures was determined by 
inoculating 400 p.1 of packed erythrocytes intravenously into Holstein calves. The F ACS data 
were analyzed statistically by multivariate analysis of variance (MANOVA) and the Tukey-
Kramer HSD (honest significant difference), as well as Wilcoxon rank sum tests and student 
t tests for comparison of the two isolates. Receiver operating characteristic (ROC) analysis 
was used to compare F ACS results with culture infectivity. Enrofloxacin inhibited A. 
marginale in a concentration dependent manner, while higher concentrations of imidocarb 
were less effective than lower concentrations in reducing the number of viable organisms. 
Oxytetracycline was found to be the least efficacious antimicrobial in this culture system. 
Differences between isolates were evident at some dilutions. Cultures of erythrocytes 
infected with the Oklahoma isolate exposed to 4.0 p.g/ml enrofloxacin and those of the 
Virginia and Oklahoma isolates exposed to 1.0 gg/ml appeared to be sterilized. This study 
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appears to be the only in vitro study demonstrating the anti-A marginale microbial effect of 
enrofloxacin. Flow cytometry proved to be useful for screening antimicrobial activity of 
drugs against bovine erythrocytes infected with A. marginale. 
Introduction 
Anaplasmosis, caused by the rickettsial hemoparasite, A. marginale, is the most 
prevalent tick-transmitted disease of cattle worldwide (Uilenberg, 1995; Dumler et al., 2001 ; 
Kocan et al., 2003). Prior to the development of imidocarb dipropionate and the tetracycline 
antimicrobials, a variety of chemotherapeutic agents, including arsenicals, antimalarials, 
antimony derivatives and dyes, were used to treat acute anaplasmosis. These compounds had 
little if any chemotherapeutic effect (Potgieter and Stoltz, 1994). Chlortetracycline and 
oxytetracycline are the only compounds available for prevention or therapy of acute 
anaplasmosis in the United States. Anaplasma infections are not sterilized at the usual 
recommended therapeutic doses of the tetracycline drugs (Kuttler and Simpson, 1978; 
Stewart et al., 1979). There are currently no antimicrobials labeled for the elimination of 
persistent infections in carrier animals. 
Successful antimicrobial therapy depends on (1) achieving adequate drug 
concentrations at the site of infection, (2) ensuring that drug concentration is maintained for a 
sufficient duration to be effective, (3) the susceptibility of the organism to the antimicrobial, 
(4) pharmacokinetic parameters of the drug, and (5) the local environment (Bidgood and 
Papich, 2003). Susceptibility tests facilitate the determination of a minimum inhibitory 
concentration (MIC), which is the lowest concentration of an antimicrobial agent that 
prevents visible growth of a microorganism in an agar or broth dilution susceptibility test 
(NCCLS, 2002). The extension of these techniques to include cell associated protozoa such 
as ehrlichia and rickettsia has been complicated by the need to grow these organisms in cell 
culture systems. 
Initial attempts to grow A. marginale outside the bovine host using cultures of bovine 
bone marrow, rabbit bone marrow, bovine lymph nodes and tissue derived from the mosquito 
Aedes albopictus, were only moderately successful (Hidalgo, 1975; Kessler et al., 1979; 
McHolland and Trueblood, 1981). Kessler et al. (1979) established a whole blood culture of 
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A. marginale based on a method used to cultivate Plasmodia. The viability of the organism in 
blood was demonstrated by inoculation of susceptible calves with blood collected from the 
13 and 33 day cultures. 
Wyatt et al. (1991) described a method for evaluating the growth and viability of 
cultured intraerythrocytic protozoan hemoparasites using flow cytometry. This assay utilized 
the selective uptake and metabolic conversion of hydroethidine (HE) to ethidium by live 
parasites in intact erythrocytes. The intercalation of ethidium, a DNA binding fluorochrome, 
into viable parasites allowed the use of fluorescence-activated cell sorting (FACS) to 
distinguish between erythrocytes containing viable organisms and those containing dead or 
no parasites. Studies with the hemoparasite Babesia bovis utilized this fluorochromasia 
technique to monitor the effect of parasiticidal drugs on parasites in vitro. 
The purpose of this study was to utilize whole blood culture and flow cytometric 
analysis (FACS) to evaluate the effect of oxytetracycline, imidocarb and enrofloxacin against 
A. marginale obtained from two different geographic locations. The percent reduction in HE 
positive cells was used to select cultures to inoculate into calves in order to determine a 
minimum rickettsiocidal concentration (MRC). 
Materials and methods 
This protocol was approved by the Committee on Animal Care (COAC) at Iowa State 
University. 
Propagation of A. marginale in splenectomized calves 
Two Holstein calves were obtained from the Iowa State University Dairy Breeding 
Research facility at Ankeny, IA. Animals were confirmed free of A. marginale antibodies by 
competitive enzyme linked immunoabsorbent assay (<30% inhibition) (cELISA Anaplasma 
Antibody Test Kit,VMRD Inc., Pullman, WA) (Torioni De Echaide et al., 1998). 
Splenectomies were performed when calves were approximately 3 months old using the 
technique described by Thompson et al. (1992). 
Approximately 6-8 weeks after splenectomy, one calf was infected with 10ml of 
blood stabilate containing an Oklahoma isolate with 31.6% parasitized erythrocytes. The 
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second calf received 10ml of blood stabilate containing a Virginia isolate with 35.5% 
parasitized erythrocytes. Blood stabilates were prepared from packed erythrocytes washed in 
phosphate-buffered saline (PBS) and frozen in liquid nitrogen at a 1:1 ratio with PBS 
containing 10% dimethylsulphoxide (DMSO). Stabilates were maintained frozen in liquid 
nitrogen and dry ice prior to inoculation. 
Post-infection monitoring 
Following infection, blood samples were collected at least once a week post-infection 
to determine percent parasitized erythrocyte (PPE) and packed cell volume (PCV). Blood in 
EDTA was refrigerated prior to PCV testing or packaged in insulated material for overnight 
delivery by courier to Oklahoma State University for determination of the PPE. 
Blood smears for PPE determination were stained using a 30-s, three-step staining 
technique (Hema 3® Staining System, Fisher Scientific) comparable to the Wright-Giemsa 
method. Two slides were prepared for each blood sample and examined for the presence of 
A. marginale at lOOOx magnification using a grid. A total of 500 cells were counted within 
the 4 squares of the grid and the number of infected cells was recorded. The PPE was the 
number of infected cells divided by the total number of cells counted, multiplied by 100. 
PCVs were determined by partially filling heparinized capillary tubes (Chase 
Scientific Glass Inc., Rockwood, TN) with blood which were then centrifuged for 3 min 
using an Adams Micro-Hematocrit centrifuge (Model CT 2900, Clay Adams Inc., New 
York). 
Preparation of erythrocyte cultures 
At the time blood was collected aseptically, in heparin from splenectomized calves, 
the PPE was 28.6% and 31.4% for animals inoculated with the Virginia and Oklahoma 
isolate respectively. Whole blood was centrifuged at 600 x g at 4 °C for 15 min and the 
plasma and buffy coat was removed. Cells were resuspended and washed twice in RPMI 
1640 culture medium (Cellgro, Mediatech Inc., Hemdon, VA) at 4 °C (Kessler et al., 1979). 
Drug susceptibility assays were performed in 96-well culture microplates in the 
presence of a final erythrocyte concentration of 10% (vol/vol) and serial dilutions of drugs. 
Forty-eight wells on each plate were inoculated with the Virginia isolate with the remainder 
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inoculated with the Oklahoma isolate. Cell culture medium comprised RPMI1640 
supplemented with 20% heat-inactivated fetal bovine serum, 25 mM HEPES buffer, 200 mM 
glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin. Controls consisted of plates 
containing erythrocytes infected with each isolate without the addition of the antimicrobials 
to be tested and non-infected bovine erythrocytes. 
Antimicrobial agents 
Stock solutions of antimicrobials at a concentration of 1 mg/ml were prepared in cell 
culture medium. These stock solutions were used to prepare the following antimicrobial 
dilutions: Oxytetracycline hydrochloride (OTC) (Sigma-Aldrich, St Louis, MO) at 1, 2, 4, 8 
and 16 pg/ml; imidocarb (IMD) (N,N'- Bis[3-(4,5-dihydro-lH-imidazol-2-yl)phenyl]urea 
dipropanoate, 99%) (Sigma-Aldrich, St Louis, MO) at 0.25, 0.5,1, 2 and 4 pg/ml and 
enrofloxacin (ENRO) (Fluka, Buchs, Switzerland) at 0.25, 0.5, 1, 2 and 4 pg/ml. For each 
drug dilution and isolate combination, a volume of 180 pi of each dilution was added to each 
of 48 wells. Following addition of 20 pi of washed packed erythrocytes, cultures were 
incubated at 37 °C and 5% CO2 for 7 days. 
Cell preparation and hydroethidine staining 
On each study day, 3 wells from each isolate and drug concentration including the 
control cultures were washed in separate centrifugation tubes containing 1 ml lx phosphate-
buffered saline (PBS). Samples were pelleted by centrifugation for 5 min at 450 x g at 4 °C. 
Cell staining for FACS was performed using a method similar to that described by 
Wyatt et al. (1991). Briefly, dihydroethidium (hydroethidine) (HE) (Molecular Probes, 
Eugene, OR) was solubilized in anhydrous DMSO at 1 mg/ml as a stock solution. Fifteen 
micrograms of solubilized HE was diluted in 1 ml PBS which was added to the cell pellet. 
Suspensions were incubated in the absence of light for 30 min at 37 °C, 5% CO2. Following 
incubation, 980 pi of suspension was removed and replaced with 1 ml PBS. Diluted samples 
were centrifuged for 5 min at 450 x g at 4 °C. Pelleted erythrocytes were resuspended in 1 ml 
FACS buffer containing 0.1% bovine serum albumin and 1 x PBS. Unused HE in DMSO 
was frozen at -20 °C in 1 ml aliquots and thawed at 37 °C prior to use. 
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Flow cytometric analysis 
Cell suspensions to be analyzed by FACS were diluted with PBS to obtain a flow rate 
of 2000-5000 fluorescent events/s. A total of 150,000 events were counted daily for each of 
the three wells harvested from culture. An inclusion gate was set based on the forward scatter 
and side scatter characteristics of the HE-treated uninfected erythrocyte control. The 
suspensions were analyzed by argon-ion laser fluorescence excitation at 488 nm and 
emission at 585 nm (range: 563-607 nm) (FL-2) in log F12 data mode using a Becton-
Dickinson FACScan and CellQuest computer software (BD Biosciences, San Jose, CA). 
Fluorescent profiles were recorded for later analysis using Flow Jo computer software (Tree 
Star Inc., Ashland, OR). 
Testing infectivity of selected cultures 
The infectivity of parasitized erythrocytes following 7 days of culture was determined 
from samples selected on the basis of the FACS results. The contents of 20 wells (4,000 jxl) 
from each selected sample were pelleted by centrifugation at 450 x g for 5 min. 
Approximately 400 ^1 packed cells were resuspended in 1.5 ml RPMI1640. Samples were 
stored on ice prior to inoculation into non-splenectomized Holstein calves. 
Fifteen Holstein calves were confirmed free of A. marginale antibodies by two 
consecutive cELISA tests (Anaplasma Antibody Test Kit, VMRD Inc., Pullman, WA). 
Resuspended erythrocytes were inoculated intravenously by jugular injection using a 16 G, 1 
in. needle. Two calves received untreated infected control culture suspensions while one calf 
received the uninfected control suspension. The remaining 12 calves received selected treated 
samples. Four calves were randomly assigned to each antimicrobial treatment with two pairs 
receiving the Oklahoma and Virginia isolate, respectively. 
Following inoculation, calves were monitored daily for clinical signs of anaplasmosis, 
including anorexia, depression and listlessness. Blood samples were collected at least once 
weekly for approximately 8 weeks post-infection for PPE, PCV and cELISA serology as 
previously described. After 8 weeks calves failing to demonstrate signs of anaplasmosis were 
splenectomized and monitored for an additional 4 weeks. Cultures exposed to antimicrobial 
concentrations that failed to cause disease following subinoculation into calves were deemed 
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sterilized. These drug concentrations were considered rickettsiocidal after 7 days. Those 
cultures in which infectivity was retained were deemed treatment failures. 
Statistical analyses 
Data were entered into a spreadsheet program (Excel 2003, Microsoft Corporation, 
Redmond, WA) for subsequent calculation and manipulation. The mean ± SEM (standard 
error of the mean) HE positive cell count was calculated from the 3 wells from each culture 
analyzed each day. The percent reduction in HE positive cells was determined as the mean 
number of HE positive (infected) cells in the test culture subtracted from the mean number of 
HE positive (infected) cells in the control culture divided by the total number of HE positive 
control cells, multiplied by 100. 
Hypothesis tests were conducted using JMP 5.1.2 analytical software (SAS Institute 
Inc., Cary, NC). FACS data were analyzed using repeated measures analysis. The null 
hypothesis was that there was no difference between treated and control cultures. The 
analysis of variance approach to repeated measures data was used based on a review by 
Everitt (1995). The Wilk's lambda test was selected to evaluate within group interactions and 
evidence of time x group interactions. This test is a likelihood ratio statistic for testing that a 
multivariate contrast is zero, assuming multivariate normality and further assuming equality 
of covariance matrices across groups (Everitt and Dunn, 2001). In all analyses the Wilk's 
lambda test indicated a statistically significant interaction (P < 0.001). 
Accordingly, differences between antimicrobials and antimicrobial dilutions were 
analyzed using ANOVA and the Tukey-Kramer HSD (honest significant difference) method 
for multiple comparisons. This test is an exact alpha-level test if the sample sizes are the 
same and conservative if the sample sizes are different (Hayter, 1984). Statistical significance 
was designated a priori as a P-value less than or equal to 0.05. Differences between isolates 
exposed to a particular drug concentration on a particular day were analyzed using Wilcoxon 
rank sum tests (chi square approximation) as these data were not normally distributed. Pooled 
differences between isolate means over the 7-day period of the study were analyzed using 
student t tests. 
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Results of cELISA testing following inoculation of selected cultures into Holstein 
calves were analyzed using a simple linear regression model (Mutapi and Roddam, 2002). In 
this model the cELISA results were taken as the response variable and days post-inoculation 
were the explanatory variable. The null hypothesis was that cultures exposed to 
antimicrobials were not infective and accordingly did not elicit a serological response 
following inoculation. This hypothesis was tested using a student t test of the slope of the 
linear regression line to determine if the gradient was zero (Zou et al., 2003). A f-value 
>0.05 indicated that the slope of the regression line could be zero suggesting lack of 
seroconversion. A statistically significant P-value (<0.05) indicated the antimicrobial dilution 
tested did not sterilize infection in culture. 
In order to determine the percent HE positive cells which most closely correlated with 
sterilization of anaplasmosis infections in culture, we conducted receiver-operating 
characteristic (ROC) analysis on each day of the study (Greiner et al., 2000). The underlying 
assumption of ROC analysis is that the diagnostic variable (FACS data) can be used to 
discriminate between two mutually exclusive states; in this case infectivity (as determined by 
PPE and cELISA >30% in infected calves) or non-infectivity of test cultures following 
inoculation into calves. An ROC curve is a plot of sensitivity by (1 - specificity) for each 
percent reduction value. The area under the ROC curve (AUC) is a common index used to 
summarize the information contained in the curve. In the case of a perfect test the AUC 
would be 1. The curve of the ROC plot can be used to determine the optimal sensitivity and 
specificity cut-off value to predict infectivity from flow cytometry data. 
Results 
Detection of parasitized erythrocytes 
Differences in HE conversion were detected between uninfected and infected 
erythrocytes incubated with HE and analyzed by flow cytometry. Representative FACS 
histograms of HE treated samples are shown in Fig. 1. Cells in uninfected cultures did not 
convert HE as demonstrated by a single population of cells represented as a single histogram 
peak. Parasitized cells in infected cultures that converted HE to ethidium had an increase in 
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fluorescent intensity and appeared as a second population of cells, seen as a second peak, on 
the histogram. 
Differences in mean percent reductions between antimicrobials 
The mean percent reduction in HE positive cells pooled across isolates for all 
antimicrobial dilutions are presented in Fig. 2. There was significant evidence of a difference 
in the mean percent reduction in HE positive erythrocytes between the enrofloxacin, 
imidocarb and oxytetracycline treated cultures on all days of the study (ANOVA P < 0.05). 
Comparisons for all pairs using Tukey-Kramer HSD indicated that after 24 h there 
were significantly fewer parasitized cells in the oxytetracycline (30.02 ±2.71% reduction) 
and enrofloxacin (23.01 ± 2.24% reduction) cultures compared with the imidocarb (10.79 ± 
1.40% reduction) (P < 0.01). On day 2 and day 6 there were fewer parasitized erythrocytes in 
the enrofloxacin treated cultures and significantly more parasites in the oxytetracycline 
treated cultures. On the remaining days of the study there was no difference between 
enrofloxacin and imidocarb treated cultures but significantly more parasitized cells in the 
oxytetracycline treated cultures. 
Differences in mean percent reductions between antimicrobial dilutions 
The mean percent reduction in HE positive cells for each antimicrobial dilution by 
isolate are presented in Fig. 3-5. The results for each antimicrobial tested are summarized 
below. 
Enrofloxacin 
When data from both isolates were pooled, the percent reduction in HE positive cells 
increased with increasing antimicrobial concentrations in cultures exposed to enrofloxacin 
for 7 days. Cultures exposed to 4 pg/ml enrofloxacin had a greater percent reduction in 
parasitized cells (44.72 ± 2.43%) when compared with cultures exposed to 0.5-2 pg/ml 
enrofloxacin (32.48 ± 1.74% to 34.51 ± 1.76%) (P < 0.01). These cultures in turn had fewer 
HE positive cells than cultures exposed to 0.25 pg/ml enrofloxacin (17.17 ± 1.99% 
reduction) (P < 0.01). 
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In comparison with the other antimicrobials, cultures exposed to 4 pg/ml enrofloxacin 
had significantly fewer parasitized erythrocytes than cultures exposed to 0.25; 0.5 and 4 
pg/ml imidocarb and 1-16 pg/ml oxytetracycline (P < 0.05). Similarly, cultures exposed to 
0.5-2 pg/ml enrofloxacin had significantly fewer parasitized erythrocytes than cultures 
exposed 0.25 pg/ml imidocarb and 1-16 pg/ml oxytetracycline (P < 0.05). 
Imidocarb 
A paradoxical increase in HE positive cells was observed in cultures exposed to 4 
pg/ml imidocarb for 7 days when data from both isolates was pooled. Cultures exposed to 1 
and 2 pg/ml imidocarb (36.64 ± 2.91% and 35.45 ± 3% reduction, respectively) had 
significantly greater percent reduction in parasitized cells when compared with cultures 
exposed to 0.5 and 4 pg/ml imidocarb (25.00 ± 2.19% and 24.44 ± 1.70% reduction, 
respectively) (P < 0.05). These cultures in turn had fewer HE positive cells than cultures 
exposed to 0.25 pg/ml imidocarb (14.77 ± 1.71%) (P < 0.05). In comparison with the other 
antimicrobials, cultures exposed to 1 and 2 pg/ml imidocarb had significantly fewer 
parasitized erythrocytes than cultures exposed to 0.25 pg/ml enrofloxacin (17.17 ± 1.99%) 
and 1-16 pg/ml oxytetracycline (10.70 ± 5.24 to 9.09 ± 3.26% reduction) (P < 0.05). 
Oxytetracycline 
There was no relationship or significant difference between the mean percent 
reduction in parasitized erythrocytes and increasing antimicrobial dilutions in cultures 
exposed to oxytetracycline for 7 days (P > 0.05) (Fig. 5). The greatest reduction in HE 
positive cells occurred within the first 24 h of exposure to oxytetracycline (Range: 23.53 ± 
2.33% (16 pg/ml OTC) to 38.59 ± 3.77% (4 pg/ml OTC)). Over the 7 days of the study the 
mean percent reduction ranged from 6.40 ± 1.64% to 9.37 ± 1.43% in the cultures exposed to 
8 pg/ml and 16 pg/ml oxytetracycline, respectively. In comparison with the other 
antimicrobials, cultures exposed to oxytetracycline had a significantly lower percent 
reduction in HE positive cells. 
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Differences between isolates 
There was considerable variation in the percent reduction in HE positive cells over 
the 7-day period of the study with statistical differences noted at various drug dilutions on 
several days. The mean percent reduction in HE positive cells for each isolate are presented 
in Fig. 3-5. 
Enrofloxacin 
There was a significantly greater percent reduction in HE positive cells in the 
Virginia isolate cultures when compared with the Oklahoma cultures exposed to 0.5 pg/ml 
enrofloxacin (34.60 ± 2.96% compared to 28.90 ± 1.53% (P = 0.04) and 2 pg/ml 
enrofloxacin (40.31 ± 2.36% compared to 28.72 ± 1.96% (P = 0.0005) for 7 days. 
Numerically there was a greater percent reduction in HE positive cells in the Oklahoma 
isolate culture exposed to 4 pg/ml enrofloxacin (47.30 ± 3.41% compared to 42.15 ± 3.47%) 
although this was not statistically significant (P = 0.296). 
Imidocarb 
Significant differences between isolates were observed in cultures exposed to 0.5—4 
pg/ml imidocarb. In all cases, a greater reduction in parasitized cells occurred in cultures 
infected with the Oklahoma isolate. This ranged from 30.61 ± 2.66% compared to 20.28 ± 
1.44% reduction in the Virginia isolates exposed to 4.0pg/ml imidocarb (P = 0.0018) to 
48.93 ± 3.97% compared to 24.34 ± 1.95% reduction in cultures exposed to 1.0pg/ml 
imidocarb (P = 0.0001). 
Oxytetracycline 
There was a significantly greater percent reduction in HE positive cells in the 
Virginia isolate cultures when compared with the Oklahoma cultures exposed to 8 pg/ml 
oxytetracycline: 11.43 ± 2.83% compared to 1.35 ± 0.68%, respectively (P = 0.002). The 
difference between isolates exposed to 16 pg/ml oxytetracycline was approaching 
significance, 12.06 ± 1.94% (VGN) compared to 6.67 ± 1.98% (OK) (P = 0.059) for 7 days. 
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Testing infectivity of selected cultures 
Percent reduction in HE positive cells obtained by FACS was used to select pairs of 
cultures infected with the Virginia and Oklahoma isolates treated with 0.25 and 4.0 pg/ml 
enrofloxacin, 0.25 and 1.0 pg/ml imidocarb and 1.0 and 16.0 pg/ml oxytetracycline for 
inoculation into calves. These data and the cELISA results used to monitor seroconversion in 
calves following inoculation is summarized in Table 1 and Fig. 6. 
Cultures containing uninfected blood and those infected with the Oklahoma isolate 
exposed to 4.0 pg/ml enrofloxacin and the Virginia and Oklahoma isolates exposed to 1.0 
pg/ml imidocarb failed to elicit a serological response or parasitemia in calves (cELISA 
<30% inhibition). Following splenectomy these animals failed to demonstrate evidence of 
infection. The remaining calves developed à parasitemia and seroconverted within 10 to 31 
days post-inoculation. Linear regression of cELISA against days post-inoculation indicated 
that calves with higher percent reductions tended to have smaller intercepts and/or reduced 
slopes and took longer to seroconvert. 
Comparison between FACS and in vivo infectivity 
The results of the ROC analysis are summarized in Table 2. The area under the ROC 
curve ranged from 0.67 on day 1 to 0.95 on day 3. On day 1, the ability of FACS to detect 
infection in culture (sensitivity) was 47% and ability of FACS to detect sterilization of 
culture (specificity) was 91% at a cut-off value of 7.89% HE positive cells. This increased to 
a sensitivity of 88% and a specificity of 86% at a cut-off of 14% HE positive cells on day 3. 
Discussion and conclusions 
The purpose of the present study was to utilize whole blood culture and flow 
cytometric analysis (FACS) to evaluate the effect of enrofloxacin, imidocarb and 
oxytetracycline against an Oklahoma and Virginia isolate of A. marginale. The percent 
reduction in HE positive cells was used to select cultures to inoculate into calves in order to 
determine the infectivity of the culture. These data indicate that the MRC of enrofloxacin 
against the Oklahoma isolate of A. marginale was greater than 0.25 pg/ml but <4.0 pg/ml. 
However, the MRC of enrofloxacin against the Virginia isolate was greater than 4.0 pg/ml. 
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In contrast the MRC of imidocarb against both isolates was between 0.25 pg/ml and 1.0 
pg/ml. The MRC of oxytetracycline required to be effective against anaplasmosis is greater 
than 16.0 pg/ml. 
The data presented suggest that flow cytometry can be a reliable predictor of 
infectivity although this varied between days of the study. The area under the ROC curve 
ranged from 0.67 on day 1 to 0.95 on day 3. ROC analysis has been increasingly used for the 
evaluation of clinical laboratory tests, however, its use in medical and veterinary literature is 
limited (Greiner et al., 2000). The area under the ROC curve is a global summary statistic of 
diagnostic accuracy. According to an arbitrary guideline suggested by S wets (1988), these 
data can distinguish between non-informative (AUC = 0.5), less accurate (0.5 < AUC <0.7), 
moderately accurate (0.7 < AUC <0.9), highly accurate (0.9 < AUC < 1.0) and perfect tests 
(AUC =1). Based on these guidelines the optimum correlation between FACS data and 
infectivity occurred on day 3 when the AUC was 0.95. This would suggest that future 
susceptibility studies using this method may be conducted over 3 as opposed to 7 days as in 
the present study. 
Our results indicate that enrofloxacin inhibits A. marginale in a concentration 
dependent manner. Enrofloxacin is a fluoroquinolone antimicrobial that inhibits bacterial 
DNA-gyrase (Topoisomerase II) and Topoisomerase IV (Blondeau, 2004). This activity 
prevents DNA supercoiling and decantenation of original chromosomes and replicates. Two 
published reports indicate that enrofloxacin (Baytril®, Bayer Animal Health) is effective 
against acute A. marginale infections in vivo at dose rates of 5-10 mg/kg (Schroder et al., 
1991; Guglielmone et al., 1996). To our knowledge this is the first report attempting to 
elucidate a minimum inhibitory concentration of enrofloxacin against A. marginale. These 
data, in conjunction with published pharmacokinetic and pharmacodynamic information, 
may facilitate an assessment of the potential use of enrofloxacin against persistent A. 
marginale infections. 
The bactericidal activity of fluoroquinolone antimicrobials is dependant on the ratios 
of the area under the plasma drug concentration curve (AUC) to the minimum inhibitory 
concentration (MIC) for bacteria. Studies reviewed by Drusano et al. (2001) investigating 
this relationship in human Pseudomonas aeruginosa infections found that the optimal 
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AUC/MIC ratio for a fluoroquinolone was >125. The AUC from 0-12 h following 
subcutaneous administration of enrofloxacin to calves challenged with Mannheimia 
haemolytica at 8 mg/kg to calves was 7.51 mgh/L (Terhune et al., 2005). Kaartinen et al. 
(1997) reported an AUC of 13.94 mg h/L in one-day-old calves and 6.73 mg h/L in one-
week-old calves. If the AUC/MIC ratio described in bacteria applies to A. marginale, this 
would suggest that a prohibitive increase in drug dose would be required in order to achieve 
rickettsiacidal plasma concentrations in vivo. 
It should be noted that enrofloxacin is de-ethylated to ciprofloxacin in calves. 
Ciprofloxacin contributes between 10% and 27% of the total concentration in serum 
(Kaartinen et al., 1997). The study reported herein only investigated the effect of 
enrofloxacin and not ciprofloxacin in vitro. Antimicrobial susceptibility studies involving 
ciprofloxacin have been conducted against Anaplasma phagocytophilum which causes 
human granulocytic anaplasmosis (HGE). When this organism is grown in the human 
promyelocyte cell line, the MIC of ciprofloxacin is between 1 pg/ml and 2 pg/ml (Klein et 
al., 1997; Branger et al., 2004). Further studies to evaluate the MIC of fluoroquinolones 
against A. marginale are necessary to fully assess the potential for eliminating carrier 
infections. 
The present study examined two geographically and phylogenetically distinct isolates 
of A marginale as described by de la Fuente et al. (2001). Our study revealed statistical 
difference between the two isolates exposed to 0.5 and 2 pg/ml enrofloxacin for 7 days. 
However only the Oklahoma isolate exposed to 4.0 pg/ml failed to infect a healthy calf. 
Maurin et al. (2003) demonstrated differences in the MIC of the fluoroquinolone 
levofloxacin against different geographic isolates of Anaplasma phagocytophilum. In vitro 
MICs varied from 0.06-0.5 pg/ml which is reported to be close to the maximum levels 
achievable in human serum. These researchers previously demonstrated a DNA gyrase-
mediated natural resistance to fluoroquinolones in Ehrlichia chaffeensis and Ehrlichia canis 
(Maurin et al., 2001). This corresponds to a single amino acid difference in gyrA which 
encodes the A subunit of DNA gyrase in A. phagocytophilum. Our study suggested that 
susceptibility differences may exist between the Oklahoma and Virginia isolate of A. 
marginale, but the exact mechanism still remains to be elucidated. This finding would limit 
108 
the widespread use of enrofloxacin in field cases of A. marginale. Federal (USA) law also 
prohibits the extra-label use of enrofloxacin in food producing animals. 
In this study, imidocarb demonstrated paradoxically more HE positive cells in 
cultures exposed to 4 pg/ml than cultures exposed to 1 and 2 pg/ml. A statistical difference 
was also found between the two isolates exposed to 0.5-4 pg/ml imidocarb for 7 days. 
Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually 
administered as the dipropionate salt by subcutaneous or intramuscular injection to cattle at a 
dose rate of 2.1 mg/kg. The mode of action of action of imidocarb is uncertain though two 
mechanisms have been proposed: interference with the production and/or utilization of 
polyamines, or prevention of entry of inositol into the erythrocyte containing the parasite 
(EMEA, 2001). 
Imidocarb dipropionate has been used for over 30 years in the treatment of bovine 
anaplasmosis in certain territories (McHardy and Simpson, 1974). Roby and Mazzola (1972) 
found that two injections of imidocarb, administered at 5 mg/kg 14 days apart, eliminated A. 
marginale from carrier animals. Pharmacokinetic data and reports on plasma concentrations 
of imidocarb that may be effective for therapy in cattle are lacking. Studies in goats, dogs and 
horses suggest that this compound has a large volume of distribution resulting in a prolonged 
elimination half-time (Abdullah and Baggot, 1983; Belloli et al., 2002). These observations 
are confirmed by studies demonstrating a prolonged retention of the drug in edible tissues 
(EMEA, 2001). This has restricted the use of this compound in food producing animals in 
many territories. 
The paradoxical effect of antibiotics is defined as a substantially reduced bacterial 
killing at antibiotic levels above the minimum bactericidal concentration in vitro (Holm et 
al., 1991). This phenomenon was originally described for /3-lactam antibiotics against Gram 
positive bacteria. Subsequent studies have described this phenomenon with aminoglycocides 
against Gram negatives and pefloxacin against Escherichia coli (Lorian et al., 1979; 
Yourassowsky, 1986). The clinical significance of the paradoxical effect is unknown. 
However, based on pharmacokinetic data derived from other species, it would appear 
unlikely that imidocarb concentrations greater than 1 pg/ml are attainable in bovine plasma 
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without significant toxic effects. This would suggest that the paradoxical effect observed in 
vitro may have little clinical relevance. 
Oxytetracycline treatment was less efficacious at reducing HE positive cells than 
treatment with enrofloxacin or imidocarb. There was no relationship between drug 
concentration and percent reduction in HE positive cells in these cultures. The greatest 
reduction occurred within the first 24 h of exposure to oxytetracycline. A statistical 
difference between the two isolates exposed to 8 pg/ml oxytetracycline was detected, with 
the Virginia isolate appearing more susceptible. 
Oxytetracycline is a tetracycline derivative obtained from Streptomyces rimosus. 
Tetracyclines bind to ribosomes and mRNA. Inhibition of protein synthesis is mediated 
principally through reversible binding with the 30S ribosomal subunit. In bacteria, this 
binding blocks the attachment of aminoacyl-tRNA to the A site of the mRNA-ribosome 
complex (Scholar and Pratt, 2000). Tetracycline antimicrobials are bacteriostatic rather than 
bacteriocidal and the activity of these compounds is believed to be dependant on the time that 
drug concentrations remain above the minimum inhibitory concentration (MIC) for the target 
organism. Our data suggest that oxytetracycline is rickettsiastatic and that a competent host 
immune response is necessary for elimination of the pathogen. 
Blouin et al. (2002) used cultivated A. marginale in a cell line derived from embryos 
of Ixodes scapular is ticks to examine the effect of tetracycline on the organism. Tetracycline 
doses of 5, 10, 20 and 100 pg/ml resulted in significant inhibition of A. marginale growth as 
determined by ELIS A. Infected cell cultures treated with medium containing 20 pg/ml 
tetracycline proved non-infective when inoculated into susceptible splenectomized calves. 
These data suggest that the MRC may be somewhere between 16-20 pg/ml tetracycline 
although this does not account for possible differences related to in vitro culture techniques. 
In vivo pharmacokinetic studies have found that the maximum plasma concentration 
(Cmax) following IM administration of a 200mg/ml long-acting oxytetracycline formulation at 
20mg/kg was 8.56 pg/ml achieved at 2.53 h after injection. The Cmax of a new formulation of 
oxytetracycline (Tetradure LA-300®, Merial LTD) containing 300mg/ml was 10.72 pg/ml 
achieved at 4.64 h after administration (Clark and Dowling, 2003). These results suggest that 
plasma concentrations of these formulations of oxytetracycline following parenteral 
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administration are insufficient to kill A. marginale based on the MIC determined in the 
present study. 
In previous studies in which successful clearance of persistent A. marginale infections 
was achieved, oxytetracycline was administered intravenously to cattle at 11-22 mg/kg for 
5-12 days (Magonigle et al., 1975; Roby et al., 1978). Intramuscular oxytetracycline 
administered at 20mg/kg on 2, 3 or 4 occasions at intervals ranging from 3-7 days was also 
reported to be effective at eliminating carrier infections (Roby et al., 1978; Kuttler et al., 
1980; Magonigle and Newby, 1982; Kuttler, 1983; Swift and Thomas, 1983; Rogers and 
Dunster, 1984; Ozlem et al., 1988). A recent study conducted by our research group 
demonstrated that the current recommended OIE treatment protocol of 5 injections of 
oxytetracycline at 22 mg/kg intravenously did not eliminate persistent Oklahoma isolate 
infections (Coetzee et al., 2005). These conflicting reports suggest that possible differences 
in susceptibility between isolates may exist. This hypothesis is supported by the recent 
identification of two multidrug resistance pumps in the genome of A. marginale (Brayton et 
al., 2005). However, the clinical significance or activity of these pumps has yet to be 
elucidated. 
The results of the present study demonstrate that short term blood culture and FACS 
can be used to determine the antimicrobial susceptibility of A. marginale and to evaluate the 
efficacy of novel antimicrobials in vitro. Cultures infected with the Oklahoma isolate 
exposed to 4.0 pg/ml enrofloxacin and the Virginia and Oklahoma isolate exposed to 1.0 
pg/ml imidocarb for 7 days were sterilized. Enrofloxacin inhibited A. marginale in a 
concentration-dependent manner whereas higher concentrations of imidocarb were 
paradoxically less effective at reducing the number of parasitized erythrocytes. 
Oxytetracycline was the least efficacious antimicrobial tested and there was no relationship 
between oxytetracycline concentration and percent reduction in HE positive cells. With the 
exception of cultures exposed to enrofloxacin at 4.0 pg/ml, the isolate differences observed 
in vitro did not translate to differences in infectivity in this experiment. Further studies are 
required to fully elucidate the susceptibility profile of different A. marginale isolates. These 
data are essential to facilitate the development of successful chemotherapeutic protocols for 
the elimination of persistent A. marginale infections. 
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Fig. 1: Flow Cytometry Histograms. Cells in uninfected cultures did not convert 
Hydroethidine (HE) as demonstrated by a single histogram peak population (A). 
Parasitized cells infected cultures converted HE to ethidium bromide and appeared as 
a second gated (18.4%) population in untreated cultures (B). Selected Oklahoma 
(OK) and Virginia (VGN) isolate cultures exposed to 16pg/ml oxytetracycline (OTC) 
(C), 4 pg/ml enrofloxacin (ENRO) (D), and 1 pg/ml imidocarb (IMD) (E) and (F) for 
5 days are presented. Samples D-F failed to infect calves after 7 days of culture. 
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Figure 2: Comparison between the total mean percent reduction in HE positive cells in cultures treated with 
enrofloxacin, imidocarb and scytetracycline for 7 days 
* Significant difference in mean % reduction between antimicrobials (p < 0.05) 
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Figure 3: Comparison between the mean percent reduction in hydroethidine positive cells in the Virginia (VGN) 
and Oklahoma (OK) isolates following exposure to enrofloxacin for 7 days 
* Significant difference in mean % reduction between isolates (p < 0.05) 
**Significant difference in mean % reduction between antimicrobial dilutions pooled across isolates (p < 0.01) 
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Figure 4. Comparison between mean percent reduction in hydroethidine positive cells in the Virginia (VGN) and 
Oklahoma (OK) isolates following exposure to imidocarb for 7 days 
**Significant difference in mean % reduction between antimicrobial dilutions across isolates (p < 0.01) 
* Significant difference in mean % reduction between isolates (p < 0.05) 
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Figure 5. Comparison between the mean percent reduction in hydroethidine positive cells in the 
Virginia (VGN) and Oklahoma (OK) isolates following exposure to oxytetracycline for 7 days 
* Significant difference in mean % reduction between isolates (p < 0.05) 
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Figure 6: Serological responses measured by competitive ELISA (cELISA) following inoculation of selected 
erythrocyte cultures into Holstein calves 
Table 1 : Flow cytometry data used for selecting erythrocyte cultures and competitive ELISA data collected from calves 
following inoculation of cultures incubated with or without the addition of antimicrobials for 7 days 
Mean % 
Isolate3-Antimicrobialb- Reduction by 
Dilution0 F ACS following 
7 days of culture 
cELISA (% inhibition) cELISA Linear Regression 
Pre-
inoculation 
59 Days Post-
inoculation 
Days to 
Seroconversion 
(cELISA > 30%) 
Intercept Slope p-Value 
Uninfected Control n/a 0 1.76 n/a -0.12 0.03 0.22 
OK-Infected Control n/a 0 87.83 10 days 23.35 1.43 0.003 
VGN- Infected Control n/a 0 89.43 18 days 24.18 1.45 0.006 
OK-ENRO- 0.25 ug/ml 15.38% 0 82.50 31 days -3.51 1.94 0.013 
VGN-ENRO- 0.25 ug/ml 18.34% 0 86.84 24 days 4.32 1.63 0.0001 
OK-ENRO- 4.0 fxg/ml 47.30% 0 0.17 n/a 6.75 -0.06 0.71 
VGN-ENRO- 4.0 ug/ml 42.15% 0 86.94 31 days -8.88 1.75 0.0007 
OK-IMD- 0.25 ug/ml 17.04% 0 88.93 18 days 18.41 1.55 0.002 
VGN-IMD-0.25 ug/ml 11.56% 0 81.65 31 days -5.13 1.79 0.002 
OK-IMD-1.0 ug/ml 48.93% 0 11.44 n/a 6.89 0.01 0.96 
VGN-IMD-1.0 ug/ml 24.34% 0 3.96 n/a -0.73 0.085 0.062 
OK-OTC-l.O ug/ml 15.03% 0 89.43 24 days 7.69 1.68 0.0004 
VGN-OTC-l.O ug/ml 6.38% 0 86.54 18 days 25.40 1.38 0.0047 
OK-OTC-16.0 ug/ml 6.12% 0 82.85 18 days 17.45 1.47 0.009 
VGN-OTC-16.0 ug/ml 12.06% 0 86.84 10 days 14.41 1.54 0.0003 
"Isolate: VGN-Virginia isolate; OK-Oklahoma isolate 
bAntimicrobial: ENRO-enrofloxacin; IMD-imidocarb; OTC-oxytetracycline 
^Dilution: 0.25 ug/ml; 1.0 ug/ml; 4.0 |ig/ml; 16.0 pg/ml 
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Table 2: Summary of the receiver-operating characteristic (ROC) analysis used to 
determine the percent HE positive cells which most closely correlated with 
sterilization of anaplasmosis infections in culture on each day of the study. 
Study Day Area Under ROC Curve (AUC) 
Cut-off Value 
(HE + ve cells) Sensitivity Specificity 
1 0.67 7.89% 47% 91% 
2 0.78 16.20% 60% 95% 
3 0.95 14% 88% 86% 
4 0.89 11.70% 80% 100% 
5 0.86 12.10% 73% 100% 
6 0.79 7.69% 68% 100% 
7 0.84 6.15% 77% 100% 
aAUC: Non-informative, AUC=0.5; less accurate, 0.5<AUC <0.7; moderately accurate, 
0.7<AUC <0.9; highly accurate, 0.9<AUC < 1.0; and perfect tests, AUC = 1 (Swets, 1988). 
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CHAPTER 5. INHIBITORY EFFECT OF ENROFLOXACIN AGAINST 
SEVERE EXPERIMENTAL ANAPLASMA MARGINALE 
INFECTIONS IN SPLENECTOMIZED CALVES 
A paper submitted for publication in Veterinary Parasitology 
Johann F. Coetzee and Michael D. Apley 
Abstract 
Anaplasma marginale is the most prevalent tick-borne pathogen of cattle world wide. 
Oxytetracycline and imidocarb dipropionate are currently the only compounds available to 
treat acute anaplasmosis infections. This study tested the efficacy of enrofloxacin 
(Baytril®100, Bayer Animal Health) against severe experimental A. marginale infections in 
splenectomized calves. Six Holstein steers, aged less than 8 months, were confirmed 
anaplasmosis free by competitive ELISA (cELISA) and then splenectomized. At least 6 
weeks after splenectomy, two calves were inoculated with a West Coast (St. Maries) isolate 
of A. marginale; three calves were infected with an Oklahoma isolate while the remaining 
calf was infected with a Virginia isolate. Calves developed peak rickettsemias ranging from 
28.6-55% parasitized erythrocytes (PPE) within 15-39 days after infection. The packed cell 
volume (PCV) at this time ranged from 12-32.5%. Two animals infected with the Oklahoma 
isolate were designated untreated control animals. The remaining four animals received two 
subcutaneous injections of enrofloxacin at a dose rate of 12.5 mg/kg, administered 48 h apart. 
Following treatment, PPE and PCV measurements were collected for approximately 6 weeks. 
These data were analyzed using analysis of variance (ANOVA), paired student t-tests and a 
simple linear regression model. Both untreated control calves became moribund when the 
PCV dropped below 10% and were euthanized for humane reasons. The difference in PPE 
between the treated and control animals was approaching significance at this time point (P = 
0.061). A precipitous decline in PPE from a pre-treatment mean of 39.13% to less than 1% 
was observed in the first 12 days following treatment with enrofloxacin (P < 0.0002). A 
recrudescence of A. marginale parasites was observed in all treated animals within 30 days 
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following treatment. In three cases the subsequent wave of rickettsemia was less severe and 
self limiting. However one animal contracted respiratory disease and had to be euthanized. 
These data indicate that enrofloxacin administered at 12.5 mg/kg twice, 48 h apart 
ameliorates, but does not clear, A. marginale infection in splenectomized calves. Untreated 
animals subjected to this model died. Further studies are warranted to investigate whether a 
dose regimen of enrofloxacin can be identified to eliminate A. marginale infection from 
persistently infected cattle. 
Introduction 
Anaplasmosis, caused by the rickettsial hemoparasite, Anaplasma marginale, is the 
most prevalent tick-transmitted disease of cattle worldwide (Uilenberg, 1995; Dumler et al., 
2001; Kocan et al., 2003). Prior to the development of imidocarb dipropionate and the 
tetracycline antimicrobials, a variety of chemotherapeutic agents, including arsenicals, 
antimalarials, antimony derivatives and dyes, were used to treat acute anaplasmosis. These 
compounds had little if any chemotherapeutic effect (Potgieter and Stoltz, 1994). 
Chlortetracycline and oxytetracycline are the only compounds available for 
prevention and control of acute anaplasmosis in the United States. Anaplasma infections are 
not sterilized at the usual recommended therapeutic doses of the tetracycline drugs (Kuttler 
and Simpson, 1978; Stewart et al., 1979). There are currently no antimicrobials labeled for 
the elimination of persistent infections in carrier animals. In previous studies in which 
successful clearance of persistent A. marginale infections was achieved, oxytetracycline was 
administered intravenously to cattle at 11-22 mg/kg for 5-12 days (Magonigle et al., 1975; 
Roby et al., 1978). Intramuscular oxytetracycline administered at 20 mg/kg on two, three, or 
four occasions at intervals ranging from 3-7 days was also reported to be effective at 
eliminating carrier infections (Roby et al., 1978; Kuttler et al.„ 1980; Magonigle and Newby, 
1982; Kuttler, 1983; Swift and Thomas, 1983; Rogers and Dunster, 1984; Ozlem et al., 
1988). 
Splenectomized calves have been used as a model for evaluating the efficacy of 
antimicrobials against A. marginale (Miller et al., 1952; Roby, 1972; Stewart et al., 1979; 
Kuttler, 1986). Successful clearance of anaplasmosis in splenectomized calves has not been 
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achieved with either imidocarb or oxytetracycline (Stewart et al., 1979; Kuttler, 1986). This 
may be due to inadequate serum drug concentrations achieved with these products or the 
absence of an adequate immune response to work in combination with the antimicrobial to 
bring about elimination of the parasite (Kuttler et al., 1980). 
Enrofloxacin is a fluoroquinolone antimicrobial that inhibits bacterial DNA-gyrase 
(Topoisomerase II) and Topoisomerase IV (Blondeau, 2004). This activity prevents DNA 
supercoiling and decatenation of original chromosomes and replicates. The bactericidal 
activity of enrofloxacin is concentration dependent, with susceptible bacteria cell death 
occurring within 20-30 min of exposure. Two published reports indicate that enrofloxacin 
(Baytril®, Bayer Animal Health) is effective against acute A. marginale infections at dose 
rates of 5-10 mg/kg (Schroder et al., 1991; Guglielmone et al., 1996). However the dynamics 
of the infection following treatment and the potential for elimination of the carrier state was 
not assessed. The need for additional trials to study whether enrofloxacin is useful to control 
severe anaplasmosis infections was also identified (Guglielmone et al., 1996). 
The purpose of this study was to test the efficacy of enrofloxacin (Baytril® 100, Bayer 
Animal Health) against experimental A. marginale infection in splenectomized calves. The 
specific aims were to evaluate the efficacy of enrofloxacin administered subcutaneously to 
severely infected animals (>25%parasitized erythrocyte (PPE) twice, 48 h apart at a dose rate 
of 12.5 mg/kg. In addition it was our intent to study the dynamics of A. marginale infection 
following treatment in order to ascertain whether this antimicrobial could be efficacious 
against persistent A. marginale infections caused by a variety of isolates. 
Materials and methods 
This protocol was approved by the Committee on Animal Care (COAC) at Iowa State 
University. 
Experimental cattle 
Five Holstein calves were obtained from the Iowa State University Dairy Breeding 
Research facility at Ankeny, IA and one animal was purchased from northwest Iowa. Both 
herds had no recorded cases of anaplasmosis. The individual animal details are summarized 
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in Table 1. Calves were aged approximately 150-240 days and weighed between 68 and 169 
kg at the time of treatment. Animals were confirmed free of A. marginale antibodies by 
competitive enzyme linked immunoabsorbent assay (Anaplasma Antibody Test Kit,VMRD 
Inc., Pullman, WA) (cELISA) (Torioni De Echaide et al., 1998). Splenectomies were 
performed when calves were approximately 3 months old using the technique described by 
Thompson et al. (1992). 
Housing and husbandry 
Calves were housed in a Biolevel 2 livestock infectious disease isolation facility at 
Iowa State University. These were housed in pairs and fed approximately 3 lbs of a corn-
based ration twice a day. The ration was manufactured without the addition of any 
oxytetracycline antibiotics. Animals also received a small amount of grass hay twice a day 
and water ad libertum for the duration of the study. 
Experimental infection with anaplasmosis 
Approximately 6-8 weeks after splenectomy, two calves were infected with 20 ml of 
blood from a carrier animal experimentally infected with a West Coast (St. Maries) isolate of 
A. marginale. Two control calves were similarly infected with blood infected with an 
Oklahoma isolate of anaplasmosis. Of the two remaining calves, one was infected with 10 ml 
of blood stabilate containing an Oklahoma isolate with 31.6% parasitized erythrocytes. The 
sixth calf received 10 ml of blood stabilate containing a Virginia isolate with 35.5% 
parasitized erythrocytes. The stabilates were prepared from packed erythrocytes washed in 
phosphate buffered saline (PBS) and frozen in liquid nitrogen at a 1:1 ratio with PBS 
containing 10% dimethylsulphoxide (DMSO). Stabilates were maintained frozen in liquid 
nitrogen and dry ice prior to inoculation. 
Post-infection monitoring 
Following infection, the calves were monitored daily for the clinical signs of 
anaplasmosis, including anorexia, depression and listlessness. Blood samples were collected 
at least once a week post-infection for determination of PPE, PCV and cELISA serology. 
Blood samples were collected by jugular venipuncture using 18 G, 1 in. needles (Air-tite 
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Products Co., Inc., VA). For serum collection, 10 ml Monoject® No Additive Sterile glass 
tubes (Sherwood Medical, St Louis, MO) were used. For whole blood (PCV and PPE), 7 ml 
K3EDTA glass tubes (Beckton Dickenson Vacutainer Systems, NJ) were used. Blood in 
EDTA was refrigerated prior to PCV testing or packaged in insulated material for overnight 
delivery by courier to Oklahoma State University for determination of the PPE. 
Blood smears for PPE determination were stained using a 30-s, three-step staining 
technique (Hema 3® Staining System, Fisher Scientific) comparable to the Wright-Giemsa 
method. Two slides were prepared for each blood sample and examined for the presence of 
A. marginale at lOOx magnification using a grid. A total of 500 cells were counted within the 
4 squares of the grid and the number of infected cells was recorded. The PPE was the number 
of infected cells divided by the total number of cells counted, multiplied by 100. 
Serologic testing by cELISA was conducted by the Iowa State University Veterinary 
Diagnostic Laboratory. The test was conducted in accordance with the method described in 
the OIE Manual of Standards for diagnostic tests and vaccines and the manufacturer 
recommendations (OIE, 2000; VMRD, 2003). Results are given as percentage inhibition. 
PCVs were determined by partially filling heparinized capillary tubes (Chase Scientific Glass 
Inc., Rockwood, TN) with blood, which were then centrifuged for 3 min using an Adams 
Micro-Hematocrit centrifuge (Model CT 2900, Clay Adams, Inc., New York). 
Treatment 
Treatment with enrofloxacin (Baytril® 100, Bayer Animal Health, Shawnee Mission, 
KS) was initiated 19-25 days after experimental infection when the PPE ranged from 28.6%-
53.2%. Each animal received two subcutaneous injections of enrofloxacin at a dose rate of 
12.5 mg/kg, administered 48 h apart. Federal (USA) law prohibits the extra-label use of 
enrofloxacin in food-producing animals. Accordingly, experimental animals were kept in an 
isolation facility after treatment and were euthanized and incinerated at the end of the study. 
Post-treatment monitoring 
Blood samples were collected at least once a week for approximately 42 days post-
treatment for PPE, PCV and cELISA serology. 
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Statistics 
Data were entered into a spreadsheet program (Excel 2003, Microsoft Corporation, 
Redmond, WA) for subsequent calculation and manipulation. The mean ± SEM (standard 
error of the mean) were calculated for all parameters. Hypothesis tests were conducted using 
JMP 5.1.2 analytical software (SAS Institute, INC, Cary, NC). Group differences between 
treated and control animals were analyzed using a Student t test. Statistical significance was 
designated a priori as a P-value less than or equal to 0.05. 
PPE results following treatment were analyzed using a simple linear regression model 
(Mutapi and Roddam, 2002). The null hypothesis was that treatment with enrofloxacin had 
no effect on PPE over time following treatment. This hypothesis was tested using a student t 
test of the slope of the linear regression line to determine if the gradient was zero (Zou et al., 
2003). An analysis of variance (ANOVA) F-test for comparing the simple linear regression 
model to a separate means (one-way ANOVA) model was used to assess the goodness of fit 
of simple linear regression. A large P value (>0.05) indicated that there was no evidence of 
lack-of-fit to the simple linear regression model (Ramsey and Schafer, 2002). 
In addition to the linear regression modeling, one-way ANOVA tests were conducted 
in order to determine whether there were statistical differences between days following 
treatment. This approach was preferred where there was evidence of lack-of-fit to the linear 
regression model. The Tukey-Kramer HSD (honest significant difference) test was used to 
compare the mean PPE, PCV and cELISA each day in order to identify statistical differences 
between days following enrofloxacin therapy. This test is an exact alpha-level test if the 
sample sizes are the same and conservative if the sample sizes are different (Hayter, 1984). 
Results 
Following infection and prior to treatment, animals in the treated and control groups 
demonstrated a similar increase in PPE and decrease in PCV (P = 0.39 and 0.72, 
respectively). Both animals in the control group became moribund when the PCV dropped 
below 10% and were euthanized (normal: 24-46%). This occurred at approximately 3—6 days 
following peak parasitemia. At this time point, the difference in PPE between the treatment 
and control group was approaching statistical significance (P = 0.061). 
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At the time of treatment the splenectomized calves had a mean rickettsemia (± SEM) 
of 39.13 ± 5.67% parasitized erythrocytes (range: 28.6%-53.2%) at 21 ± 1.35 days after 
infection. The mean PCV was 26.45 ± 3.02% and the cELISA was 82.66 ± 3.879% 
inhibition. By 6 days after treatment the mean PPE had decreased by 62% to 14.88 ± 4.64%. 
The mean PCV had also decreased by 48% to 13.80 ± 2.17%. The mean PPE remained 
between 3.60 ± 2.34% and 4.97 ± 4.78% for the next 18 days with levels fluctuating for 
individual animals. Recrudescence of rickettsemia was however self limiting and did not 
require further treatment. A progressive increase in mean PCV was observed from 6 days 
after treatment to the end of the study. The cELISA remained constant throughout the study. 
These results are summarized in Table 2 and represented graphically in Fig. 1. 
Linear regression of PPE against days post-treatment provided substantial evidence 
that the slope of the regression line was not zero (P < 0.0002). The lack-of-fit F-test (P = 
0.0028), however, indicated that variability between the group means for all the data could 
not be explained by a simple linear regression model (Ramsey and Schafer, 2002). A one­
way ANOVA was conducted which provided substantial evidence (P < 0.0001) of post-
treatment PPE differences. The Tukey-Kramer HSD test indicated that only the PPE at 
treatment was significantly different (P < 0.001). 
Based on these findings the PPE measurements taken over the first 12 days were 
subjected to simple linear regression. This is similar to the approach used by Kuttler and 
Simpson (1978). 
The equation of the regression line was determined to be: 
PPE = 29.875 - 3.196 (days post-first treatment) 
A lack-of-fit F-test indicated that a regression line was appropriate to describe these 
data (P = 0.17). Linear regression provided substantial evidence to reject the null hypothesis 
that treatment with enrofloxacin had no effect on PPE over time based on the slope of the 
regression line (P < 0.0002). Instead, these data supported the alternative hypothesis that 
enrofloxacin substantially reduced the PPE over time following treatment. 
Similar simple linear regression analyses were also conducted on the PCV and 
cELISA results. There was evidence of lack-of-fit indicating that a one-way ANOVA test 
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provided a more appropriate analysis. Despite the large fluctuation in PCV observed during 
the first 2 weeks of the study there was no evidence of a statistically significant difference in 
PCV and cELISA in treated animals over the course of the study. 
Discussion and conclusions 
The purpose of this study was to evaluate the efficacy of enrofloxacin (Baytril® 100, 
Bayer HealthCare LLC) against severe (> 25% PPE) experimental A. marginale infections in 
splenectomized calves. Our study found treated animals survived severe infections whereas 
untreated calves became moribund and were euthanized on welfare grounds. In surviving 
animals there was substantial evidence that enrofloxacin administered at 12.5 mg/kg twice, 
48 h apart, suppressed but did not eliminate severe A. marginale infections in splenectomized 
calves. A recrudescence of A. marginale parasites was observed in all animals within 30 days 
following treatment. Subsequent rickettsemias were less severe and self limiting. The PCV 
returned to pretreatment levels within 6 weeks following treatment. 
The present study was constrained by the small number of animals enrolled. This 
arose due to limited availability and cost of study animals. In the present study the control 
calves became moribund and were euthanized when the PCV dropped below 10%. Failure to 
intervene at this point in the study when the PPE was greater than 40% could not be justified 
on welfare grounds. Previous studies have indicated that a severe anaplasmosis infection in 
splenectomized calves is fatal if left untreated (Roby, 1972; Kuttler and Simpson, 1978). 
Given the loss of the control animals, the simple linear regression model was used to analyze 
these data. 
The efficacy of enrofloxacin against acute A. marginale infections has been studied in 
two previous reports. Schroder et al. (1991) examined the effect of enrofloxacin on A 
marginale in 3 trials. Splenectomized and intact calves were treated with two injections of 
either 5 or 10 mg/kg enrofloxacin when the PCV decreased to 25%. Either dose rate was 
deemed effective based on the disappearance of parasites from blood smears and the return of 
PCVs to pre-treatment levels. Guglielmone et al. (1996) treated intact Holstein steers with 
10mg/kg enrofloxacin for 2 consecutive days when the PPE ranged from 3-10%. A 
significantly lower rickettsemia (P < 0.01) was found 72 h following treatment. In both of 
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these studies, animals were not evaluated for recrudescence of rickettsemia or inactivity 
following treatment. Furthermore the disease described in these studies was not as severe as 
the infection model utilized in the present study. 
The utility of splenectomized calves in the study of chemotherapeutic agents against 
A. marginale has been described in the literature. Splenectomized calves have been used to 
emphasize the drug effect and minimize possible immune responses that might camouflage 
specific drug actions. Furthermore, splenectomized calves present an obvious advantage in 
early screening trials due to the consistent relapse pattern occurring in those instances where 
treatment is ineffective (Kuttler, 1972). 
Roby (1972) demonstrated increased survival of splenectomized calves treated 
parentally with imidocarb at 2.5, 5.0 and 10.0 mg/kg. Kuttler (1986) observed a similar 
pattern of parasite suppression and recrudescence in splenectomized calves following 
administration of imidocarb dipropionate (at 5 mg/kg) and oxytetracycline hydrochloride (at 
20 mg/kg) which is similar to that reported in the present study. 
All calves evaluated in our study remained persistently infected with anaplasmosis 
after treatment. Non-splenectomized cattle that recover from acute anaplasmosis remain 
lifelong carriers of the disease. Persistent infection is characterized by sequential rickettsemic 
cycles ranging from 102—107 that occur at approximately 5-week intervals (Eriks et al., 1989). 
Each cycle of persistent rickettsemia reflects emergence of antigenically variant A. marginale 
that are subsequently controlled by variant-specific primary immune responses (French et al., 
1999; Brayton et al., 2003). These cycles are microscopically undetectable in the intact 
animals (Kieser et al., 1990). In contrast, microscopically detectable cycles occur in 
splenectomized animals that survive primary infection, presumably due to the absence of 
phagocytosis of parasitized erythrocytes in the spleen (Buening, 1973). It is noteworthy that 
subsequent cycles appear more frequently but are self limiting in splenectomized calves 
following therapy. 
In the United States, the labeled dose of enrofloxacin for single dose therapy of 
bovine respiratory disease in cattle is 12.5 mg/kg bodyweight administered subcutaneously. 
The bactericidal activity of fluoroquinolone antimicrobials is dependant on the ratio of the 
area under the plasma drug concentration curve (AUC) to the minimum inhibitory 
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concentration (MIC) for the organism (Drusano et al., 2001). Enrofloxacin is metabolized to 
ciprofloxacin in calves, which contributes between 10% and 27% of the total concentration 
present in the serum (Kaartinen et al., 1997). The MIC of enrofloxacin and ciprofloxacin 
against A. marginale has not been determined. Antimicrobial susceptibility studies involving 
ciprofloxacin have been conducted on Anaplasma phagocytophilum, a closely related agent 
responsible for human granulocytic anaplasmosis (HGE). These studies have determined the 
MIC of ciprofloxacin to be between 1 ug/ml and 2 ug/ml (Klein et al., 1997; Branger et al., 
2004). We therefore administered enrofloxacin twice, 48 h apart in an attempt to maximize 
AUC above the hypothesized MIC against A. marginale. 
Our study examined three geographically and phylogenetically distinct isolates of A. 
marginale as described by de la Fuente et al. (2001). This closely resembles the heterologous 
situation that is likely to be encountered in the field application of antimicrobial therapy in a 
diverse population of animals. It is noteworthy that Maurin et al. (2003) demonstrated 
differences in the MIC of the fluoroquinolone levofloxacin against different geographic 
isolates of A. phagocytophilum. In vitro MICs varied from 0.06-0.5 ug/ml, which is reported 
to be close to the maximum levels achievable in human serum. Our very limited study did 
not show any evidence of a difference in susceptibility of these A. marginale isolates to 
enrofloxacin in vivo. However this finding requires further evaluation before a definitive 
conclusion can be made. 
In an earlier study, Maurin et al. (2001) demonstrated a DNA gyrase-mediated natural 
resistance to fluoroquinolones in Ehrlichia chaffeensis and Ehrlichia canis. This corresponds 
to a single amino acid difference in gyrA which encodes the A subunit of DNA gyrase in A. 
phagocytophilum. Concern has been expressed that acquired fluoroquinolone resistance in A. 
phagocytophilum could be expected following widespread use. The recent publication of the 
complete genome sequencing of A. marginale (Brayton et al., 2005) may allow DNA 
sequence alignment of the quinolone resistance-determining region (QRDR) of gyrA which 
encodes the A subunit of DNA gyrase. This would be helpful to assess potential differences 
in quinolone susceptibility between A. marginale and A. phagocytophilum and also the 
potential for quinolone resistance. 
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The results of the present study indicate that enrofloxacin administered at 12.5 mg/kg 
twice, 48 h apart ameliorates severe A. marginale infections in splenectomized calves. 
Untreated control animals became moribund and were euthanized. Recovering treated 
animals remained persistently infected after treatment with this regimen. Further studies are 
warranted to investigate whether a dose regimen of enrofloxacin can be identified to 
eliminate A. marginale infection from carrier cattle. 
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Figure 1 : Mean percent parasitized erythrocytes (PPE) and packed cell volume (PCV) following treatment on Day 0 
with 2 subcutaneous injections of enrofloxacin (Baytril, Bayer Animal Health) at 12.5 mg/kg bodyweight 
Q48H 
Table 1: Individual animal details 
Calf ID Isolate Infection to Peak PPE Peak PPE
: 
15 Oklahoma 39 days 55.50% 
63 St Maries 19 days 43.30% 
65 Oklahoma 15 days 41.90% 
67 Virginia 20 days 28.60% 
70 Oklahoma 20 days 31.40% 
71 St Maries 25 days 53.20% 
aPPE: Percent Parasitized Erythrocytes 
Weight 
Control 
169 kg 
Control 
169kg 
147kg 
Dose of Enrofloxacin 
jmgL 
Control 
2112 mg 
Control 
2112 mg 
1838 mg 
Dose Administered 
(ml) 
Control 
21ml 
Control 
21ml 
18ml 
Table 2: Summary of the mean percent parasitized erythrocytes (PPE) and packed cell volume (PCV) following 
administration of enrofloxacin (Baytril, Bayer) twice at 12.5mg/kg body weight SQ, Q48H 
Days Post Treatment 0 6 12 18 24 30 36 42 
Mean PPE 39.13** 14.88** 3.83 4.98 3.60 7.40 2.07 1.30 
SEMa 5.67 4.64 2.94 4.78 2.34 6.04 1.37 0.55 
Lower 95% CI^ 21.08 0.09 -5.53 -10.23 -3.86 -11.81 -3.83 -1.07 
Upper 95% CI 57.17 29.66 13.18 20.18 11.06 26.61 7.97 3.67 
Mean PCV 26.45 13.80 19.35 23.38 24.88 21.88 20.50 25.17 
SEM 3.02 2.17 3.12 3.14 1.20 2.16 4.24 0.67 
Lower 95% CI 16.85 6.89 9.43 13.39 21.07 14.99 7.01 22.30 
Upper 95% CI 36.05 20.71 29.27 33.36 28.68 28.76 33.99 28.04 
aSEM: Standard Error of the Mean 
bCI: Confidence Interval 
**Statistically Significant Difference (p < 0.01) 
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CHAPTER 6. A STUDY TO COMPARE THE EFFICACY OF 
ENROFLOXACIN, IMIDOCARB AND OXYTETRACYCLINE 
AGAINST PERSISTENT ANAPLASMA MARGINALE INFECTIONS 
A paper submitted for publication in Veterinary Parasitology 
Johann F. Coetzee, Michael D. Apley and Katherine M. Kocan 
Abstract 
Anaplasma marginale is the most prevalent tick-borne pathogen of cattle worldwide. 
Cattle that recover from acute anaplasmosis become carriers in which low or microscopically 
undetectable rickettsemia persists. There are currently no antimicrobials approved for 
elimination of these carrier infections. This study compared the efficacy of enrofloxacin, 
imidocarb and oxytetracycline against persistent Anaplasma marginale infections. Twelve 
Holstein calves, aged 4—12 months, were experimentally infected with an Oklahoma (OK), 
Virginia (VGN) or St Maries (StM) isolate of A. marginale as part of a previous experiment. 
Following infection, calves demonstrated a brief parasitemia and seroconverted as 
determined by competitive ELISA test (>30% inhibition). Approximately 66 days after 
infection, calves were blocked by bodyweight and randomly assigned to one of three 
treatment groups. Treatment A consisted of enrofloxacin (ENRO) (Baytril® 100, Bayer 
Animal Health) administered at 5 mg/kg bodyweight, intravenously (IV), q 24 h for 5 days; 
Treatment B consisted of imidocarb dipropionate (LMD) (Imizol Injectable Solution®, 
Schering Plough Animal Health) administered at 5 mg/kg bodyweight, by intramuscular (IM) 
injection twice, 7 days apart; Treatment C consisted of oxytetracycline (OTC) (Liquamycin 
LA-200®, Pfizer Animal Health) administered at 22 mg/kg, intravenously (IV), q 24 h for 5 
days (a treatment regimen that corresponds with current Office International des Epizootics 
(OIE) recommendations for treating persistent infections prior to export). Approximately 7-
18 days after treatment calves were splenectomized and monitored for evidence of 
parasitemia, anemia and changes in serological status. Inactivity of blood from negative 
calves was tested after 7 weeks by inoculation into splenectomized calves. Eighty days after 
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first treatment, parasite negative animals were further tested by direct and nested PCR. A calf 
infected with the OK isolate treated with IMD and a calf infected with the VGN isolate 
treated with OTC failed to develop parasitemia following splenectomy. Both calves became 
seronegative at 43 days after treatment. Subinoculation of blood pooled from these calves 
failed to infect a splenectomized calf. The OTC treated calf and the subinoculated 
splenectomized calf were negative on PCR and nPCR, but the IMD treated calf was positive. 
These data indicate that two of the regimens described were efficacious against persistent A. 
marginale infections in two animals infected with an OK and VGN isolate. 
Introduction 
Anaplasmosis, caused by the rickettsial hemoparasite, A. marginale, is the most 
prevalent tick-transmitted disease of cattle worldwide (Uilenberg, 1995; Dumler et al., 2001; 
Kocan et al., 2003). The existence of persistent A. marginale infections restricts the export of 
animals to areas where the disease is not regarded as endemic. Kocan et al. (2003) estimated 
the cost of anaplasmosis in the USA to be over $300 million per year. 
Prior to the development of imidocarb dipropionate and the tetracycline 
antimicrobials, a variety of chemotherapeutic agents, including arsenicals, antimalarials, 
antimony derivatives and dyes, were used to treat acute anaplasmosis. These compounds had 
little if any chemotherapeutic effect (Potgieter and Stoltsz, 1994). Chlortetracycline and 
oxytetracycline are the only compounds available for the control of acute anaplasmosis in the 
United States. A. marginale infections are not sterilized at the usual recommended 
therapeutic doses of the tetracycline drugs (Kuttler and Simpson, 1978; Stewart et al., 1979). 
There are currently no antimicrobials labeled for the elimination of persistent infections in 
carrier animals. 
Tetracyclines bind to ribosomes and mRNA, although inhibition of protein synthesis 
is mediated principally through reversible binding with the 30S ribosomal subunit (Scholar 
and Pratt, 2000). Previous studies in which successful clearance of persistent A. marginale 
infections was reported administered oxytetracycline intravenously to cattle at 11-22 mg/kg 
for 5-12 days (Magonigle et al., 1975; Roby et al., 1978). Intramuscular oxytetracycline 
administered at 20 mg/kg on 2, 3 or 4 occasions at intervals ranging from 3-7 days was also 
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reported to be effective at eliminating carrier infections (Roby et al., 1978; Kuttler et al., 
1980; Magonigle and Newby, 1982; Kuttler, 1983; Swift and Thomas, 1983; Rogers and 
Dunster, 1984; Ozlem, 1988). A recent study conducted by our research group demonstrated 
that the current recommended OIE treatment protocol of 5 daily injections of oxytetracycline 
administered intravenously at 22 mg/kg did not eliminate persistent Oklahoma isolate 
infections (Coetzee et al., 2005a). 
Enrofloxacin is a fluoroquinolone antimicrobial that inhibits bacterial DNA-gyrase 
(Topoisomerase II) and Topoisomerase IV (Blondeau, 2004). This activity prevents DNA 
supercoiling and decatenation of original chromosomes and replicates. Two published 
reports indicate that enrofloxacin (Baytril®, Bayer Animal Health) is effective against acute 
A. marginale infections at dose rates of 5 to 10 mg/kg (Schroder et al., 1991; Guglielmone et 
al., 1996). However, the dynamics of the infection following treatment and the potential for 
elimination of the carrier state was not assessed. 
Imidocarb is a carbanilide derivative with antiprotozoal activity. The mode of action 
of action of imidocarb is uncertain though two mechanisms have been proposed: interference 
with the production and/or utilization of polyamines, or prevention of entry of inositol into 
the erythrocyte containing the parasite (EMEA, 2001). Roby and Mazzola (1972) found that 
two injections of imidocarb, administered at 5 mg/kg 14 days apart, eliminated A. marginale 
from carrier animals. 
The purpose of this study was to compare the efficacy of enrofloxacin administered at 
5 mg/kg IV q 24 h for 5 days; imidocarb dipropionate at 5 mg/kg administered IM twice, 7 
days apart and oxytetracycline administered at 22 mg/kg q 24 h for 5 days, against 
experimental persistent A. marginale infections. Multiple A. marginale isolates obtained 
from Oklahoma, Virginia and Idaho (St. Maries) were used to replicate field cases of 
anaplasmosis. Our study also allowed us to assess the effect of chemosterilisation on 
seropositivity in splenectomized calves as determined by a newly developed commercial 
competitive ELISA test. 
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Materials and methods 
This protocol was approved by the Committee on Animal Care (COAC) at Iowa State 
University. 
Experimental cattle 
Twelve Holstein calves were obtained from the Iowa State University Dairy Breeding 
Research facility at Ankeny, Iowa and from a dairy herd in northwest Iowa. Both herds had 
no recorded cases of anaplasmosis. The individual animal details are summarized in Table 1. 
Calves were aged approximately 4—12 months and weighed between 59 and 206 kg at the 
time of treatment. Animals were confirmed free of A. marginale antibodies by competitive 
enzyme linked immunoabsorbent assay (cELISA) (Anaplasma Antibody Test Kit,VMRD 
Inc., Pullman, WA) (Torioni De Echaide et al., 1998). 
Housing and husbandry 
Calves were housed in a Biolevel 2 livestock infectious disease isolation facility at 
Iowa State University. These were housed in pairs and fed approximately 3 lbs. of a corn-
based ration twice daily. The ration was manufactured without the addition of any 
oxytetracycline antibiotics. Animals also received a small amount of grass hay twice a day 
and water ad libertum for the duration of the study. 
Experimental infection with anaplasmosis 
Calves on this study were infected as part of a study to investigate the infectivity of 
whole blood cultures. Parasitized erythrocytes, frozen in liquid nitrogen, were obtained from 
splenectomized calves infected with an Oklahoma, Virginia or West Coast (St Maries) 
isolates. Cultures were incubated for 7 days at 37 °C, 5% CO2 in 96 well plates containing 
RPMI1640 supplemented with 20% heat-inactivated fetal bovine serum, 25 mM HEPES 
buffer; 200 mM glutamine, 100 U/ml penicillin and 100 |ig/ml streptomycin. The contents of 
20 wells (4,000 p.1) from each selected sample were pelleted by centrifugation at 450 x g for 
5 min. 400 pi packed parasitized erythrocytes were resuspended in 1.5 ml RPMI 1640 and 
inoculated by intravenously jugular injection using a 16G, 1 in. needle. Seven calves were 
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infected with a Virginia isolate of A. marginale and 4 calves were infected with an Oklahoma 
isolate. The remaining calf was infected with a West Coast (St Maries) isolate. 
Post-infection monitoring 
Following infection, calves were monitored daily for the clinical signs of 
anaplasmosis, including anorexia, depression and listlessness. Blood samples were collected 
at least once a week post-infection for determination of PPE, PCV and cELISA serology. 
Persons conducting these analyses were blinded to treatment group. Blood samples were 
collected by jugular venipuncture using 18 G, 1 in. needles (Air-tite Products Co., Inc., VA). 
For serum collection, 10 ml Monoject® No Additive Sterile glass tubes (Sherwood Medical, 
St Louis, MO) were used. For whole blood (PCV and PPE), 7 ml K3EDTA glass tubes 
(Beckton Dickenson Vacutainer Systems, NJ) were used. Blood in EDTA was refrigerated 
prior to PCV testing or packaged in insulated material for overnight delivery by courier to 
Oklahoma State University for determination of the PPE. 
Blood smears for PPE determination were stained using a 30-s, three-step staining 
technique (Hema 3® Staining System, Fisher Scientific) comparable to the Wright-Giemsa 
method. Two slides were prepared for each blood sample and examined for the presence of 
A. marginale at lOOx magnification using a grid. A total of 500 cells were counted within the 
four squares of the grid and the number of infected cells was recorded. The PPE was the 
number of infected cells divided by the total number of cells counted, multiplied by 100. 
Serologic testing by cELISA was conducted by the Iowa State University Veterinary 
Diagnostic Laboratory. Technicians conducting the test were blinded to treatment group. The 
test was conducted in accordance with the method described in the OIE Manual of Standards 
for diagnostic tests and vaccines and the manufacturer recommendations (OIE, 2000; 
VMRD, 2003). Results are given as percentage inhibition. PCVs were determined by 
partially filling heparinized capillary tubes (Chase Scientific Glass Inc., Rockwood, TN) with 
blood which were centrifuged for 3 min using an Adams Micro-Hematocrit centrifuge 
(Model CT 2900, Clay Adams Inc., New York). 
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Infected calves were classified as carriers based on the presence of antibodies on the 
cELISA test (> 30% inhibition) and after rickettsemias had fallen below 1%. This occurred at 
least 66 days after infection. 
Group assignment and randomization procedures 
Carrier steers were blocked by bodyweight prior to being randomly assigned to 
treatment groups. Designation to treatment within a weight block occurred by assigning 
random numbers (Microsoft Excel, Microsoft Corporation, Redmond, WA). 
Treatment 
Antimicrobial formulations were administered at the dose rates and dosing frequency 
described below. Treatment A consisted of a 100 mg/ml solution of enrofloxacin 
(Baytril®100, Bayer Animal Health, Shawnee Mission, KS) administered at 5 mg/kg 
bodyweight, intravenously (IV), once daily (q 24 h) for 5 days. Federal (USA) law prohibits 
the extra-label use of enrofloxacin in food producing animals. Accordingly, experimental 
animals were kept in an isolation facility after treatment and were euthanized and incinerated 
at the end of the study. 
Treatment B consisted of a 120 mg/ml solution of imidocarb dipropionate (Imizol 
Injectable Solution®, Schering Plough Animal Health, Union, NJ) administered by 
intramuscular (IM) injection at a dose rate of 5 mg/kg bodyweight, twice, 7 days apart. 
Treatment C consisted of oxytetracycline (OTC) (Liquamycin LA-200®, Pfizer Animal 
Health, Exton, PA) administered at 22 mg/kg IV, q 24 h for 5 days. This treatment regimen 
corresponds with current Office International des Epizootics (OIE) recommendations for 
treating persistent infections prior to export. 
Enrofloxacin and oxytetracycline were administered to Group A and C by slow IV 
injection into the left or right jugular vein. A 14 gauge x 5.25 in. indwelling catheter (BD 
Angiocath, Beckton Dickinson, Sandy, UT) was used for each administration. The nominal 
content of active ingredient for each formulation and the bodyweights obtained 24 h prior to 
administration were used to calculate the theoretical dosage for each animal. For dosing, a 10 
ml or 20 ml hypodermic syringe was used and the required dose was rounded to the nearest 
whole milliliter. 
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Imidocarb dipropionate was administered by deep intramuscular injection using an 18 
gauge x 1.5 in. needle in the left and right neck, which is one of the recommended routes of 
administration. The nominal imidocarb content for the formulation and the animal 
bodyweights obtained 24 h prior to administration were used to calculate the theoretical dose 
for each animal. For dosing, a 10 ml hypodermic syringe was used and the required dose was 
rounded to the nearest whole milliliter. 
Post-treatment splenectomy and monitoring 
At 15, 16, 22 and 24 days after first treatment, one animal from each treatment group 
was randomly selected and splenectomized on each day using the technique described by 
Thompson et al. (1992). Anaplasmosis carrier animals develop clinical anaplasmosis in 
approximately 14 days after splenectomy (Foote et al., 1951). This phenomenon has been 
used to evaluate the carrier status of calves and the success of chemosterilization regimens by 
splenectomizing animals after treatment (Roby and Mazzola, 1972; Stewart, 1979). Blood 
samples were collected at surgery and again on day 28, 43 and 49 post-treatment for PPE, 
PCV and cELISA serology. At 7 weeks after first treatment, all animals that had 
demonstrated a parasitemia were designated treatment failures and were removed from the 
study. 
Determination of post-treatment infectivity 
At 7 weeks post-treatment, 5 ml of blood was collected in heparinized vacutainers 
from each calf that failed to develop a parasitemia following splenectomy. Blood from 2 
calves was pooled and injected into a seronegative splenectomized calf. Blood was also 
collected from a parasitemic calf designated a treatment failure and inoculated into a 
splenectomized calf, which served as an infected control. Following inoculation, calves were 
monitored on day 56, 63, 70, 76 and 80 for the presence or absence of A. marginale infection 
as described previously. 
Polymerase chain reaction (PCR) and nested PCR determination 
Blood samples from carrier and splenectomized animals failing to demonstrate a 
parasitemia at 80 days after first treatment were submitted for direct PCR and semi-nested 
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PCR. Testing was conducted at Washington Animal Disease Diagnostic Laboratory. 
Technicians conducting the test were blinded to treatment group. Briefly, genomic DNA was 
isolated from 300 pi of blood using a DNA isolation kit (Purogene, Centra Systems, Inc.) 
following the manufacturer's instructions. DNA of each sample was resuspended in 100 |xl of 
hydration solution. Primers were designed from the published sequence of msp5 from A. 
marginale Florida as described by Torioni De Eschaide et. al. (1998) and were as follows (5-
3' sequence and location): external forward, 5'-GCA TAG CCT CCG CGT CTT TC-3' (msp5 
positions 254-273); external reverse, 5' TCC TCG CCT TGG CCC TCA GA-3' (msp5 
positions 710-692); internal forward, 5'-TAC ACG TGC CCT ACC GAG TTA-3' (msp5 
positions 367-387). 
Two PCR rounds in a final volume of 50 pi consisting of 5 pi of lOx PCR buffer [200 
mM Tris-HCl (pH 8.4), O.lmM KC1 ], 1.5 pi of 50mM MgCl2,l pi dNTPS lOmM, 1 pi of 20 
pmol of each external primers, 1 pi of Taq DNA polymerase [GIBCO, 5 U per pi ], 34.5 pi 
of HaO and finally 5 pi of the sample DNA in case of direct PCR or 5 pi of the amplicon 
from the direct PCR in case of the semi-nested PCR were carried out in a Perkin Elmer 
GeneAmp 9600 thermocycler. Cycling conditions were preheating at 95 °C for 3 min and 35 
cycles of 94 °C for 15s, 65 °C for 58 s, and 72 °C for 70 s with final extension at 72 °C for 10 
min for each round. nPCR was carried out only on samples that were negative for direct 
PCR. PCR and nPCR products were visualized in a 2% agarose gel following electrophoresis 
and staining with ethidium bromide. 
Statistics 
Data were entered into a spreadsheet program (Excel 2003, Microsoft Corporation, 
Redmond, WA) for subsequent calculation and manipulation. The mean ± SEM (standard 
error of the mean) were calculated for all parameters. Hypothesis tests were conducted using 
JMP 5.1.2 analytical software (SAS Institute, Inc., Cary, NC). Group differences between 
treated animals were analyzed using a student t test. Statistical significance was designated a 
priori as a P-value less than or equal to 0.05. 
The analysis of variance approach to repeated measures data was used to analyze 
differences between cELISA, PCV and PPE results (Everitt, 1995). The Wilk's lambda test 
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was selected to evaluate within group interactions and evidence of time x group interactions. 
This test is a likelihood ratio statistic for testing that a multivariate contrast is zero, assuming 
multivariate normality and further assuming equality of covariance matrices across groups 
(Everitt and Dunn, 2001). 
Where the Wilk's lambda test indicated a statistically significant interaction, 
differences between antimicrobials were analyzed using ANOVA and the Tukey-Kramer 
HSD (honest significant difference) method for multiple comparisons. This test is an exact 
alpha-level test if the sample sizes are the same and conservative if the sample sizes are 
different (Hayter, 1984). 
Results 
Infection phase of the study 
The PPE results from the infection phase of the study are summarized in Fig. 1. 
cELISA and PCV results from both the infection and treatment phase are summarized in 
Figs. 2-3. Treatment group assignments were designated after randomization on day 66 post­
infection. 
Prior to inoculation, all calves were seronegative for anaplasmosis (<30% inhibition). 
The mean PCV ranged from 31.08 ± 2.36% to 35.75 ± 4.05% in the groups later assigned to 
treatment with imidocarb and enrofloxacin respectively. Thirty-two days after infection, all 
calves had seroconverted with a mean cELISA (± SEM) ranging from 76.66 ± 8.36% 
inhibition (IMD group) to 85.37% inhibition (ENRO group). By 38 days post-infection, all 
calves demonstrated evidence of A. marginale infection based on a mean PPE (± SEM) 
ranging from of 1.37 ± 0.67% (IMD group) to 2.05 ± 2.2% (ENRO group). Peak PPE was 
associated with a trough in PCV ranging from 24.75 ± 2.18% (ENRO Group) to 26.88 ± 
1.89% (OTC Group). 
Prior to treatment, 66 days post-infection, the mean PPE ranged from 0.13 ± 0.13% 
(ENRO group) to 0.25 ± 0.17% (OTC group). All animals were seropositive with the mean 
cELISA ranging from 76.95 ± 5.78% (IMD group) to 86.57 ± 1.55% (ENRO group). Mean 
packed cell volume (PCV) had returned to pre-infection levels and ranged from 32.38 ± 
2.30% (IMD group) to 38.00 ± 2.79% (ENRO group). 
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Following assignment to treatment groups, these data were retrospectively analyzed 
and no statistical difference between groups was evident. The Wilks' lambda f-value was 
0.41 for PPE, 0.63 for cELISA and 0.94 for PCV indicating that there was no group x time 
interaction. 
Post-treatment phase in carrier calves 
All treatments were well tolerated with the exception of imidocarb dipropionate, 
which caused mild discomfort immediately following injection. Transient cholinergic 
systemic reactions consisting of excessive lacrimation, serous nasal discharge, urination and 
increased frequency of defecation were also observed for approximately 20 min after 
administration. Two of the calves also demonstrated mild hind limb ataxia and apparent loss 
of hind limb proprioception. These signs were less severe following the second injection. 
Percent parasitized erythrocytes (PPE) 
At 36 days after first treatment, all four calves treated with enrofloxacin demonstrated 
a PPE ranging from 1-34% with a mean (± SEM) of 15.85 ± 7.55% (Table 1). This occurred 
between 12 and 21 days following splenectomy. At this time point, one calf infected with the 
OK isolate (#7) and treated with oxytetracycline developed a PPE of 17.8% (12 days 
following splenectomy). One week later, 19 days after splenectomy, a calf infected with the 
VGN isolate (#14) and treated with imidocarb developed a PPE of 4%. At 7 weeks after first 
treatment these six calves were designated treatment failures and euthanized. 
At the end of the study only two of the remaining animals had demonstrated a 
parasitemia. One calf (#16) infected with the VGN isolate in the OTC group developed a 
PPE of 3.8% and the other (#61) infected with the StM isolate in the IMD group developed a 
PPE of approximately 50%. Two of the four calves that failed to demonstrate a parasitemia 
following treatment and splenectomy were infected with the VGN isolate and were in the 
OTC treated group (# 2 and #12). The remaining two parasite-negative calves were infected 
with the OK and VGN isolate, respectively, and were treated with imidocarb (#10 and #72). 
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Competitive ELISA (cELISA) 
At 7 days after first treatment the mean cELISA ranged from 76.47 ± 8.57% to 90.31 
± 0.85% inhibition in the groups treated with imidocarb and enrofloxacin, respectively (Fig. 
2). By 28 days after treatment the cELISA for all calves remained above 30% inhibition with 
the mean ranging from 81.92 ± 5.02% inhibition (ENRO group) to 86.13 ± 2.50% inhibition 
(OTC group). Between 28 and 43 days after first treatment the cELISA for calf #10, infected 
with the Oklahoma isolate and treated with IMD at 5 mg/kg EM twice, 7 days apart, 
decreased from 79.77% to 32.18% inhibition. From this point to the end of the study the 
cELISA for this animal ranged from 4.15-29.50% inhibition. 
Similarly, over the same period of time, the cELISA for calf #2, infected with the 
Virginia isolate and treated with five daily IV injections of OTC at 22 mg/kg, decreased from 
89.07% to 30.42% inhibition. From this point to the end of the study the cELISA for this 
animal ranged from 10.74—19.66% inhibition. The cELISA for the remaining animals 
remained above 30% inhibition for the duration of the study. Accordingly, there were no 
statistically significant differences between treatment groups. 
Packed cell volume (PCV) 
At the time of splenectomy, 15-24 days after first treatment, the mean PCV ranged 
from 31.5 ± 2.02% (IMD group) to 35.75 ± 1.25% (ENRO group). At 43 days after treatment 
the mean PCV for all calves ranged from 20.40 ± 2.31% (ENRO group) to 28.95 ± 1.41% 
(IMD group). At 7 weeks after treatment, all animals that demonstrated a parasitemia and 
decrease in PCV were designated treatment failures and withdrawn from the study. The 
remaining animals all demonstrated fluctuations in PCV, which were not always associated 
with parasitemia. The most significant of these occurred in calf #2, which demonstrated a 
PCV of 17.5% but no parasites were evident on blood smear. At the end of the study the 
mean PCV of the two surviving animals was 27% and 31% in the IMD- and OTC-treated 
groups, respectively. 
Post-treatment subinoculation of blood into splenectomized calves 
The results following subinoculation of carrier blood into splenectomized calves 7 
weeks after carrier treatment are summarized in Table 2. Prior to inoculation, splenectomized 
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calves were seronegative for anaplasmosis (<30% inhibition). The mean PCV ranged from 
26-34%. Fourteen days after subinoculation, calves exposed to infected blood and pooled 
blood from two calves treated with EMD had seroconverted (> 30% inhibition). By 20 days 
after subinoculation only the calf subinoculated with blood from calf #2 and #10 was 
seronegative. At the end of the study, 30 days after inoculation, this calf (#1) remained 
seronegative and failed to demonstrate a parasitemia or significant decrease in PCV. 
Post-treatment PCR and nPCR testing 
PCR was conducted on all animals that failed to demonstrate a parasitemia at the end 
of the study (80 days after treatment). This included four treated calves and one 
subinoculated splenectomized calf. Of the infected animals, calf #2 infected with the VGN 
isolate and treated with OTC was negative by direct and nested PCR. Splenectomized calf 
#1, which had received a pooled blood sample from calf #2 and calf #10, was also PCR and 
nPCR negative. All the remaining treated calves were positive by direct PCR. 
Discussion and conclusions 
Our study found that apparent clearance of persistent infections occurred in two 
animals treated with IMD and OTC, respectively. This conclusion was supported by the 
absence of parasitemia following splenectomy and a decrease in cELISA to seronegative 
levels (<30% inhibition) at 44 days post-treatment. Fluctuations in PCV did occur in both 
animals, most notably in calf #2, however these appeared to be idiopathic. It is noteworthy 
that only the OTC treated calf (#2) was negative on direct and nested PCR at 80 days post-
treatment. However, a pooled blood sample subinoculated into a splenectomized calf at 7 
weeks post-treatment did not result in parasitemia or seroconversion at 30 days post-
inoculation. This calf was also negative on direct and nested PCR. Both chemosterilized 
calves were splenectomized 22 days after treatment. The significance or possible clinical 
relevance of this is unknown. 
Two published reports indicate that enrofloxacin (Baytril®, Bayer Animal Health) is 
effective against acute A. marginale infections in vivo at dose rates of 5 to 10 mg/kg 
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(Schroder et al., 1991; Guglielmone et al., 1996). In this study, enrofloxacin failed to clear 
persistent infections in calves treated with 5 mg/kg once daily for 5 days. 
Roby and Mazzola (1972) found that two injections of imidocarb, administered at 5 
mg/kg 14 days apart, eliminated A. marginale from carrier animals. Our results indicate that 
shortening the interval between treatments to 7 days cleared persistent infections in 1/4 of the 
animals treated. Magonigle et al. (1975) evaluated the effect of five daily treatments with 
oxytetracycline hydrochloride at a dose of 22mg/kg IV on the carrier status of bovine 
anaplasmosis in 11, 2- to 3-year-old serologically-positive cattle. Our study found that this 
regimen was only effective in one treated animal. 
There may be several reasons why the treatment regimens evaluated in this study 
failed to eliminate persistent A. marginale infections. Successful antimicrobial therapy 
depends on (1) achieving adequate drug concentrations at the site of infection, (2) ensuring 
that drug concentration is maintained for a sufficient duration to be effective, (3) 
pharmacokinetic parameters of the drug, (4) the susceptibility of the organism to the 
antimicrobial and (5) the local environment (Bidgood and Papich, 2003). Based on the 
pharmacokinetics and pharmacodynamics of these antimicrobials it may be hypothesized that 
plasma drug concentrations achieved with the regimens tested in the present study were not 
high enough or maintained above the minimum inhibitory concentration (MIC) for long 
enough in all animals to eliminate persistent infections. 
Susceptibility tests facilitate the determination of the MIC, which is the lowest 
concentration of an antimicrobial agent that prevents visible growth of a microorganism in an 
agar or broth dilution susceptibility test (NCCLS, 2002). Our research group developed a 
system using whole blood culture and flow cytometric analysis (FACS) to evaluate the effect 
of enrofloxacin, imidocarb and oxytetracycline against an Oklahoma and Virginia isolate of 
A. marginale (Coetzee et al., 2005b). The percent reduction in HE positive cells over a 7 day 
period was used to select cultures to inoculate into calves in order to determine the infectivity 
of the culture. Based on these data we concluded that the MIC of enrofloxacin against the 
Oklahoma isolate of A. marginale was greater than 0.25 pg/ml but <4.0 (xg/ml. However, the 
MIC of enrofloxacin against the Virginia isolate was greater than 4.0 pg/ml. Furthermore, we 
found that the MIC of imidocarb against both isolates was between 0.25 fig/ml and 1.0 
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|4.g/ml. For oxytetracycline the MIC required to be effective against anaplasmosis was greater 
than 16.0 pg/ml. 
The bactericidal activity of fluoroquinolone antimicrobials is dependant on the ratio 
of the area under the plasma drug concentration curve (AUC) to the minimum inhibitory 
concentration (MIC). The optimal ratio in bacteria has been proposed as >125 (Drusano et 
al., 2001). Kaartinen et al. (1997) reported an AUC for enrofloxacin of 13.94 mg h/L in 1-
day-old calves and 6.73 mg-h/L in 1-week-old calves following IV administration of 
enrofloxacin at 2.5 mg/kg. If the AUC/MIC ratio described in bacteria applies to A. 
marginale, this would suggest that a prohibitive increase in drug dose would be required in 
order to achieve rickettsiacidal plasma concentrations in vivo. However, it should be noted 
that enrofloxacin is de-ethylated to ciprofloxacin in calves which contributes between 10% 
and 27% of the total concentration in serum (Kaartinen et al., 1997). Ciprofloxacin may also 
have some activity against A. marginale as the MIC against Anaplasma phagocytophilum is 
reported to be between 1 and 2 pg/ml (Klein et al., 1997; Branger et al., 2004). Further 
studies to evaluate the MIC of fluoroquinolones against A. marginale are necessary to fully 
assess the potential use of this compound for eliminating carrier infections. 
Imidocarb dipropionate has been used for over 30 years in the treatment of bovine 
anaplasmosis in certain territories (McHardy, 1974). It is usually administered by 
subcutaneous or intramuscular injection to cattle at a dose rate of 2.1 mg/kg. Adverse effects 
as observed following first administration in our study have been reported at the 5 mg/kg 
dosage (Adams and Corrier, 1980). Pharmacokinetic data and reports on plasma 
concentrations of imidocarb that may be effective for therapy in cattle are deficient in the 
published literature. Studies in goats, dogs and horses suggest that this compound has a large 
volume of distribution resulting in a prolonged elimination half-time (Abdullah and Baggot, 
1983; Belloli et al., 2002). These observations are confirmed by studies demonstrating a 
prolonged retention of the drug in edible tissues (EMEA, 2001). This has restricted the use of 
this compound in food producing animals in many territories. 
Tetracycline antimicrobials are bacteriostatic rather than bacteriocidal and the activity 
of these compounds is believed to be dependant on the time that drug concentrations remain 
above the minimum inhibitory concentration (MIC) for the target organism. Blouin et al., 
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(2002) used cultivated A. marginale in a cell line derived from embryos of Ixodes scapularis 
ticks to examine the effect of tetracycline on the organism. Infected cell cultures treated with 
medium containing 20 pg/ml tetracycline proved non-infective when inoculated into 
susceptible splenectomized calves. These data and the results of our flow cytometry research 
suggest that the MIC may be somewhere between 16 fig/ml tetracycline and 20 (xg/ml 
tetracycline although this does not account for possible differences related to in vitro culture 
methods. 
In vivo pharmacokinetic studies report a mean oxytetracycline plasma concentration 
of 38.5 ± 6.3 pg/ml achieved at 1 h following IV administration to adult cows at 22mg/kg 
bodyweight (Bretzlaff et al., 1982). The mean elimination half-life (Ti/2(s) was 6.52 h. These 
data suggest that plasma drug concentrations will decrease to concentrations below an MIC 
of 20 |ig/ml within 7-8 h after administration. Nouws et al. (1983) found that OTC exhibits 
age-dependent pharmacokinetics in ruminants. This may be related to decreases in volume of 
distribution and plasma clearance in older animals. Although there was no association 
between age or bodyweight and successful elimination of carrier infections in the present 
study, it is possible that individual pharmacokinetic variation could give rise to the 
inconsistent results observed. 
A potential criticism of the present study is the use of three geographically and 
phylogenetically distinct isolates of A. marginale (de la Fuente, 2001). This may be 
compounded by the small number of animals enrolled. To counter this we would suggest that 
field cases of anaplasmosis are seldom composed of one isolate and that chemotherapy 
studies should be designed to account for this diversity. Conflicting reports regarding the 
success of chemosterilization protocols suggest that possible differences in susceptibility 
between isolates may exist. This hypothesis is supported by the recent identification of two 
multidrug resistance pumps in the genome of A. marginale; although the clinical significance 
of these pumps has yet to be elucidated (Brayton et al., 2005). Furthermore, Maurin et al. 
(2003) demonstrated that the MIC of the fluoroquinolone levofloxacin varied from 0.06-0.5 
(ig/ml depending on geographic location of A. phagocytophilum. 
Our previous in vitro study revealed that statistically, the VGN isolate was more 
susceptible to 8 pg/ml oxytetracycline than the OK isolate. Our data also found statistical 
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evidence that the OK isolate was more susceptible to IMD at concentrations ranging from 
0.5-4 ng/ml. Furthermore, the Oklahoma isolate cultures exposed to 4.0 pg/ml enrofloxacin 
failed to infect a healthy calf whereas the VGN isolate was infectious. In the present study, a 
calf infected with the OK isolate and treated with IMD and a calf infected with the VGN 
isolate and treated with OTC were cleared of infection. These findings, when viewed in 
conjunction with the in vitro data, may support a hypothesis of susceptibility differences 
between isolates. However, a larger study is required to investigate this further. 
The present study suggests that direct PCR and nPCR are not reliable means of 
definitively determining the success of chemosterilization in calves. This finding is based on 
one calf that was positive on direct and nested PCR but failed to infect a subinoculated 
splenectomized calf. It is noteworthy that our study found that splenectomized calves will 
become seronegative following clearance of persistent infections with antimicrobials. Goff et 
al. (1990) observed that application of the antimicrobial interrupted continuity of stimulation 
of antibody as detected by complement fixation. A similar finding was reported by Coetzee 
et al. (2005a) using the cELISA test; however, results remained above 30% inhibition and 
returned to pre-treatment levels as the study progressed. Further research to establish the time 
frame to seronegativity in intact animals would allow the cELISA test to be used to evaluate 
the clearance of carrier infections in field cases of anaplasmosis. 
The results of this study suggest that apparent clearance of persistent infections 
occurred in one calf treated with imidocarb dipropionate at 5 mg/kg administered IM twice, 7 
days apart, and one calf treated with oxytetracycline (OTC) administered at 22 mg/kg q 24 h 
for 5 days. This conclusion was supported by the absence of parasitemia following 
splenectomy, a decrease in cELISA to seronegative levels (<30% inhibition) at 44 days post-
treatment and the absence of disease following sub inoculation of blood into a splenectomized 
calf. Further studies are warranted to investigate whether dose regimens can be identified to 
reliably eliminate persistent A. marginale infections from carrier cattle. 
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Table 1: Individual animal details 
Calf Treatment Bodyweight Dose PPEb 
ID Isolate Group" (kg) (ml) (7 wk) 80 days Subinoculation Outcome 
3 Oklahoma A 202 10 22= Withdrawn 2.5 ml (Calf 9) Died 
11 Virginia A 180 9 Ie Withdrawn 
13 Virginia A 163 8 34= Withdrawn 2.5 ml (Calf 9) Died 
17 Oklahoma A 69 3 26= Withdrawn 2.5 ml (Calf 9) Died 
10 Oklahoma B 152 6 0 PCR +ve 5ml (Calf l) nPCR -ve 
14 Virginia B 154 6 32= Withdrawn 
61 St Maries B 198 8 0 PPE = 50% 5ml (Calf 8) Died 
72 Virginia B 201 8 0 PCR +ve 5ml (Calf 8) Died 
2 Virginia C 152 17 0 PCR -ve 5ml (Calf 1) nPCR -ve 
7 Oklahoma C 175 19 18= Withdrawn 2.5 ml (Calf 9) Died 
12 Virginia C 206 23 0 PCR +ve 5ml (Calf 4) Died 
16 Virginia C 59 6 0 PPE = 3.8% 5ml (Calf 4) Died 
aGroup A: 100 mg/ml solution of enrofloxacin (Baytril®100, Bayer Animal Health) administered at 5 mg/kg bodyweight, 
intravenously (IV), q24h for 5 days 
Group B: 120 mg/ml solution of imidocarb dipropionate (Imizol Injectable Solution®, Schering Plough Animal Health) 
administered at 5 mg/kg bodyweight, by intramuscular (IM) injection twice, 7 days apart 
Group C: 200 mg/ml solution of oxytetracycline (Liquamycin LA-200, Pfizer Animal Health) administered at 22 mg/kg, 
intravenously (IV), q24h for 5 days 
bPPE> Percent Parasitized Erythrocytes 
cEuthanised due to clinical signs of anaplasmosis (PPE, PCV, cELISA) 
Table 2. Summary of competitive ELISA, packed cell volume (PCV), percent parasitized erythrocytes (PPE) and PCR 
following subinoculation of carrier blood into splenectomized calves 7 weeks after carrier treatment 
Animal Donor Donor Pre-inoculation 7 days 14 Days 20 days End of Study Outcome 
Treatments' cELISA PCV cELISA PCV cELISA PCV cELISA PCV cELISA PCV 
1 10 & 2 OTC & IMD 0 26 0 26 10.54 24 0 30 2.521 30 PCR/nPCR -ve 
4 16 & 12 OTC 8.4 28.0 0 29 3.56 30 66.097 32 85.586 21.5 Parasite +ve 
8 61 & 72 IMD 4.0 29.5 3.29 31 44.55 33 66.457 25 69.881 9.7 Parasite +ve 
9 3, 7, 13, 17 Control 4.6 34.0 11.06 32 72.08 19 Died 72.08 13 Parasite +ve 
aOTC: 200 mg/ml solution of oxytetracycline (Liquamycin LA-200, Pfizer Animal Health) administered at 22 mg/kg, intravenously (IV), q24h for 5 days; 
IMD: 120 mg/ml solution of imidocarb dipropionate (Imizol Injectable Solution®, Schering Plough Animal Health) administered at 5 mg/kg bodyweight, 
by intramuscular (IM) injection twice, 7 days apart; 
Control: Infected blood. 
Infection 10 
OTC 
• ENRO 
--A- IMD 
24 31 38 
Days post infection (DPI) 
2 
Figure 1 : Mean percent parasitized erythrocytes (PPE) following intravenous inoculation of 400 mcl cultured 
erythrocytes infected with A. margini and retrospective assignment to treatment groups 66 DPI 
ENRO—Assigned to enrofloxacin treated group; IMD—Assigned to Imidocarb treated group; OTC—Assigned to 
Oxytetracycline treated group 
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Figure 2: Mean competitive ELIS A (cELISA) results following infection with 40 Oui A. marginale infected erythrocytes 
and treatment with enrofloxacin, oxytetracycline and imidocarb 66 DPI 
ENRO—Enrofloxacin administered at 5mg/kg IV q24h for 5 days; IMD—Imidocarb dipropionate at 5mg/kg 
administered IM twice, 7 days apart; OTC—Oxytetracycline administered at 22mg/kg q24h for 5 days. 
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Figure 3: Mean packed cell volume (PCV) following infection with 40 Oui A. marginale infected erythrocytes and 
treatment with enrofloxacin, oxytetracycline and imidocarb 66 DPI 
ENRO—Enrofloxacin administered at 5mg/kg IV q24h for 5 days; IMD—Imidocarb dipropionate at 5mg/kg 
administered IM twice, 7 days apart; OTC—Oxytetracycline administered at 22mg/kg q24h for 5 days. 
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CHAPTER 7. GENERAL CONCLUSIONS 
The results of the study presented in chapter 3 demonstrate that subinoculation of 
blood from all except one of the carrier steers treated with one of the 3 regimens of 
oxytetracycline resulted in infection and clinical anaplasmosis in splenectomized calves. The 
splenectomized calf in which infection could not be confirmed did however die in the early 
stages of the study and it may be possible that it was still in the prepatent period. 
Administration of a 300 mg/ml solution of oxytetracycline (Tetradure LA-300) administered 
at a dose of 30 mg/kg intramuscularly once or twice 5 days apart was not effective for 
elimination of the persistent A. marginale in beef cattle. Furthermore, the study demonstrated 
that the current recommended OIE treatment protocol of 5 injections of a 200 mg/ml solution 
of oxytetracycline administered at a dose of 22 mg/kg intravenously was also not effective 
for elimination of persistent A. marginale infection with an Oklahoma isolate. 
These results are contradictory to findings of previous studies in which successful 
clearance of anaplasmosis carrier infections was achieved using intravenous oxytetracycline 
dosing regimens ranging from 11 to 22 mg/kg given for 5 to 12 days (Magonigle et al., 1975; 
Roby et al., 1978). Previous studies reported clearance of the carrier state in cattle using 
intramuscular oxytetracycline at 20 mg/kg following 2, 3 or 4 administrations at intervals 
ranging from 3-7 days (Roby et al., 1978; Kuttler, 1980; Magonigle and Newby, 1982; 
Kuttler, 1983; Swift and Thomas, 1983; Rogers and Dunster, 1984; Ozlem et al., 1988). Our 
results are however in agreement with those of Kuttler et al. (1980) and Goff et al. (1990) 
who report a failure of carrier clearance in naturally infected range cattle using 2 injections of 
long acting oxytetracycline administered at 20mg/kg by intramuscular injection. 
As a result of our findings, the Canadian government removed anaplasmosis 
treatment requirements from feeder cattle imported from most U.S. states in March 2004 
(CFIA, 2005). Although these new provisions facilitate year-round movement of feeder cattle 
from 39 U.S. states to Canada, there are control provisions for the movement of imported 
feeders between approved feedlots and for Canadian cattle to leave importing feedlots to re­
enter Canada's breeding herd. Imported animals are eligible to leave the feedlot only for 
immediate slaughter, movement to another feedlot that is approved to import restricted feeder 
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cattle or to be re-exported to the U.S. There are requirements for comprehensive management 
programs for animals in the feedlot, enhanced insect vector control programs and periodic 
inspection of animals within importing feedlots. 
In order to explain our findings, we hypothesized that the failure to sterilize persistent 
A. marginale infections could be attributed to one or more of the following factors: (1) drug 
concentrations at the site of infection were inadequate, (2) drug concentration was 
maintained for a insufficient duration to be effective, (3) the organism was not susceptible to 
the antimicrobial, (4) the pharmacokinetic parameters of the drug were inadequate and (5) 
local factors in the environment where the organism was located were not conducive for 
optimum drug activity (Bidgood and Papich, 2003). 
In the second experiment we hypothesized that an in vitro whole blood culture system 
for A. marginale previously described by Kessler et al. (1979) could be used in conjunction 
with a fluorescent activated cell sorting (FACS) method described by Wyatt et al. (1991) to 
evaluate antimicrobials against A marginale. Once established, this technique could also be 
used to test the hypothesis that anaplasmosis isolates from different geographic locations 
differ in their susceptibility to antimicrobials. Enrofloxacin inhibited A. marginale in a 
concentration dependent manner, while higher concentrations of imidocarb were less 
effective in reducing the number of viable organisms. Oxytetracycline was found to be the 
least efficacious antimicrobial in this culture system. Differences between isolates were 
evident at some dilutions. Cultures of erythrocytes infected with the Oklahoma isolate 
exposed to 4.0 gg/ml enrofloxacin and those of the Virginia and Oklahoma isolates exposed 
to 1.0 n-g/ml imidocarb appeared to be sterilized. 
These data indicate that short-term erythrocyte cultures could be used to assess novel 
antimicrobial agents against A. marginale using FACS and the vital dye, hydroethidine. 
Further studies are required to assess other A. marginale isolates for differences in 
antimicrobial susceptibility. Our studies were constrained by the number of animals we had 
available for subinoculation studies and we would suggest that additional testing should be 
conducted using a narrower range of dilutions. This is especially the case with Imidocarb 
where the MIC is judged to be between 0.25 and 1 fig/ml. Our study also demonstrated that 
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future in vitro erythrocyte culture studies may only need to be conducted over 3 days based 
on the results of the ROC analysis. 
Based on the results of the in vitro trial we hypothesized that enrofloxacin could 
potentially be used to sterilize persistent A. marginale infections. Accordingly we designed 
the study reported in chapter 5 to test the efficacy of enrofloxacin (Baytril®100, Bayer 
Animal Health) against severe experimental A. marginale infections in splenectomized 
calves. The results of this study indicated that enrofloxacin administered at 12.5 mg/kg twice, 
48 h apart ameliorates, but does not clear, A. marginale infection in splenectomized calves. 
Further studies are required to determine whether an efficacious dose rate, route, duration 
and frequency of enrofloxacin administration can be found to eliminate persistent A. 
marginale infections. 
Finally we compared the efficacy of enrofloxacin, imidocarb and oxytetracycline 
against persistent Anaplasma marginale infections established experimentally using an 
Oklahoma (OK), Virginia (VGN) or St Maries (StM) strain. A calf infected with the OK 
isolate treated with imidocarb dipropionate at 5 mg/kg administered IM twice, 7 days apart, 
and one calf infected with the VGN isolate treated with oxytetracycline administered at 
22mg/kg q 24 h for 5 days failed to develop parasitemia following splenectomy. 
Subinoculation of blood pooled from these calves failed to infect a splenectomized calf. The 
OTC treated calf and the subinoculated splenectomized calf were negative on PCR and nPCR 
but the IMD treated calf was positive. These data indicate that two of the regimens described 
were efficacious against persistent A. marginale infections in only two animals infected with 
either the OK or VGN isolate. No calves treated with 5 mg/kg intravenous enrofloxacin for 5 
days were cleared. 
Conflicting reports regarding the success of chemosterilization protocols suggest that 
possible differences in susceptibility between isolates may exist. This hypothesis is supported 
by the recent identification of two multidrug resistance pumps in the genome of A. 
marginale-, although the clinical significance of these pumps has yet to be elucidated 
(Brayton et al., 2005). Future studies where these efflux pumps can be cloned would be 
useful to determine their significance. Once genomic sequences of other A. marginale 
isolates are elucidated, these can be compared with this first sequence obtained from a St. 
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Maries isolate. Future in vivo studies should involve groups of cattle infected with multiple 
isolates. The studies presented herein are limited in the number of animals utilized, which 
significantly restricts the extent of the inferences that can be drawn from these. 
The study presented in chapter 6 suggests that direct PGR and nPCR are not reliable 
means of definitively determining the success of chemosterilization in calves. This finding is 
based on one calf that was positive on direct and nested PGR but failed to infect a 
subinoculated splenectomized calf. 
It is noteworthy that our study found that splenectomized calves will become 
seronegative following clearance of persistent infections with antimicrobials. Goff et al. 
(1990) observed that application of an antimicrobial interrupted continuity of stimulation of 
antibody as detected by complement fixation. A similar finding was reported in our study 
presented in chapter 3 using the cELISA test; however, results remained above 30% 
inhibition and returned to pre-treatment levels as the study progressed. Further research to 
establish the timeframe to seronegativity in intact animals would allow the cELISA test to be 
used to evaluate the clearance of carrier infections in field cases of anaplasmosis. 
Significant deficiencies exist in our understanding of many of the chemotherapeutic 
agents used in the treatment of bovine anaplasmosis. The tissue disposition of imidocarb 
dipropionate has been extensively evaluated due to violative residue potential in food 
animals. However, there are currently no published reports detailing the pharmacokinetics of 
this compound in cattle. The obligate intraerythrocytic nature of A. marginale lends itself 
very well to the conduct of pharmacokinetic/pharmacodynamic (PK/PD) modeling. Blood 
samples in heparin can be simultaneously evaluated for parasite activity using the FACS 
method described herein and plasma drug concentrations can be determined by HPLC. These 
data may provide very useful information regarding the relationship between the drug and the 
organism. 
A general deficiency of previous studies examining the elimination of persistent A. 
marginale was the lack of random assignment to treatment groups. Furthermore, many of the 
techniques, such as serology, which was used to determine whether an animal was a carrier, 
have since been found to be inadequate. The advent of more sensitive molecular diagnostic 
techniques such as PGR may be helpful in the future. These may be particularly applicable 
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where field trials are conducted as these tests may be a useful indicator of carrier status when 
used in conjunction with the new cELISA test. 
Taken together, these studies suggest that reliable clearance of persistent A. 
marginale infections could not be achieved with oxytetracycline, imidocarb dipropionate or 
enrofloxacin at the dose, route, frequency and duration of administration tested. We also 
showed that flow cytometry proved to be useful for screening antimicrobial activity of drugs 
against bovine erythrocytes infected with A. marginale. Based on the data obtained from 
these analyses we were able to make predictions about the minimum inhibitory concentration 
of antimicrobials required to be effective against anaplasmosis. We also demonstrated in 
vitro susceptibility differences between a Virginia and Oklahoma isolate, especially in the 
imidocarb treated cultures. We also identified enrofloxacin as a compound that could 
potentially be used against A. marginale. Further research is required to investigate why 
current chemosterilization protocols against A. marginale provide inconsistent results. This 
may require further elucidation of the relationship between pharmacotherapy and the immune 
system and the determinants of between-isolate susceptibility differences. 
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